var title_f19_24_19840="Portable ventilator";
var content_f19_24_19840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Portable positive pressure ventilator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PLV-102 (Respironics, Inc, Murrysville PA) portable volume- limited positive pressure ventilator. This offers assist/control and SIMV modes, high and low pressure alarms, and a battery backup.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19840=[""].join("\n");
var outline_f19_24_19840=null;
var title_f19_24_19841="Calculator: SI unit conversions for immunology lab values";
var content_f19_24_19841=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"SI_Immuno_form\" name=\"SI_Immuno_form\" onkeydown=\"to_param.value='';\" onkeyup=\"unitConvert();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: SI unit conversions for immunology lab values",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_main\">",
"      <div id=\"calc_input\">",
"       <table summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td colspan=\"2\">",
"          <span class=\"medCalcFontZeroBold\">",
"           FROM:",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\">",
"          <b>",
"           <input name=\"from_param\" onchange=\"unitConvert();\" size=\"8\" type=\"text\"/>",
"          </b>",
"         </td>",
"         <td align=\"left\">",
"          <b>",
"           <select class=\"medCalcFontSelect\" name=\"from_unit\" onchange=\"unitLoad();\" style=\"width:400px;\">",
"            <option selected=\"selected\" value=\"Pull-Down|0|1|0\">",
"             Pull-Down",
"            </option>",
"            <option value=\"Alpha1-antitrypsin [g/L]|1|1|0|\">",
"             Alpha1-antitrypsin [g/L]",
"            </option>",
"            <option value=\"Alpha1-antitrypsin [mg/dL]|1|0.01|0|\">",
"             Alpha1-antitrypsin [mg/dL]",
"            </option>",
"            <option value=\"ANCA, cytoplasmic (C-ANCA) [kU/L]|3|1|0|\">",
"             ANCA, cytoplasmic (C-ANCA) [kU/L]",
"            </option>",
"            <option value=\"ANCA, cytoplasmic (C-ANCA) [U/mL]|3|1|0|\">",
"             ANCA, cytoplasmic (C-ANCA) [U/mL]",
"            </option>",
"            <option value=\"ANCA, perinuclear (P-ANCA) [kU/L]|4|1|0|\">",
"             ANCA, perinuclear (P-ANCA) [kU/L]",
"            </option>",
"            <option value=\"ANCA, perinuclear (P-ANCA) [U/mL]|4|1|0|\">",
"             ANCA, perinuclear (P-ANCA) [U/mL]",
"            </option>",
"            <option value=\"Anti-GBM antibodies [kU/L]|2|1|0|\">",
"             Anti-GBM antibodies [kU/L]",
"            </option>",
"            <option value=\"Anti-GBM antibodies [U/mL]|2|1|0|\">",
"             Anti-GBM antibodies [U/mL]",
"            </option>",
"            <option value=\"Antithyroid antibody [IU/mL]|5|1|0|\">",
"             Antithyroid antibody [IU/mL]",
"            </option>",
"            <option value=\"Antithyroid antibody [kIU/L]|5|1|0|\">",
"             Antithyroid antibody [kIU/L]",
"            </option>",
"            <option value=\"Bence Jones protein (quantitative) [g/L]|6|1|0|\">",
"             Bence Jones protein (quantitative) [g/L]",
"            </option>",
"            <option value=\"Bence Jones protein (quantitative) [mg/dL]|6|0.01|0|\">",
"             Bence Jones protein (quantitative) [mg/dL]",
"            </option>",
"            <option value=\"C1-esterase-inhibitor protein [g/L]|7|1|0|\">",
"             C1-esterase-inhibitor protein [g/L]",
"            </option>",
"            <option value=\"C1-esterase-inhibitor protein [mg/dL]|7|0.01|0|\">",
"             C1-esterase-inhibitor protein [mg/dL]",
"            </option>",
"            <option value=\"C3 [g/L]|8|1|0|\">",
"             C3 [g/L]",
"            </option>",
"            <option value=\"C3 [mg/dL]|8|0.01|0|\">",
"             C3 [mg/dL]",
"            </option>",
"            <option value=\"C4 [g/L]|9|1|0|\">",
"             C4 [g/L]",
"            </option>",
"            <option value=\"C4 [mg/dL]|9|0.01|0|\">",
"             C4 [mg/dL]",
"            </option>",
"            <option value=\"Factor B [g/L]|11|1|0|\">",
"             Factor B [g/L]",
"            </option>",
"            <option value=\"Factor B [mg/dL]|11|0.01|0|\">",
"             Factor B [mg/dL]",
"            </option>",
"            <option value=\"Haptoglobin [g/L]|12|1|0|\">",
"             Haptoglobin [g/L]",
"            </option>",
"            <option value=\"Haptoglobin [mg/dL]|12|0.01|0|\">",
"             Haptoglobin [mg/dL]",
"            </option>",
"            <option value=\"IgA [g/L]|13|1|0|\">",
"             IgA [g/L]",
"            </option>",
"            <option value=\"IgA [mg/dL]|13|0.01|0|\">",
"             IgA [mg/dL]",
"            </option>",
"            <option value=\"IgE [g/L]|14|1|0|\">",
"             IgE [g/L]",
"            </option>",
"            <option value=\"IgE [IU/mL]|14|2.4|0|\">",
"             IgE [IU/mL]",
"            </option>",
"            <option value=\"IgG [g/L]|15|1|0|\">",
"             IgG [g/L]",
"            </option>",
"            <option value=\"IgG [mg/dL]|15|0.01|0|\">",
"             IgG [mg/dL]",
"            </option>",
"            <option value=\"IgM [g/L]|16|1|0|\">",
"             IgM [g/L]",
"            </option>",
"            <option value=\"IgM [mg/dL]|16|0.01|0|\">",
"             IgM [mg/dL]",
"            </option>",
"            <option value=\"Rheumatoid factor [IU/mL]|17|1|0|\">",
"             Rheumatoid factor [IU/mL]",
"            </option>",
"            <option value=\"Rheumatoid factor [kIU/L]|17|1|0|\">",
"             Rheumatoid factor [kIU/L]",
"            </option>",
"            <option value=\"Total complement [kU/L]|10|1|0|\">",
"             Total complement [kU/L]",
"            </option>",
"            <option value=\"Total complement [U/mL]|10|1|0|\">",
"             Total complement [U/mL]",
"            </option>",
"           </select>",
"          </b>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td colspan=\"2\">",
"          <span class=\"medCalcFontZeroBold\">",
"           TO:",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\">",
"          <input name=\"to_param\" onfocus=\"blur();\" size=\"8\" type=\"text\"/>",
"         </td>",
"         <td align=\"left\">",
"          <b>",
"           <select class=\"medCalcFontSelect\" name=\"to_unit\" onchange=\"unitConvert();\" style=\"width:400px;\">",
"            <option>",
"             &nbsp;",
"            </option>",
"            <option value=\"0|_________________|1|0\">",
"             &nbsp;",
"            </option>",
"            <option value=\"0|_________________|1|0\">",
"             &nbsp;",
"            </option>",
"            <option value=\"0|_________________|1|0\">",
"             &nbsp;",
"            </option>",
"            <option value=\"0|_________________|1|0\">",
"             &nbsp;",
"            </option>",
"            <option value=\"0|_________________|1|0\">",
"             &nbsp;",
"            </option>",
"            <option value=\"0|_________________|1|0\">",
"             &nbsp;",
"            </option>",
"            <option value=\"0|_________________|1|0\">",
"             &nbsp;",
"            </option>",
"            <option value=\"0|_________________|1|0\">",
"             &nbsp;",
"            </option>",
"            <option value=\"0|_________________|1|0\">",
"             &nbsp;",
"            </option>",
"            <option value=\"0|_________________|1|0\">",
"             &nbsp;",
"            </option>",
"            <option value=\"0|_________________|1|0\">",
"             &nbsp;",
"            </option>",
"           </select>",
"          </b>",
"         </td>",
"        </tr>",
"       </table>",
"       <br/>",
"       &nbsp;",
"       <br/>",
"       <span class=\"medCalcFontOneBold\">",
"        Set maximal display precision in decimal points:",
"       </span>",
"       <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"setDecPts();\">",
"        <option>",
"         0",
"        </option>",
"        <option selected=\"selected\">",
"         1",
"        </option>",
"        <option>",
"         2",
"        </option>",
"        <option>",
"         3",
"        </option>",
"       </select>",
"      </div>",
"     </div>",
"    </center>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <div id=\"calc_hints\">",
"    <span class=\"medCalcFontOne\">",
"     To make simple unit conversions, select the starting units with the pull-down selector on the right. ",
"Then type a starting value in the top",
"     <b>",
"      FROM",
"     </b>",
"     input box. To convert the value, choose the ",
"new unit in the lower right selector. The converted value will appear immediately in the",
"     <b>",
"      TO",
"     </b>",
"     box.",
"    </span>",
"   </div>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19841=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"codes = new Array;",
"codeparts = new Array;",
"var dp = 1;",
"var tovalue;",
"var to_selected = 0;",
"",
"function showToValue(){",
"with (document.SI_Immuno_form){",
"to_param.value = fixDP(tovalue, dp);",
"}}",
"",
"function setDecPts(){",
"with (document.SI_Immuno_form){",
"dp = decpts.options[decpts.selectedIndex].text;",
"unitConvert();",
"}}",
"",
"function unitLoad(){",
"with (document.SI_Immuno_form){",
"",
"to_selected = 0;",
"",
"for (i = 0; i < from_unit.options.length; i++) {codes[i] = from_unit.options[i].value;}",
"",
"codeparts = from_unit.options[from_unit.selectedIndex].value.split('|');",
"findunit = codeparts[0];",
"findtype = codeparts[1];",
"to_unit.options.length = 0;",
"",
"for (i = 0; i < codes.length; i++){",
"codeparts = codes[i].split('|');",
"if (codeparts[1]  == findtype) {",
"	to_unit.options[to_unit.options.length] = new Option(codeparts[0],codes[i]);",
"	if ((to_selected == 0) && (codeparts[0] != findunit)) {to_unit.options[to_unit.options.length - 1].selected = true; to_selected = 1;}",
"	}",
"}",
"to_param.value = \"\";",
"unitConvert();",
"}}",
"",
"function unitConvert(){",
"with (document.SI_Immuno_form){",
"",
"if (to_unit.selectedIndex + from_unit.selectedIndex == 0) return;",
"",
"if (from_param.value > ''){",
"unitcode = from_unit.options[from_unit.selectedIndex].value;",
"codeparts = unitcode.split('|');",
"fromtype = codeparts[1];",
"frommult = parseFloat(codeparts[2]);",
"fromadd = parseFloat(codeparts[3]);",
"",
"unitcode = to_unit.options[to_unit.selectedIndex].value;",
"codeparts = unitcode.split('|');",
"totype = codeparts[1];",
"tomult = parseFloat(codeparts[2]);",
"toadd = parseFloat(codeparts[3]);",
"",
"fromvalue = parseFloat(from_param.value);",
"tovalue = ((fromvalue * frommult + fromadd) - toadd) / tomult;",
"showToValue();",
"}}}",
""].join("\n");
var outline_f19_24_19841=null;
var title_f19_24_19842="ST segment changes in MI tutorial";
var content_f19_24_19842=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 117px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    J point and ST segment elevation are the hallmarks of acute myocardial infarction. The ST segment eventually becomes indistinguishable from the T wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19842=[""].join("\n");
var outline_f19_24_19842=null;
var title_f19_24_19843="Axial MRI Sturge-Weber";
var content_f19_24_19843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Sturge-Weber syndrome axial MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 252px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD8AdIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5kooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoop0aPJIqRqzuxCqqjJJPQAUANoqa7tp7K6ltryCW3uYmKSRSoUdGHUEHkH2NQ0AVbr/WD6VDU11/rB9KhoAKKKKACiiigAooooAKKlt4JrmVYreJ5ZGOAqKSSfoK9p8Cfs4+LvEUSXOq+Xotq2CPtAJkI/3R0/GgDxGlVSxwoJPoK+4vCX7NXgzR1jk1UXOr3K8kzPtQn/AHV/rXpGjfD3wjosgk03w9pkEg6OIFJH4kUAfm+mnXrxGVLS4aMEAsIzjNbNh4H8UahBJNZeH9TmijXczLbtgD8q/SWaOxtYczR28URIGWUAZ7VANd0n7ZLaDUrP7TCu54vNXco9SKAPznsvh74vvkVrTw1qsqt0K2zYP6V0MfwP8ftpUl+2gzRohw0UhCyD32+lfY938Y/A9q12JNbiJtTiXYpOD6VT/wCFtW19p6XmgaPfajBIcRui/e/DtxQB8aTfCbxrAsTT6DdxpKP3bMvDewqK7+FXjq0eNJvC2qgycrtgJB/Kvvi38Y6bJaLPc77aPy/MlMowI+Pun3rW/trTPNtovt9sJbld0KeYMuPUUAfm/qngbxRpds1zqGgalbwL1keBto/GsKS0uI40eSCVUf7rMhAP0r9TGVXQqwDKRyDyDVS60vT7uFYrqytpol+6kkSsB9ARQB+XGKSv0K174J+B9XtXhOkRWodizNb/ACtk+h7fhXkPxB/ZdRLGS58FXzNOnItLo/fHoG9aAPlOitvX/Cuu+HgDrelXdkpYoGmjIBI7ZrEoAKKKKACiiigAor1rTPBujeDvAcniT4h2ss2o6rC8ei6MJDG7Ar/x8yY5VRkEDvxwcjHktABRRRQBoUUUUAFFFFABRRSgZNACUUp4oxxQACl9iKs2FjcXsvl28ZLYzz0xXT6f4NdhHJezxjd/BnFAHIEfIGGCM1NHZXUhHl20rg9MLXpcmkabZRRwCFPNUbmUnP61TtvEVnDL9okKxGLKrAoz07k0ActF4Z1NmRJYNiP90gZP41oy+DvsVu91qt2kFsFxGBy0kn90CtWbxsULvAQZZQQuVyFrDh8QNHIlzcJ9rkgbcqyHKo30oA0Y/AFxDpMF1qEhS6uT+6tFGXC9nPtWHqXh99Nuxa3M6/aD/ABx+ddFd6nqF8EvlvH+2TnJx/CP7o9BVQ69BeHyL5VEsR+Z3GSfxoAxx4V1d4fMitw6eoNUbjS723LB7Zzt6kDOK7628bpZxlImiMI+XG3NdFb+IbG4gtonMAldcuCvWgDxIjA5BBHqKO2eK9vudP0S+V0jSElh/CO9clf/AA+kuPMk0xhtT7+f4aAPO6K1dV0K901yJo2aMf8ALQDisv6dKAEop2B2OTU+nWVxqN/bWVlE011cSLFFGo5dmOAB+JoAr7SQODycD3r2jQNNsPhFolp4l8TWq3XjS8TzdI0mYfLZr2uJh6/3V6/jkr9L+Fvhp4f8M+CNFsb610+a60cNdi+uYwVjuSvzynJHy5xwT0Ve6gj4e8eXt7qHjDVrjU9Wi1i6M7Br6FiY5gDgFOBhcdAOAOnFAGXq2pXmr6nc6hqdzJdXty5klmkOWdj3/wDrVUoooAq3X+sH0qGprr/WD6VDQAUUUUAFFFFABXoXws+FOv8AxDuidPhNvp6f6y8lGEB9B6mut/Z6+DM/jm9TWddjaLw5A3Q8NdMP4V/2fU19aeKdf0D4Y+E45XhhtNPgwkVvCAv5DvQBlfDT4YeG/hzo8bxwwtqAQfaL6c5LN3xngDPTFVfFvxv8IeG57y2mupLi8tQGaGJfvA+h6Gvmz4wfFnWPiPJKmjXJ03w/b8fZ3lCPK394kcn2HavEppZJ33zSPI/952JNAH13r/7TKXWmTN4S0aaW6Pyp9oGdp9SB1rzm7+LfxOfS57+91+ytreQELb/Z4ww9gAuR+dW/2f8Awxo2qWs7WsiXmoIqyz78gQD6f1rrviNY6Boem3WstiW+gITyUg3pz+goA8B1Xx/428WNDZ3utaheHPyRI23n6Liuuh+G+o2NnZ6w1/di+yGuW3fdz2z1NbH7Na6PqfxJ1q+1W3iinitHntYDwA2RnC9+K+ho/skujWmo3qRIJQcREDarZwC1AHzv4q8L6dohS4sLKW/lngM0kYGYywGfnFeofBf40aHH4HdNRsktNUtpdksNrHtRwfusPT0rF8beJLqXWp9N0XT2050j/eF13LdcfdTP9K8s+FOrWOk+JfFx162jtBNYSxrbyL9yTcuAAe/WgD0n4u/EDSb6e3gMb6fDK4kdV+ZZVPXOOlcJrHii1sPD8tjFEtvds4Nte5JKofQ15ve397Kv2G8YBGTMK4VuvTntWr/bV7piPp97ZrLCluF2tGJBux1z2H0oA660+L2r6PGbPTPEepTwtEAZrli2xh2UE02y/aA8Y2zOzXrTEkbRIcjj1rj9b1nT/EWn2Mn2Ox0y506ARNHDHj7WfX61jQWlmlqsd95kV5KdyfKcKvuKAPpXSv2pJ5Ly0t7nRYpg5USPESD74Ga9z8FfEzwt4yk8jRdTSS8A+a2cFZF/A1+eeq6dNpF1G0Uruu0Ok6oyDJ9M1N4Y1+80TW01C2vbm3mB3NJEfmY0AfpF4p8OaX4p0mTTtbtI7m1fnaw6HsRXx18XP2ftb8O3Vzf+GrdtQ0dFaVghzJGBz93v+FekfCP4v6vqekXWq69ffaLezJR4diqzk/dwfWvbPDXjfQ/EUUSWtygu5Fy9o3LpnswFAH5qEEEgjBHakr6h/aM+B00MupeLvDKq8BIknsIYsFP7zrjr6mvl8jBIPBoA0fDmjXviLXrDSNLi829vZlhiXtknqT2A6k9gDX1DrnwU8OfCxZ/Gs4vtfstKtkeLTGiDB7kceZIw4EQOGIxx3yBg85+zPpuh+C9GvPiR41u4bKBt9ppYlGXkxxI8a9WP8Ax/t54rL+Lf7RuteJ1n03wmsujaO4KNNkfaZ1PqR/qx7Lz/ALXagDx3xh4m1Xxf4gudZ165a4vZzyeiovZFHZR2H9c1i0UUAFFFFAGhRRRQAUUUUAFKM56Uq88U+GN5pVjjXc7HAxQBH3roNC0Rbkie9ysA7VtaFoEFjCZ9SjL3WMrEegHrVXV9Zt4okW0UiYHOwdD9aAN3+0LGwXZCscIUfebqfaszUvE7XWpCO1t1lRUz8ozzWRFpNxq6fbY5d4ZsuhB+Wup8L+GpY3aazCs3dTQBzFvZ63rMzbi6RkFmc5G1fSn+EvCVz4luL0WfmeTbcGTBIJ+te5aD4PF1byefPHZmaMo65zuz6e9b3hj4a33hTw1e2Fv4pstN0u9kDTG4GJQvfaaAPDYPhldHTjdLceZPu2CKPk/lU+seAY9K8O3EskpMkaeZMyfNg+hr2jw5o3h/wL4ztm8Paub3T7qJhdC5fdlj3U1g+Nr62bUZbG0hWPS5G/esp3bzQB5H4V0a5mayazZ2S5+U+YMYHtXSXPwm1G8ldI0ITduVyPvdzk17Z8KItP1PWLWCOxRorZCVZlxgD2r3GGztoQRFBGoPJAWgD4WufhTcGKSVVeBV4CEHJPtWHqPgLWLCRGTeWYfK/PSvv68tbEFXuLeM5+UfJmsaXwfo15DPG9u+12yMgjb9M0AfA7WuvaaZG8uUqvL4B/OtHSvGNxbERXhdFPAAPP419car8MhfW9xA8MHlrxEynDEe9eP+MPg9HZR3H+i5m25DZoAyNOYatpDXF0kf2bp83FcjrngaC5VrjSXC9SVzWdr3hvXtHtgXuZpUTkRpnaBTfDPiOVbpTcXDfLx5CjJagDkby3ltLhoLhCkinnIr0X4Ka74d8F6lc+K/EIa8vrRTFpunxD53lYcyMTwqqDjJzyxIBK1ranoun+KrLz0l2XY/5ZY+YV5Vq+ny6ZfSW84Pyn5W7EUAdn8Tfix4l+IEzR6lcfZdLDZj0+2JWIehbu59z+AFefUppKACiiigCrdf6wfSoamuv9YPpUNABRRRQAV6f8Dfhbc/EXWneaVbfRbJlN3MTgkddq+5/SuG8LaBqHifXbTSdHt5Li8uXCqqDOB3Y+gA5r691HU9C+EHhVfCOmxPdXzwGW9uNmN7Y6nHGfbPFAHVeMfih4c+HMVvottbHEcISDygPKBA4HHP6V8e+NfFOs+O9bvNV1q98y1tmA8gy7QEz0Rap+J/Glxrc12Z7aMF/ljY5zGvp9ap+H/DrX2qaCl5Ki2+p3Kw4D4cLuAJOeg9DQBteHdL0PWNeiDabrEmiw4Wae0jL4Pqx7Cuk8QfBrU725uL7wfbGfRQuY2klBdjjoMV9S2PhfToo5vCNlaNBotpCA4tSIxNx/y1fqT60y4srfRbix0zQdONskYxJDG5KSIfRj1NAHzp+y5HBHr3iqw1JZVd7HYY0fa+VY5A9TX0Vo1hDNoscljc3A0yTC3MctukhZhwBz9BXhnxF8OXvw0+LuleKdKtJGsLlhJJGoLBCeGU/wA69g82az0sXEl4Ht78mV4IWC+XnkcH8KAOf+Ivgz7RBf8AiWK2ttL8QafF5kJg+QzQjruUcZxW14W8R6V4n0fRwunGW2vbf95Hkje68nHvxVuy1K4v9O1d9SjMltFp0y+eynhdvGT0rj/gMJ2+CkUx2boNQl+yP0YIcg/zNAHca1odtqIsRp9q4kRvtCTPybcLzg/lXjfxX0H/AIRfXbzxPZWdrrVp4ltZImlumCm0mxkkAd8Cva/A2sSf8I5rcs8gf7PvSIOOW4ryD4+6jaPrPhTw7DbxP5lu08mxiAjOpAGPxzQB8/eAdAbxR4y03SBg/aZdrZOMDvzX1LF4K0mz08aMJIfMRvJO1d25fTca+Y/h/dalonxA0260pBJd2dyHK5+UqD8wPtjNfY3jCzi8TW+nawI5oLVhz5Xyqr46k8UAeGfEv4U2PguC71+K4Ee9R9gsdu47/Un+lcL8J9A1DxT8SrLSbh2S4cmR3kUMYwBnNfTlulvefDjU59UePU5tGd5Y1f8AxPWsH4P2EOleHtX+I5sPNvdQUxRwRsDsXODj0oA6O/8AAemX2i3Ok6pbiO1lVkjuFAZmkHfnp+FfFevaVNpOvXumSRuJYJmjCnknnjp6jFfbfhbVX1rW/sd9Ntkgt2lQlsAMRwDXD6L8LLPTjc6x4t2N4j1S4drKAtux83HPTkAUAfLNvcXelXDRt50WfvxElcj6V7R8J/F2oW0sl54WuIba7tYt1xYNF5jXqDnG485+lWPjPpelG5ZNQs20zV44CpUgASkdCDXjuiprWiSRa7ZQzRJbuCJjwpP9RQB+g3wz8c2fjnw7DeCI2l8QVuLKXh42HXg84r5v/ah+D8eiSS+LvDkbfYZ5M3lqi5ELH+NcdFPcdqk0XxdZa5pza74auHt/FyQZuVJ2At7Dv+Fe2fBPxxD8SvBE0OrxK+o2wNrqEMijD5HXHoRQB8C3t9dXogF3cSzLBEsMQdiRGg6Ko7D6epNVq9K+PXw9f4f+OLi1tkkOkXX7+zkZeNp6pnuV6V5rQAUUUUAFFFFAGhRRRQAUUUoGTQAq89DXYaFplrZWIvL2QGRuV2nlaxfD2nve3O/YssMB3shOCfpV3XruNLhmtVMKsNvlHnFAE+r6rPcAQW8/nM3AI4IH1rc+H3gp9R1JBqKtl+F74pPh54WF3FJe3qMoByCa9g8I3en+HJ2murcygLkZPegCt4g0Wx8P2sdlHDH5kQy7quMj0qjoYE58yNdkI7AVl69qsuq61NdHeBKcbM5GK2pr/wDsq0itbWBS+zcxPTFAHSw6/a6Xp6kW8Ts5+83UfSuN17VZtTmaa8kE8fIRX+YKKqarq0t/DCpjWNE67VrMkm8xWijO7J44/nQBKSpkjDYKqflx1FJDcB7qUKHBB4Qj71QyRPCQjZ3EcnHSrEMsMyQhV+ePhZA3XHrQB6p8F9Mv01qG+mYQqzFPJZvm24649K9/r5t+EOumDxJawzQrdSSy7ftLHLRjste7eMfEVr4Z0Oe/u2GVH7tO7t6CgDbZQSCRkjpS18na58YvFGo3ji2vhY2xJ2CNMHHua9M+DHiLX9ajjuLySe7tydjM7cD3oA9lqtd2UF7EyXUSODwMjtUxljBI3rkdRnpWTd6jcWHmPPEZIs5DqPlAoA4rxz4J+02sotbdGhZcEKOa+WPHHgqbRllmsrVo2QklweRX3LpurWmpKRbvlscqRXIfEPwbFqlhK1shBcEMqjJJoA+JNE15obiNGkkikxh3P8VdZrGkjxLoZu2VYZ4R8hB+/XPfEPw8+j6jKFUFYWw+Kl8D6zqEAaPyhdW0hwcnmOgDiHjZJGRlwynBFNxXZ+P9BFnINSgAFvJhSB/erjW447igBtFFFAFW6/1g+lQ1Ndf6wfSoaACiip7G1lvb23tbdd008ixIvqzHAH5mgD6X/Za8NzaF4W1z4gskczRwSwQQudvyphnbP4Y/OuV+KGp22q6FJrF28g1m6uQJwGKx89Nv4V6j8cpU+HfwD0TwtbStHNc+VauyDBZR80hOPXGPxrw6awvPif4ug0TwwQmmWsQKlzhFwMMx9ST0oA7f4E/DrT5PEE1zrdnZ3kaRebCJpSVHf7uOa9u8Q+B9P13RDd3el2dzdRN/ok9smw2qjoQBycVwy+Hp/AWg6VPG1zruqySrDLIi7Vtk9/UCvRIr2e21e2vdJujerJHtuFf5Ej+g7mgDnrfV9a0+/i07U5oZ9KdAn24Ehmb1cdc1p+I5dQWTTptNuYbjUrV9ww37sxe9U9HurFtX1W1u5IJpGlMyxy9Tk9u1dJq8MqaKGkgi+zO2BEg2yYx6+lAHOaheHXUja/iS5uicSKrfu0qHU9LtNPsILfRLuW7ctiWSSMsFBPTPt0qsuny6dDJMkd3a2BfIT5W/XOatma51HQJrma3CTLJ+6jQlQAOMnFAGt4gvnj8IzafaWkcqTxeQ+JAAc8ciuevDB4L8GaRpNppckWpxAtHCh3ISwIyfzoXUbmz0uZ0SO8uWYNs8tsIfripovC19rOoHW9QvJWkWAlYC42qcfWgDZ0TH/CMQWMoFrqgQvNIi53E1xHi3wvYat4z8L+I9QuwbO3ja0uIyu13kwduPatnUvGtv4ctrGK9gae6ZMFYEywI6MTXCt4pvtd+IXgnSrUR3DzzfaXkZfvKMnaR06DrQBxHwd0ezHx6l02+XylS6fyopON+GyFPrkV9AfEea/tdYaxBkhsnAMdtH/q5RXjXh/X4tS/awlu9Wto4HF49tCoIAjZQVUt6nivd/F1x/al7fxtKslxZcps7j2oAx/h7fW+s6Nr+iW9mLDUU3eXbXGMTk/wAxVG4eTR/Blr4bvbiKz1qeTLaXbD7q5znI9ua87TXH0rxCZrxJ45JHzAS4DFvTNdnBrFxfzXPiLXbLP2RPkbafN9Bhu9AG34XiNgLxNSFjqWnyMFlkgB89F9+K6zUbBtTe01LQoxJFZIBbxzKfkPrzzXn/AIIv1ubu8urqKELcDaTBJg7f9oV6RZ6voGmxINRvo0MibFK7yPTrjGaAOI+Kd9beJNDm0bWtNtbq9jAcSx9c/wB1Tjj864SH4Hwaxok1ql7e2uqNB50NlcNkIOuBjI/OvVdY0zTdU8PbfDemi4s4ZjLcSvLskcD0Y81gaHbrJdXWtwT3MUkUZVEa4UsqjsOeaAPj/VLDUfCniB7W6EtteWzg8HB4PBr37Sby/szp/j3wZqqXcwgC6narAyr5akFgQBjcfWoPjDo1x4o+HbeKGtY5JLS4MaywqA+3PIk9cVxP7Omv3tl4xTSkuo4rG9Uo4mb5FY8A47n2oA+jvi9Y6f8AFr4JS6pozK9zbwDUYEI3SIyrloyq5IYjIx64r4XIIODwfSvtv4Ey23hXx94u8EXcX/EzaX7ct1ggXCHsAemM/Svlr4z+Gm8J/EnW9M2bIRMZYR/0zf5l/Q0AcRRRRQAUUUUAaFFFFABSnoeOaKs2MLXV9BbqMmVwlAHR6TH9h0d3dvJJ+cS+vtWdpdnNr+rDnGSMn1rX8bomnW8WnDJ8s7ge3SvRP2efCP8AaEc+oXUOY1O7cewFAGlbWzWmli3GUtVUZYdzWbftLM+19+1f1rr/ABH4n0N557OCwkMqHbuH3cj2rKi1q3XBmiAwPl+UUAZWmWcl1MI4YGAA3bj7U/UblmuDvHKjZVuPxNPb3m+GJdinLAr1Xvipb3Sr67tp9U0jZd2dwP3qZG+L8KAOXVlMbJIzJyce9WbGa3tiskEReVeST0NRPpct1EVewujEv8YPP6Vg6jaS2PzWzylOjIxIK/WgDotV1qXUF/0mOOJRwDHVbSFj82BbiWXyGYglVrE06SWflx8melddoKWkd5CNQmMVvzwvNAHrngnSbKwsdMn0a4ia1luwsvmxZlZ/QH0rX+O9nda7owstECX95aMJrizhkHnLGf4tvU07wlHpb+GNIk0i4P7u/wArnBw3f9K5f42X/wDwiHiaXUdCs107U9VhWKfU1Yl5QMAKM5AIAHOKAPB760nt55VuILi1kzwkq9K7HQfiPqOl6B9hsbh44kPAjXBFch4i8QXt2TFfXM91MhyHbBzn6Cr3hrwlrOrur2lrlZOq5IJ96ALVr4k1KfULi8W7umlk5ZmkJJH0r0PwN8Ub+zn8rVXeazHHly81jah4bi8E6RJLqjwS3sg2hFIJjB715my3DSCC3eSYFvNDDlh7UAfX3hjx14R1q9jS0uUtb3OBE/yZPt613dwglhdC5RSPvKa+LfDWg63rV9b3Fppl1EA4HmGMj8c19feGLW+g0a3g1V1lkVQOnPTofWgD56+NPgSCzu5ruO48yO45Cnua8Dit0sBJDcSTu6vkRY2IPxr751/QLbUXQNaJKr5DbuinHBr5F+M/h6aC/vYIfma0f50K4H4GgDkPEWvf2z4fNrBGEjgKgjOea4ckbenPrXZ/Djw//bk9yC+2IKQR2zXLara/YdQurUtkxSFce1AFOiiigCrdf6wfSoamuv8AWD6VDQAV6R+zz4eh8S/FrQ7S8hkltIna5l2HG3YpZST6bwv515vX05+xNoLvreu68+8RxW4s04+UlmDE59tv60AY/wC2PrU+ofEKw0OJneGxtlYRryC8n8zgAVpfBlLHwzoDI9pPHeXhVrm5K7xFjoBtrh9YuW8Q/HvXbyRTIou5dqZ3naPlAB9q9yf4eSaDp1hN4evb3S2jIkkhJ85Js84zQB6RY38ctssmmJJqdlIBv2rsww6Bt1c7dRNezzJNBb25Rt32eCTGB/jWdrh137J9uSGa0MihBEhwr/7W0d6ytDuL5oWi1Cw2MORcRZd2+ooARdOxr639pbzIpcIwYZ3Ae9dZ4nuXv4jaJOlogUFFkzgnHQEd6nu7y9uNBgtbYW0KkgGVlw/1xXNXdrMySw3GqwOsI8yOTGMv6E0AR2MMFhps1prEkpu53zAElLD8q1LwaZBZW8tlNIblk2PGrnZn6GsjwXqNjCr/AG2ze8uVY/vX52fSqd7DDe75w+1UZmE33ccntQBJpk97HqQgkuYy3O2HkK1dno9rJNFdz3jTyZQgQW4AA/GuQtbA3+gLdtcsWR8RyIMM4713Wko8OnW9vumNkwBdicc+5oA5rTrcQS3N7cWcs0QiZBFJHzGvPJ71zN5pmnW+veA9Ut5Ft/skkqLJAMSPlSduP8a9C1SVhqCXFndW0cCDypnaYkL+fWvNfG/iBIPFWiafplutxDEXlbUI0DIG2npQBW8H/D6y06fX/GXjATxS3WolbIDlkBfJc+9dzdy20uoo2jRzPGVBe4mIVZB6fWuB+H3i678Zadf6Nqri6tIr1mEhYhxzx8tdVf6XMZbG3vbxbK3ifKR93FAHH+NNBa/vBPd3VrpaxP5ixTKZHx6gr61Oi32rWsIminl0iLjerlBKR6jriuuvtMgu7vZDcGe3yQJGj2sp9Oe1R6haGx0kmNPJgiPzTNICJfYDtQByt+XlSK205oLbnabbGJG/EVuy2ENhoDW91qbW6ggyQ7fNeLPp/OsXR/CcMuoTanc3cyS4zlsgKPaup8JWqajcX1m9pNd2UCbjdS/IW79e9AHU+GzBe6LbaD4eAltWXfcT33ytIOPugc1VvoNM0S4Szt/D6vJ5gRzI5HB7j2qxp+u2FjeW4tzaTyohWNVGSv1NcrrbeItc1G+1KfcbOzUvnZiMAc0AM+JF7Lp9n/Yuk6Y13B5vnmC3YARA/wB71FeIeJfDR8Ga5YeLtGSO+s/M8xolGPIl64x3xXq3h/X4Nahnt9Xl8hLtcxTwriTHTGOuK8//AGjH1XT7vTPsGnNYaRFD5K3UMu5bhiOrY6Nj1oAf4C+LNxf/ABx0LWtXkFybmMafK/lBPLDnAwB6Eiug/bZ0URaz4f1qOIKs8T28jj+JlOVz+BNcX+y94bh1rx095cwLNJp8YubbzD8vmqcgn16V9D/tQeGz4p+FE93ZsJJtMb7YoT5tygYYDHtmgD4QooooAKKKKANCiil60AA6jPSuo8B2TTawlyFLRwk4+tcvivRPCKy6T4PvNQ2/Mx3KDQBX1yeO+8U2+ntEJV37i39K+jPAWo6V4X07yLmExQTLtbb7ivnH4W3MDeMI7zVZI/JY5bf2/wDrV6T4z1iC7upI9MaQ22cLOPuCgB/jjRrnQtR81mVtPuWLR3S8rz2OOlcxOl7HCw82NgBuXmt3wz4mk05Gilh/tLSX4ktrg5x7rW7LcfD6SLdHoepG4mOSxl4X32+lAHl8lxq0ccEwjaRs5wuDV3TdegjmlF0Ly1uJBh0Vyu78K7248N6SqG8stXSO0zxEVwV/GuF8YxWaQyNbS+b/ANNz978KANzTNVkitRd2d1MjI2F3NkH2IqbxFKLsG6lVfMkTMhxgGsPw7bwLo9rFOXkDHduFS+JLrZZOFYjnaFPUCgDmrCZjJKTwN2AgPFdbZl44olMYEbDHPOK5zRrKOaRcuM9WreuElS5htpElTef3WR9/6UAei/CR7i21ewti5S0+0lyeucD0rb+MfxJtZJLrRbXS7W/hUbHnmGdjZ6rxxWH8OkuglxdeRKIrXd8zLgbsdM15zrkhlv7hsuXM5Z4wOTQBzGuMJtRUINiIckoMV6B4Y8TyaP4ZuBZOzXTcJIxO5RXAahasssjxF/m7HtT4r02emuVIIRtuT3oAXXtda/uyGaW5uD9+R2JOfTFep/AqKybxVbtexK8vl7trLkjj0rifCvhe0vpA19qcNmJv3hZuoHoK9Y+HWo+DfCct95l6ZLjyysVy45J9FoA6nxp8X7fw9cfYdI05GkBxuc7VH4AV5tqPxc8W3N4strfLCqNkwRxggj05FcB4x1D+0NbMzSOGZztU9SM16V8M9E0W4BfUW/0o7doPb1zQB7h4H8Uz+JLKzkaCOJvL3TfNzn2GKwfjN4WtNS0We6eJASMOwGCfxpmivB4f1AtFIksGQB5ddZ46jW+8IXRVWIKBwB1oA+NvAMQ0PXdbhM2yFXHl+/Nc18UrOO38USTQZ8u5QScjHPtWxrMsdl4xcMx+xyv096v/ABP037X4ettSUbniAAC9h70AeT0UuKSgCrdf6wfSoamuv9YPpUNABX2R4CtV+H37Leoao7ypdX9s9yRu2MrSfIoHpgYNfJfhnSZ9d8Q6dpdogee7nSJQTgcnnPtivp39rjU10LwR4b8H2QeGIhZH2jKMka7QuTz1IP4UAeOfBHwtrOv+JV1HTXjijsW82VpXKiYd0z3zX1D4b1W6kklgMZjiKEJCk26ND6A1w37OWl6avgK3+1mPF67+a4bkD+7z0P0rt7jSLV45f+EbgAjtWy0sreWT7L2NAG1B4mjtbNRcWsc+oQgrs3EkD1rE8O3banPLdRXQ08qx3YXGap21vpFyl07axY2mozIRKJ7oK8XsB3zWXo+lavpssF7ZX1pf+GoSTeNGweVT60AegRra6xpcptbgSSWw3SPt5NcdJo97qFlLcRpFHYs5GZgMlh7VmaXry2+r3gsrfVIbafLRyTIAkqnoeBW7p0lnqETrNeG3mVeCzkp/3z0B96AOYtbq/tGnuJ9TtY7eP5FBhC/rXQXUFhqV9pqPHcO00JOIVwrVGlis0dxY3iRy2yfMrFc7jVi2lu9umot3Jp0tmcJ+7BGzPY45oAo6ckNrLDHFBdzPDIwWyYlFPrk139qDcyxTQlRFt2yaW7fKPUg+tcFFcT6l46lS7laOyjGVll+TzT36V2NpdXdl57WrWThziLdyQPXmgCC48KXOv6kbfUoY/wDhGkJRdPVAkrN6tIMHH41zviDRdK03Q9S0yyVormwGy38tT+6JP3Sf4jjvXpGmy39vpk16ZfOKglVAGD+ArxP49eOdSsNJsF0DT5IGmnW5v5SNzvg48sZBx68elAGlbeAtNhl0278MRz2OqCDffOM4kkx/ED71o2lzNptxFpPiKNNR1edt1vcAZEY+tdV4X8T2OraVpGszsbG31WFbZ7OUASK/TJI7VJeR6PYX15Bd24j2Jut7ncTvPoDQBh+Mp79dJ83T7ZTqNsdrjOUx6kVgaNHcas/lahYPboF8x5OsTH/ZFW5La70yxfUYZEna4JDRmYnI+hp/hKdjrNqLr7TKJmIEKZ8uP6nsKAJ4JLOTUZI7hnW0KAMp+YED0z0rUuPEnhZr+306y06/nEahTKrskcY9TzhqZ4jtPPuVGqW8J8sfumtm2Jj0Yjr+Ncl4g0qyubNbkarLb3ROI7JBtjHbkjk560Adbe2kBtpJNK1PSJpM4CpEsbIO5J74rKk1O+Nm+jQXAubCRSJLlZBsz3BrkvD/AIV1PULtjqwjGloDuK/Kc9hkYJFS6L4VbyL60l1jS7K1aX91GzsrAfieaAIdZ0uHT7W3Jgcaov8Aq7iOT5RH6D2qTxNqNhqHwC8QyLZeVLGwjJcZLNn7w/xqxqOnW119ps9DuZ9Ta0j2SGFDsRh1OT2+leb/ABs8URWnhi18L2kj7nCyXAQAISCOMjnNAGV+zFrjWPxAXS5pCtnqMLxPhRkHaTweor7asNJsoPDzaRGwmtliMTAtkkEd/wA6/On4b6zBoHjXStRu0d7aOUCUI2DtPB5/GvvHQdRtLP4izaNY20Vva3WmpfCR5SWuHLY+UE9AvXFAH5767YSaXrN9YzLse3maMj0wcVQr2P8Aaq0T+x/itdyCOJUvoxcqYxjOeOR68V45QAUUUUAaFOXoabTk75A/GgCaztmvLqC2j4aRgufTJrtfHbanpen2umyosVrEu3zFPL1nfDXTm1HxRb8ERwAu7HpkdKf8S7173xLKoZ3C4AQnIH0oA7L4P+E9Q1aKGS2sw67yzDGSVra1XSryLVLqF9NnESHAVVIBNesfszaObPw7LqCgtHINoyMYIwcCq3xK8Y6jAJreJYoWZu4AJoA8VvtPnsLYSBJ4ct901LpwuLu5iiWUncnIxyKk1W+vdSUC5keXJ6ZyBWr4Su4NLvD9tg84suAdvSgB13CmnWggJLMeTmuJ1OQ3d0sSrhP7tdf4huBLckhG2MCVJPT2rkoEc6om47cHrQB1Gmp5KRLEw8sL0PrXMa7eC4vBAjYKsfNJ/SuqiVfKUpgBcnIripVludQunJ3Lu6+tAG1oEBmknG8KijIPrW5DqdxE9nFcQpdqjEx+qVhaNuSMqpBUsM1pT4MwwNzZyDQB7X4T8aQ614PvNOuokjltwSzIMArnj8a8f1meyl1C5ltUYQO+CQPm/Cup8C6abnTb5hJ5ckmIwq9QPU1y3irRr/S7g+bGzwFvleDkD/eoAz9SisxHm1+ckc+Z2rkriJB+82hlD/MqdCa1p3kt5D5WVU/eVu9UXGxRIqjY3JQdFNAHTaUn2jTJEtYt1zwUB7D0rn9ROqWt2JMKojHK471Y0rU20uQfvSZmbKH39K6e1ZLn+0PttmrkR+Z5x6qaAOD0Vp7vVi94RlTn5q9v8N6NLcCyms2hdnBzk4xXh2oSC2vYxG24N9/3Hauy8MeJ5dNgAim2hASBn7v0oA+ifC+hzR3WzUZYwpbJG4c16NdWscthJbhRsZCoA+lfFeq+JbnUJllnvLlt5wSrkV9A/AfWtRm8PS2+oySXCxsBb7zlselAHy58WYZNI8du0qExI5wMcAZrq/DdzD4j8K6lDKuV8vCD6VY/aI0+9uvE11PG0IhgUtIF/iPoaxPhI0Frp8UpuS89wxUW5+6KAPKJ4/LnkiwQyuV5+tRHrXTfEG0Wy8UXCxIEjPzDHSuZNAFS6/1g+lQ1Ndf6wfSoqAPc/wBkPwx/bXxJfU54FktNKgMm5v4ZWOE/HG4/hWD+0X4t1DxH8TdWjumMVtpzm0t4GA+VR1P1J5/KvcP2bP8Ail/gFrviKCzX7cXuLgMwx5qxp8mfYHd+tfI+t6nc61q95qV8++6upWlkYf3ic0Adr8MfEuqaTcyWUOl3Oq2iZl+yxuylG9cjt619MeDLS98SaJBfeOrO8gmR/Lg06zBSO2jPRpMnJ/M1wfwA0zSn8Bz3VjdSpqMxKXRWMsQR0GfSvWL7W9Wgtn0vzI2vpdomduAE+vrigDF1TwZ4N1bULqxvdN0syWqiSC/jVvnP91zmsTSPClr4T1OfVvDN4kcTkLd2P2gtBICecAmuxC6VcedFY3KpCsYidHX5XkPfd9ax9N8L6dd3D2F7CtjJEDI5Mnyyge9AFq91m2n1xrS2Kw2pt924HckXH3RmuemsoIrWF7gF7aWfYskZIcn39q2LXR7BdFu7wwGNGkMUcjHGwZ4+oq3NZf2RaQWl+XuUnXMLhCRnH6fWgDPmeZdW+x6YHmEagAljj8TXZ2VtFbW2obA19IkW4JMvRsc7foa47Smt4Y/sL3DRXl3krGg3Pit0XFxbKZorS/8AKhXY8wG4nseBzQBzdjFcrZNc6uTJ5zkRq2NyY7VKY7SWF83Pl3CDCIHGV+oouBIllNdeXJqFpK/UAh4ifbtWDcLYP4gs4n0qQpHhpplk+Zj256HmgD07SLu+sNIto0mSRk6rgn86w9e1LTJPijoGl6nDObi6jJVIEBVjjq2e1dGVMksTWuowQu0YZotmdv19K4HxtJqM3xs8Drb3VpEFgcyTjHPFAHdQ6Jbaemqf6GgaSVljidgcehXPesRl1CaNbO7lgtymWt/tShlz6EirF/YXl02p3YuF1OSKdtuyQALj0ArLe/iisY7bUJY0vJW3gydEHpmgDMnU6fI+o6+I7mc/L5NkBtX3xTvD7X7zyTWFw8EFzwUdsYHv6VEltENVkawkSRb7h5HbAi9wTxWnpdwtpa6np1rakR26b5LudC4m9higB2sXrrLDp93BIbZxljbsNv1JNbNzoMB0uFdPkt7ySLBWB+CB1O81yMupLemJGtJZXVeJEBVV/Cup0zTpTdWd1a3dveRzptdEkGz0+Ye1AGhYWWkjUrd7Y3l3Lt/eJGSLeNvQnv8AhWUdIn1+y1C71CztmCT7IBDCMqP9rPWukjsNSgTy9MuIHhibdIpceUvsMc1n+KX1C208tBMscSsJH8slT+VAHNazq9/asNGsrpHnKbPItbcJx6NgZry/4j+B7XUdCknmsTp9/CSwc7t8zY+7g8V74lzYeGEOuamyNJcQ7o2VMu3Hf3rzzRNfHjO+vf7RsNUcl/Mt5Xiwgweoz14oA+S7XSlkN7HcXC29zboXEbqfmI6r9a9y+BHxEe9+IHhkeJha3E8cDaZb3Up2vCuPlHpz0ya2fiF8PD4s8VrrPhSO3hS2QG8GAruR1wh6mvAL6OLR/GShJpwtvcqzSOgVwQ2ScUAfTv7a2ixy+HtE1hIZGnhnaBpFTKqhGfmPbnpXyDX6H/Ge0j8UfBfXG09xMktj9qgZOd4A3jH1FfnhQAUUUUAaFOXrk4wOabUkEbTyJDGMvIwUUAel/D3T7JfAWvXd9JcQ3MgP2eSPgDA6Gud+G/hq+8UeIbNIY3kiDZll6/hzXVePb+HRvA9hocEey6dQzkDGa9c/Za8M/Z9Ca+uco27zjx2oA9e+36f8P/CFpHcgAqmAi4BZsV4j4j+KMHiHVBDfeH7RrdSRu3Hew+tV/i14yXV/Ecqoxa1jfy0QnjA71wGoaG80X2uxlZ4zy6p1X6UAdW58A3oy51vT7gnkRFSgrRt9D0u4tyNA17zXAwqXKgN+leQrHrNhdlA++H+445rUsdfWxlAuoWSftsoA6fxLp72MKrMyS3CnkxE4rnLWMyyFnR8npzzUura/DcNiCRmyPmQ9Qaq20jiJXAbFAF2e4a3PlhmMZGDjrWVYvtlkhj+bccsatOS3zKM59arCVYZ9zptJPYdaANKzjEYYhZC+c4FaEWHdS7YJ647VJpr4UXnk5QjaR/Wp5o4xbs0C5kY/lQB3Xws81dSbyhvt2yJCe+OwrlfE3iKVr7U4bVzHaeeQImGTwa6X4cx3EfivTxHP5cDxkPFjqe5rC8XaTG/iG/VHX/XNwB1oA4vVtRhnCyJGSRwRWfJIkkRECnGMsM9K6mXwhO0TywkGMDJOeBXK6rbyWSYhjOP4jQBJounrf3kckgxHGdxJ7V1lxqNvY6dcQwyB3k4lY9CvoK5DwzPnKIzKWOPqfStLUdNmuJ8yRmMJztA4agDO03TDq2qmQjy4ZDtXd/DXU6x4CeyUS20iXKbPmEZ5Fcy+oXWmpteMJnhSBXYeCvGaWFzG13EL1EIMkbHkj2oATwF4EvPFGoRWVpBKluhzNcOuERe/419LyRaF4M0lI4riG3mii2pub5nPrivNtZ+M9nbaZ9n0DT0sy4yQ/BX16V5Brfiy71u5aSYK0n8BY0AdD8SLyPVp5bq3jVxKSJNp+8e9eQaTqZ0jxOojRliB2hPQ16d4bgl1OAwlVMvO1U6Zrz7xpot1a6rJJHbnzIDulAHPX0oA6P4sadDLottqEMYjmODJu7e1eTNjd8oIHbNeuW+rQ+JPBd5b7fMkgTNxnqPpXkRGCRnODjNAFS6/1g+lP060kv8AULWzhx5txKsSZ9WIA/nTLr/WD6V6b+zX4Z/4SX4saUJrcT2ViTdzhh8o2j5c/wDAip/CgD6B+PV43w7+Aen+H9OnjiuJ1jsCBwWTaTIVH1H/AI9XxZX0T+2nrv2zxto+jLjbp9q0pIPVpSOPwCD86+dqAPRPg54vvPB3iO3eWWeLSL9vKnUD5W5xn6ivpzxin2XVIrHTWWaR4RLFNK2TJkc5+lfOHg/SYrvQkVUt5dQgXzoZJGJCd+le2+F9Xurnwbpp121i1GdD5azxAhox05NAFnQ9Rmmvv7MluIns05nRVAAf2NdhDfW1xbC1ismW5J2lpyp+XtiuPSysLIXcFtGTbyEOxByVJ7+taNpZvYQfa7SaecTDa08kZwgoA6zS44RZ3Vhd3dv9jwXkWXop9Aa5268XhrO4gk8+azi/dRKkfyfVW7/Ss17yRobm1vbxDMf9U7JgSL2rW0yO7vksoorcTInBt1X5V/26AK+n210l7b6hp9vFCUTblxiXn3auuaaSKzhvbXUsvFnzYx1OeorH1C1KagjTH7Tc7vmjLbQuPamQ30LpqEH2SUTqMoYMFF+poA56SbUI9SuLuRfLtZ87AWwp9ciodBWG6vhbxu0VizZkRly7H/ZNLqIvWK7li+yP/rZJD/6DVuw06FtQt765vVhihx5eeAx7DigDtIoLPSgZ7OKdN6hBAw3s3+8a4zX9QNh4+s7fUrjTkSWP5I9ozFn1Y9K6eO9vNO1D7aYTHLcMAIMFg/8AtCsX4n6Bc+K7Z9Euo7OWa+ZZkmRNssWPf+lAHY2cYj0i9hngtrZ7bMkMscigTHqM46ivKZZRLPeXusQLIJzsjSM5CH1xXe2ekWukeCdN0u2jW/XSQFmkuH+ZiP4a4++sbHUvELTXFm1rbSLhkt5Mk/hQBl6zYwto1pbXgke7hkMiop2fIeh966zTdSuYdDkjlleWCRAvlJHhkH9a5rU7q9XVIvs7SfZbYCOIzR5BUds+orY1CGObTblv7SnWeWPPmQ4IH+yAOlAFGe4ubWfzIWEETEKIh85ce/pVjUImt9SWfTLaSCOBQ4ggcbTkZOefXNYd5ObaG1+z2xujGvzoCRI59av2X2SzhllaSaxvZVzJ5h3PHntigDV0TxJOt/FJp9q3lTNun4OEI7nPBrZ1vxHFqekG8fUH2rL5cj/ZyI1HoDXnl7aXuqaYxt76eYwt8uxSrsvf5RyRUt9YXcOjpYrdmKwlXzJIcHJI74NAHQ6v4otmlhtLmN7ryk+W6P8Aq1T3FcSfFeo6p9otoHNvpVoxCyb9hyf7vr9KebGe4u7K71G9jhtHj2AHhXUdNw9aq6ldfYLr7PYrbzwTfc8hN43ev5UAdD4Tk1GwurOaEkKXwkz8b8+7YFeQftE+G7TQ/GTPaXpuJ7wedcISpCuefvA/pXvnw/8ADk3iTURPqN1dSWtmgcwOmEd/QVlfHLwLdap4C1HU7Dw3HpV1bt5syoRPLcoO/wAucetAHb/s3a+vin4OafbzxDfYRHTnXqGVBhfzXFfDniyxbTPFGrWTxeUYLqWPZ/dAYjFfR/7FmreTf67o9zOEadVuIYS4ySOGwvUcYrxn486F/wAI78WvEdiJTKGuPtIY+koEmPw34/CgDgKKKKANCur+F+lPqvjKzVRmKA+Y57DFcttypPpXpPwjWLT7TVNVnlMSlfKXuDQBU+IFy/iLx/DYWxyscixcDtmvtHwXov8AY3gQ26RhZGt2OP8AgNfI/wAENFl8SfEeS9lQNFHJuyO/OP5V90RRrHCkYHyqoXHtQB8E61ve/uURsMkrbvrmodL16TSr3bFI5J4IPQ19BfFP4S6Gb+XVY9SfTTNlmUrlSe+OleFeI9J0+AbdPvjeLnblY9pJ+tAHY2F7pWvW+JrdVuFGSx71y3iHTY0uHkgf93niqWhSNZ6mArodoyynvXYR3Gk6/aywJutbw8KrHgmgDz0R+fcIkC/Nnlq3ba1kDFJWBTHNXbrw5qWg2fnXVpsiZ9ol3bgc1m2kkkksgY5NAFiaMvEGcYVTgVjTOLu8ESDcEPX0roNT8i2sFBdnYjPymubjKROzoSu4jdQB2Vqu6GKGEb2A59qnmSQTiB0aKFV5l9ayo9Te1McXysWXO+NeQPerbXtzPbGMnET8B5OB+FAHo/wsga61u2klf7PbqDGJD/FisTxxH9m12/WIkIZfvf3hmui+EtreTS2lxNGz6fBMIi4GVJP9a6r4ieFfDC3bvqmvJp7yfOImALfhz60AeNz6zDp3hu/Msm0TOEihHJY1h+J45BaWqvHskjh+eumv/DemWl5/aY1e21SFOIYlXaB6EjJrifE2o4ZhLIWm6MM5AoAwNOUopeKUDJ6H1rsNLvr65igdJWJB24fpXOWaWotRO5XcvKr711OgmO7hsohKqxmTLcYxQBV8ftbLMkMKjftBb6964mzjke4AkYqmegJ5rp/GMEk17cGBgXRtv4Vd+HvhLUtV1BPIjcIpyxk+6aAJ9A+Guv62BNpemy3FuTyzTYGPxrorb4OeM3vhFHpkEEbfKZppgQorsb/4hXHgq3+waY0Es4+QoRuCn14rnLf4n/EC51SNYr1TFu3bfsfykemaAPXPAvwntvDgt557vz7xBlmVcAH29q8W+Pukz23iS7kuLyO1mkXMbwdXX0avoPwJ4yj13SppNT2QXcTbJEAI3e4rx/4uaSy32pa/9lMdtMnlBbv5gR/eUdjQB5n8K4Ptlrd21vaqpkQ/vx/H9a8s12BrXW7+BwoaOUghen4V7F8OlXR7cvDch9NcMFkUZyx7V5L4oQL4k1D5Su6QnB7UAc/df6wfSvrv9jDws9l4c1TxHcRyRtfSCCHcuA0aclh6jcSPwNfIt1/rB9K+6/g832L9meym80/Lpl1IGJxt5kOBQB8e/F69lv8A4meI55rj7QTeOocNuGAcAA1yHaldizFmJLE5JPevoG/+FGgWugafbxvK9zNbrdtfNnJJXOwIO3NAHEeGPB/ja20iDU7Apa2t2u2MSyqGZfUL1rt9N0TxQPCltbz+JLy0QyZMcVsQCP8AeIGa6rw9pp/4R+xuLu2SR4CY4nafBAHoO1XksrlpW+2Q3U0QO1laUHA9cCgBYdHtWMcw1e4SKKLbNHM65mb1GDXoGjwWFtp8Fp589zb3A4iDZx9a5vQtOslvS2lw2yxxKfMdgWf6YPGK2LHSI59Xa8bVYlEA8wRngcduKAKmsW0Gm3UgnjjVVXEcO07wO3J4qt4VvLi+uZGsb/8Asq5iyF3oSZh/d9KTxBqNvrWiX14yuxE2wM52sMH+HPUU4SWg06C7g82G5hUBYtmfN4oAurfx3MFw9paGbU43InmuH2qfcVBpMV9odnc3BtS0dyCBJMfkkJ7Lj+tZM2ovqlwTBaq6IuZsNtKfWtWWKHSNOnspNTaSzlTdaQhi4RiMnn65oAwrBk/ti1S+uvNtw582xRgSpPSvQNY8N28sYiWeG0kkXMKFgQPQH3rlfCGly2+nbrFZI7+V8vPPDu4Hoa6+1t3i1OKezctdMuySK5wVYnjK+lAHP7b6PVtPe4tc3dqvlqBMCn41u+INUmtbjw2W08200118+znK45OazvCekr/wkN/b6jOILqGQyIN+TL35HatW6ntLxra81LUHkntp8w2scfAx/CaAM/xTI0N1rNlozBEnYNOxOVGeuB1zWRa29nqUltcXCyWdxbDy18tGAk9zkUni27+yTT+IJrDyZZJAiw+Zjf8A/XpdJ83WdPubi0Jt7rIIjlPyj8aAG3em3VsL2Oyu0dVzI4cZGD1rE8O6XYJpd1JosMtqjkmeady/zeqjsK6i90hre9jW+njTdEGIifO5sdDXNWraoseqNaQLDDACSr8KwoAyJ7hb3UFmS4dDbrskHA80+2K3NC0lWWXXIbaS/vI/9ZaXx2R+2G78VT+xWOn2djLBFG19cPmRncACugu7+W6i8ucRxQ2pCupyC2fbvQBW067u7rUHnjt7W3jZT5lmhJIHsw6Cqtlqnh6GedL8yRXAPDq29QPStOztr9ppLGK4EVvcoZVudgQRqOqkn1zUuheBLHXC+BC2w/NPEwIJ9xQBRD+D55Y21WXdbHJRYT5hYe6rnFPt9N8P3envcaXqttFCcxxW3l4mUnvt69K6m++FllKI/JuDZRxxnL2kY3uawR8LkfT47zwxqs1xOMhmuAFcn0B7H60AUfCeia74dvfJ0O5vtTtM7pc4jIJ9mwcV0uj3sWqaT4gV9RnvNbmiaKS3nJjjjA/hTjGa5/SPh74mXStRjluruC6aTKyG4G9v91gcYp+l3epeDvDN3Mto2o3yymMW0QEjg4+8zd6APFPglqS6Z8dtKFtpkguZnmsZ0LjEYPG8fQDn1rJ/avgMXxr1d9+7zobd8Y6fulGP0qbwPfXWmeK4/Ed3phhuB4gjS5vGyBArNyh7c9K6n9tm2RfGGgXSQ4MtiVaULw+HOBnuQD+WKAPm+iiigDTJODjpjmvUbKWDT/hDdRYQy3JyCevPQg15d1AGcA8V6b40tI9P+Gmk/ZZFYTkCQHt6UAek/sqaUBplze2au0oYtIx6KQOg/KvRpfiXc6Jr3l6qc2Ltgs3JWud/ZSSSLw3MIrVvLjbEjbhySK3vjf8ADK78SQRXnh+MCccyQg4z9KAN34w6HdeNvBMUnhqWOeZGEqBW++MdPr7V81WHw/8AE9zNLHNpd7AyEnd5LAZ9vWnx3fjTwDOVNxfaVhsBXyyn354rYT4r+PblMQ61mNRlnSBc4/OgDj9Z8PXmj/LLHLHKD/rHBDE/SsOSS6iut0odT1PYn6V6vYfEW41lktvHdtb31ox2iZU2OPxFdDq/gb4eSpHc23idtNluADHFL8+z2oA8lstdu57QxXEsxtxyscrZ59afblkhedwBu6c12Hjj4dXnhy0guEv7fUrGVflmiGDk9OK4TSybh3t5MjYcUAOvpGkjUeYEP0zmmWA8y5CsUbsAeAaZfx7JhGoO31pVh5QE/d5VhQB2GnaZHJFtVkjBPzOeqj2rSVNA0i7tpbvztZjQ/wCq+6K4gapdDaHUb1+UAHt61La3c7t8xVyH9aAPp/4cePdE1vSZ7S100aU1tJhLbIw/PUEd68Y+PUdw3jrUGuNxjkiV4nYfc6cYqj4cupLO4+1t+7ZZV24OAOepr23x/wCBx4ma11W71O3sVNqoeRhx0B6UAfJxvdUZ9tjHGqjggmq4icvuvDuc8kV7FN4f+H2kWsqSX9xqt2rH5ovlUn0rgPE99Zx3GLKzMCyfcjY5Kj60AY9ssLEheFA9K2bSQ21tFkiM7srgVQtrKX7IZJlChjgEdver6aYI7El5md2+5IOgoAS3H2vVgw3M7OCwxwRXttzr0Vp4Sa209YLSZF5mbAJ+leF6VcPp5ImBBB++a1rzWlv7ZbW6BkhPcdqACy1eIa4tzOsMt0rhjvGRJg/yNe8+D/i9oWpTW1jd6OLORmEKlFVk3e3tXiHh/wAMy6xqa28QjRAP9cT0WvZ/Dfw98O+E7OHXNUuWufJbdEgPBagD2K1sbGJ3e2t4Edj8xVQK8y/aHt2m8JOWgLxAFd2eATWzoXjf+0tW8q2hVjNgCIHkAd81R/aBd1+HtwdmBnLEnpQB8xfDBzbafc6fI4MMMhLylcqD6AVw/joL/wAJResnKs3B/Cu18D3st3YFbWJDGWPnMK4DxSgTxDeqG3Yk59uKAMC8/wBYo/2a+vIppI/2Kd6uyt9gK5U4OPtWMflxXyFd/wCsH0r648O79f8A2NLuz09Ge4traSNl9Sk/mHH/AAE0AfIryvJCiMw2R52j69a+gPB/xNgPhGxu/ENv9qvdPPkJMhx5cWMAsvftXhFrHGlvJczxI8eDGqlyCX9ePSq8E8sG7ynK7hhgOhGc8/lQB9YfDbxD4d8YXdxYQLOlwcsbhkxGPwreuPDcVnrEv9lKbueJsSTPOVLfRa+ffBzeOYYF1vQ7BYrNwIhKU2xk9M17T4Ct9VtL4Q+J7lbu/gHmvcwc4z0XPQ0Ad7bfb7eWENC8Vi3E8k0QTH496xUg+26nqDtp88lvGP8ARp4ZAA59xXXS6nJfxNBdRTXEYUyM8jDag/ukD+dY0MVpLcrcWVqSo42QSHavvigDi/EF6yWsFjNpdxvyHLjkA1tR392LCO7htlO1fKjjkOMN61N4ggh0+d4YiZ7q85RXc/uias6XpelSG1je8868jP8ApX3sgew6ZoAoW+lS2yDUdRWBrWfmdIGwRTpjBexJbadEbMnO2WT7ijsea2r7RAmpPb2N6G0uRcyW8i/vCfY0/wAWaXYjw/ZSzMTDG2025OD7HNADdJtL2HTVt01FSynD3L52sPbtVjTytrqRXFw5XG253DYfXrWjawRL4cGn3ySpFMm5Jo2GUX0xWSZbrTNNWG1s8wnIgNxzv/8A10AOvNbni8Q26WMVtJbyybWuXwD/AN9VL4vujB4auRZo7Pb3i/vowDgn6da5G4tri8t7Z7rT4bWRLncUcttAz/DjrXReM9YOieGkZIpYnvrqOOBRgAnPXBoAZ40gNzBbWxkSQiAT3CyL9wYySPeuY0gLPYXNul4Wg3DZvUoPz712Xibw+b7VHiAlGoyW6bJJ5h5cjY+7xismaNtK1G20/UJIrVXwGgjw67vUE0AaOj6TcW97icQzQJGH82XOG/2RXPT3Nx/aN8dH0ZxIeNruSD6lQeK9A1/w5JqdlbvbahJerb/N5YcLj6BcfrXMxard21rIVtfOkU7TIOCB7igDJTSdH1PUYomNzbso3ZnwAX9BXQaVYSSavLFrtjidoS8G2ZdrbRx/KrEohltoGhiguJLj/lljmP3zVbxBpyiS1+zahYxWdumL6QAtIo9Ac0Ac1qOqteacC1tcQzRy+XLj5l2Z5FagutN0ywlbTY5YklQKYwSufWqupW+mwx2sXhzWTbadKd7GbJLY69aw7zWr3U9Wkk07T4riC1GwozEGYeowaAJtfv77TDaT6fq99GAR5cInOQD1Ue1dLZ/EyHQI7mO/8mMeUGhWR+ZJO+T+deUavf3PiS98mOV4JIGKGDyseWPRT3Ndh8Nvh1Y2tosl/F9uu5Jt0Ud428D656GgDpv+Fk2+rqq65Hp8+i3i7Fgt2Zpw3uPSuf8AFulR6Poeow2q3zWMB+0oQ7IyqeQrN1Ira1fwfc23iGG8kt9LsrQyAQzqyptPpijxnrZv4tU0ie5giSK2JuL1jtW4AH3VzxQB4N4EaLXPC9+J7hkW58R2m21JLCTLjuetdp+25dBb/wAMWKqAqQySjH1x/SuX+DOnWMug6dLcXX2W8ufE1qbCJhneqsN2PXFav7bZH/CceHxnkacTj/tq1AHzjRRRQBpk4weOa9M8bIl38PtMuLVvlRV3qOgIrzInKgV3vh+4N94JvrNhs8tMKTyGPb6UAfQH7K7MdHMm8mG6XcU7Ajj+lfQtfIn7KWuTQ31zpcsw3xfNFHjO4en519aW00ktssjwskh6oeo5oAz/ABO+kxac0mtwwS2wP3ZUDAn8a8C1+68CPdzMmmtHluFtm25/Krv7QXiSR9cXS48iCBRvycAk15Ro4srq7liE2bjqg7A/WgCbWYdIleaPT7OeKPOR5shOKyHtfKljd1aZMggnmtu6YCSRWCnjGMZqCCYmFiAixRjp/SgCfU9evNRgjSKQpDGm0R54/Kua0wPDeOzHLE1rSW0VyRPbB43x88bDB+tZko8qTfEOB3oAteIISWaQLtDqMAVnWyyKUZSNmMMG5q3dym5NthmIHUY61JYwLK7hVPBzg9PzoAs2UlpZS/aLi3M24Y55C0ha3N3vjiCxnptGBSXFlv2J5nl55APSoIo7qKZhlHRcYHQmgDWsftFxaSAws8RnVTjrjNex/FWe7ig0zSrabbbJZI+xzkscDpXmHhq1vpI9UgWKZ2SNZum3aM8GvVPiVYqvhnQL2WQi+NuBubnjaOP1oA+etSSS1eZQjgE54HANYUcclw4MzMz78gk9q9g8qIaYWv2jJkBIyvNeXzzIl7cSRjYFYqqkfrQB2GmW1klkW1J5EUjIA5BrOkvoZLwW9qzC06DK8Vk3WrXF+lvZ2+HJGGfOMUkdpLFKITO5ZOSMYoA2724tG+RpVbHGNlU7GwkvrxIIQ6Rsc5VKmuPD93ewAwQSb1Xc205IFdj8L7SeTcIi5m6bH6kj+VAG9od7pvhaxWSS0Erjg7jj9KzvFXxEm1K18hII4oR9xFGAfwrM8Z6Rq6Xchu7KVYmyemVH41zOnaet1qlpZbWeZjlRntQB6b8AGu7vxZNPDuaJV/e5HC/jWp+0dq9ybG/sJB5VvHFuAJ/1v0q5YeJ7DwVpQ0nR4kjnb95cTHkhj2rxH42eI77xG8Nxdz74ZD5dvGp5BB6k0AZ/gTavhrNpIsUy7vNj6FhXm2pMG1K6ZScGQ9Tk16guk/2T4Ia9uJT5rrhdqY/WvJidxJ55JPNAFS6/1g+lfXP7L+p2+o/BDxLoqyKb2A3OYgfm2PENpx9QR+FfI11/rB9K9p/ZF19NJ+KS6fKhZdVt2t1OejL84/RTQB5DZQvNOkDQF/s5aR1X7xAxkfp/OquzMyOU/du/Az79K9U8daKng7466hDqgENs87XMRi+7sfJU49OvFeXXU7fb5pI3ziVnUgcdeuKAPtHwjcQT/Cm1/sZY7m3AEctts+aJvUmucubvU9OH2cWpS23fvPLH7xvxrjvgr4v1q1s4LSeFZ9IaUfadg2lhn17mvc08R6VFd3Udno0jtkeUk5wenYHrQByS6pf6fHFJYeH9SnS4IFxNNJhCnoBWzpssl7LG81m+n2QYCGG2OHLerE8YrVN5Le6nbtqUktudh2Wrjbk9uKpajrELwXs15vtHthtFsFwH9waAM/UoFsdWuVvbeUyq+9JEbcST71esYbdZ5R9raK8YBlkZAEcHtn1rmL7xBH5On3Fzd+RA42+UyYYg9Mmuo03xBpiWEdtJaXMjKchZIyVbPcGgDtRCbcLI8sVzIEyWjTgf1Ncz4ss4tShhkbz5n3jzYApXYPUmth764GmiW1gjkt4huEu8KsftnvTvFS3Op+HoLaweW3mmIacE8unfB70AYa3j2moY02CG9soYgJcsx259Dmk0HVDqWoi2uw0sa7jHETgL7ZNZ7QT2Os29jpF0BYqmXhZOZW9Cah1S7S9k23kQspYM/wCjom2RgO4oAvx/b1sXjnilWd7nMUTlWVFz24q54yni1rw0uTDNd6bdxECNA8nBHQVk+GfEeh3VvIG87EeVQySfOD9KxPFWn36eFrfVPBepSafrUV6PtBMYkd4yfQjp0NAHpmvajFDr0XnWrKklqB5zqMAnoDnp9a4Dxzq7Xmp2yRW+nPGmFBiJLr7k5rpPHerC3mja5hSQNaozOWOZjjkBB0rNs/Daf2euurdWGnWzDlXjyV9ue9AD7e2u/wDhIreHQL5YFaBGnuwSwz3UjNSeK1httR2pIk4dQJpIiVyfwPFXvC8Ogym6to9aa6mZTI7wR7MexrA8YSwWmiC7iuc25lMQVItrnH96gCq2vTRRzX2nW8dqkBCBc72k/Oo9Ye5IhkkuVtTfMGe2wvA/Lv1ql4KW11vXzBAy291Kp2xMcq+P611aeAGvry5iv4ZBKW+e6DZWPjjH4YoA5KXTZL7Vjpkoe5tWHyMuFaL9Oa1l8J/8IhpVxqs+otKz5SABcMvsRXVaH4P/ALFvXvbjV4761tULfd2uv41W8ZeH38c6Zpq6ddyvC0u9mSTDRY/veooA830fV7q182R1tb1ZAQ8cajzof9sn1rtfDlla6lowM+oyWQ37lkkyJJTjpnNZureG/wDhH/N0ubS3kuLo4/tG0Bzs9WHrXL+Kp/FGl6KNN06/tp7G2Ikt5po/n3/3SaAOn1Cy06HxFDeXesi8jihK/wBm3Cblz6/WodYu9N1H4da/aXkELBELbplwYl9VJrB0bT5NeazvNYuQL1gGnERxtx6+lT/tCana6V8OkgvI4otXumEcUMZ4MX95vWgDD+EupaP4w8bfD/Q9EspUtvDMMl3PdSc+bJt4GO3zd64j9rLWE1T4vXkETB47CCK3BB4zt3MPwLEfhXt/7Lng+38JfD648W6t5cN3qcRnMshAWK3HK/QH735V8ieNNWk13xbq+pzSLK91dSSb1GAQWOMD0xigDGopKKANMYyueldV8P5llv5tLuHKwXS9vUVyVT2crQXUMsblGRwQwOMUAdp4KmuvCnxDjhd5LQtIV8zHO3OQa+8fDGovqWmxytG4XaAsjjBk464r4X+ISzX2n6frMXlyeWFDSxtk5FfSv7O3ju28R6QllPcs1/BHgo7dAMdKALXxk+F9z4maTUdHlH2vb80LfxkelfOGoaRfaTdNFfW8ljPEcMdpG419jax4vt7R5YYY2kkUfeUjj3xXmni7V4L+1Z9aso7u2BzHc7drIfcd6APAfNngAV5CyP3xXe/DrQxe3K3l2yrp9kPMZXH+sb+tZvi60Rp0ks0VbUjIIHSsrS9dvLECGORpIz8u31oA2/FOo3ur61NNPaR26MdkCQJjKe/vXLXdoI5mRtwH8Skc12dhPc28sNxcRhgzcbucVkeLZWe+lkQoDKPvYoAwfIbywVYrgHAxWx4NhRm3SrKXyflPAP1rPF4k0YS5Xy3UYBHel0y/utLvS/EkMnGW7UAdlqfia808JHbTWvlKDmOWEMB+NZEvi+zljf7TptibhwNrRqRmuf8AE2txy2TJt5ZsHaKseHF8P3FpHBfXdxHdfwhEUgfjigD07wD4mV4tftWgj8ya0GJB/CBng16J4ns/7S8DaBdJJA3lRgfvG+Vsrj+lef8AgLT9KW31qKLKH7KdjOQS7VpeNvFNrong3w5pMqpJc+WXkiPTAzQBwmu+A/Euo+VdWkSXFmMnLSbQB7V5vc6Q1pP5L/63JUruyc+gPevbPDmrabrH2a3ury7s0uDiMR7iiVN4rg+GvhmWS6vbq41bVypSCCEH5GxwcAcfU0AeD6U0+i60kUsYWRT5irIOfyr1m00fQtUtv7SXU2hncf6TFImAPpXleu3s2oatHcbdjxtknGWx2BrqLu78/SYogoy4+Y45oAu6L4ifw1rq3NtcC7hjkw6v910z0H4V7dpl14e8U3cU/h62a3vZgC+35QPWvCvD3gTWtflS2061ZxkFpGGFUV7hp9ppPwn0R7q6uBeau6hBEpHyn6UAT/HK21G38KWkFkjtZpxNIoy34+1eD+FJLu1u55IlRp+kUrdFr2Dwz8Qde1i/m8q3bUIRxLamMYwfwrr9T8A6HqUMGoXkZ0zcN8kUYCqDQB86anJdqJZp2V2fIkwc59cVy9lEdUvo7eyhSW0jfLFzyprsPitPZRajNpegkvPu2I3oPWpvDWgWXhnSJbxi0s8UfmShujE0AcX8VL6ezht9H+1o6BQWjjOdvsa8yPBrU8SX/wDamtXV2VKtIxAUVlnqaAKl1/rB9K1vBOty+G/F2kaxDK0TWlykjMoydmcMMe6kism6/wBYPpUVAH1F+154ch1fTNB8eaKoktZohBczBjkow3RHHb+MH6ivmW4kilt4iFCSoNjYH3h619efs5+IbD4i/CzUfAuuvuurOEwjftJeBs7WUdSUPXjjK8818ua5pN14S8R6ppl/E0d7ZSNFskAIYZwD+IIPFAHpnwB1AalrWneGrmNo5AzyxknHmZ5xivc/El1pOl6oJ7eO4vr2I4KdTGR6V8m6Dd+J5fEOnazpLMdUtyn2Zl2qSF6DHQjtX2Bpt/ay+B7LWdf0+NfEk+DIq8bnzzj2oA42/wDEWu6xrUd1ZwE3CDG2VcsE74pkDzRXFzc3E1xcM/D28q5K/St7/hJIIdfke/s3s40TKSxpyp/rVK619tSv3utC0q8S2xtneSPiT/a9qAK+r3H27SITem0uIYj+7tyoDoO2fetnwxaLNYx3lzPdeRI/kmMH5Yx61V0I6LYH7XGGnvQ5abcuQAe3NbzX1tfaFqsGlac6yyrvVt+EQe1AF+60h7e3t9PijW90xn3mEy7d1SXt/P8A2nY/OFjuHEMYTnyUHGKqgf27pGlbpbW1khj24Eh3MwHtViHS57Dw1FfafHJLdvLsMcpG3GevtQBveJ4LK3TdYnZqUC/unGCAfVq5nw/cwXMV3ca5ew/2snIujHjAHYZqLUHu7nVvs+oiG0l2hiytkuF/hH51ka1p9p4glbUb2O4js4yEAi4ZCO5HegDb1DSbXV7VtQ0yezNxOVXN5CIEBHUgirfiZz4asr/VkhjnZkjhkS2bKpnHJ71x98up3FvOsGpQXtjCo8uG6XYwx6V1181tJoQXUF+yXupW4VyOkuMYx2FAG7q15pWn6DYXeoWkd5eSRDyQq/Mxxnqe1eT/ABE8aXusWMOlRaQI4h88giHKntmvQ/FeqaL4e0zw9per6TdarJNGIonhXKqAMElsjFYdv4v8KWAuGtfDbwXhO0xTMN0n05OaAPJ9A1C5uTFpxa6Rnbc6258uQ/U1qeK9ZudEsU02CTeblxhbxw2D7mo/E9zc6prP23VQun4YG2it49mF9CRzVqREutWs/s9pFK7kL5kg37B680AaXhq6vNFmOo6bp5e4UBrt/L3pGfRTXqvjeDWNc8K2N7pF7/ZbZE06NkF19K0/Ddna6F4XllmXNuAZZAFzux1OK42+8ZaL4v0y60/Vbl9FdW32txuxux0OP6GgDir/AMWrBrE1m9xcR2xjxMdnysaboHiG9bVkn8NW1++nRDEnlrgNXaTeFtN/4QFtU1C5+0XaqX+0qB+/Azhce9eWfD7xRr0cGp3bK8eg7yq2ca4aMf3s9aAOol8aeLH8SSJHpskdkV+/M/Qe9RN/wkPiCV0ltNPksmOECgqY3z98muz8HeNPDeraX9gurRTdMSgQ9Zh/eJPetSK00678+1lkNrplv+8VEO2UsP4c9xQBm+GNIi0zUX0u0tob6S5g/wBNvFX5Ymx0zXz9run3fxe+NcGh2s3n2Fiximuoh8qwqfmb09h6mvQ/jZ8SYNG8ENbeHA9hLqDGPy3BEjqOC+R0rrf2YPAT+CvA8urawixanqgE8m8ANDCBlVJ/8eNAGh+0Hrdh4J+D1zYWsEaR3ES6faW4HyhcYxj0CivgevV/2h/iQ3j/AMYstmXXRtPLQ2yFshznmT8e3tivKKACiiigDQpy88YptKuAeaAOy8FXkd3YXWhTkkzAm3GOh9Kj8O3+peBvEY83dbyONrEHtXMWl1NaXMNzbuUnhOUNeoro+n+OdEnvEunOvKgwjDC5780AeqafeDxBpmj6rotw7PG/lTgH7ze9dX4gs7iTw5Fd6raLBHC/zEEESV85/D/xXc+EppdMvovLRWLSKzYGfUV6H4l1258QaRawafeTpbn5ysjcE0ATvqug3ck1hc74pJB+4K8gH3rl2bTdImead/td1AdoVOF+tc9LBKJXzP5bIflBGd340xEEN1HJMxXPBQ8/nQB3ehXmp65qEFtBJbbLlgFL8CP61qeO7XStFae0kuoLq5iT5hAdwVvrU2i2+k6b4LupNGQy30vJkYfc+leVzK8s7OFdIznzA33pDQBb0eL7Zulkf92OQpHWrcgTy28qPOP7xq3pts84SWKERR4x8xwKsNJas4iuYynVQw6E0AQaJb6ZqTJb3NxFAxBB3Lnms7XvC8mh+bIGje2xkSRMcVDfaadNuyyKd3XD8ZHtW7omtGPT5IdWh3WcoKqMbiKANLwJf+UsyOw8p7XOAefrVj4lvp91H4buI53ecRFGcjp14ruvhz8MrK8W38Qx6iJ9Pe2dRboOc+/+FReB/All8QfBMcuoJLZXVlqE0SOOuxWI5H0NAHjml6rqdjDPZ6PNKxkchhFGZMD69qyryS9R42dpEeQEPLIPmP8AhX0Zq11pHgHTW8P+EYITfZzPcSIGbJ/rXhPiBb3Udan+0DfcyNuChcD8BQBmx6ZKbYMkcjhesq8nHvXT+A/Fln4akuTqukLqcQX5fMHStvwFLNZWrJdQIUPyNuGR9PrXX+OPhvLrmnW2peD7ZJHxtkhLBcmgDb+EnxJ/trVbjR5NNFkrxmS3aJfboa88+IN7e3d9L8sbkSsrs3Xg16l8Ifh/c+DIZdQ1XZLrV2NiQI2ViX0zU/jzwz4fs7j+0pkPnbzI6lvkLH1oA8o8HzeI9Hvln04vaKy5LSp8rj8etbnjX4x3L6edNitvMkA2zzKO/sK5rx38RJtRuFsIowtrCu1I0GBntzXIeH9Hu9R1Ha7mO7mOUWTsPb1oAk8O6FceIdaGo3M7ytvyqKMMo9TVn4u+IkisV0nT5D8i4lYYz+Ndp4i/s/wppSrMxtdW2YlnhIJZfpXzv4n1SPUtQkeBWCg8yE8ye5FAGSD82cnI6Uw9aDRQBUuv9YPpUNTXX+sH0qGgDu/gp4x/4Qb4h6bqshAtGP2e6J7RORk/hgH8K+k/2n/hxL4o0i18Y+GIxc39pDmaNAD59uVJ3r6leuPQn0r4xr6y/ZQ+Ksb2a+DfEFy3nocadI4J3KesZPbHUZ96APMPhTAPFGgSaRbKRrelubyFlIV2jXlgB1OPSvodpLK6udFt7uzEt9IgMbh8JGR/eFeYftC/DXU/BfihfH3gmNorTzRNcRwKf9Gkzktgf8s27joPxrpPAHjfS/iFZyywWsNpr0KDzLcSAFj/AHox1I9fSgC3fanq/wDwkmoWd14cub6GKQKJLdl2H35Oa77wzdam5+yandWVouP3cJxwvofeuJM/iNFNktt5TO25LtW+UgdVZugNVon1rSdYZW0mICdMSTzyZVv909KAOt8YacgmklNpHBDEPl8ojbOOx49a4G1u555wtrbm3klPlGAMcbPWr1l/bUceppA6XGn7DuMr/Nb+yj2qh4KkvNNSK8uIo9UiExCgsBIc8dPSgDWl0hIdSsrBkuLVwuY7yNS0ZY9q6mXTv7E023sb/U5rnU2k8wBG/dEds1BHqEsOqf2Pb3JkslH2qWLG5k/2Qag8MhNR1Frq5tZ4YEZvmnPOMmgBNaR3mjvLdo5NRgyyRRNuI9c1j6d8QDqJksUtRHdTSBJVZeQc9QKsa2bFNQF1pJZZRMA/lfMW+tP1CO3m1q2l0+1WLUiRiQL8pPqfegDorW/00XklvfR2l0EULKJV2ODVXxbexJouvXug2ty99p1qPItpSGhbJHzDGeazLlIrS8uLC9YTXsy+ZJNKpGfYGooYbe61G+l09LuNF02TfbhxsmIHX6+1AHSa/qpk+GPhq91JLdnmjieYZwAduSFrn/hro9hqf27X5bdnjkJSKa64EH0rovghBF4k+E+jnXrFZGhlk2RzrnYVcgHFddrM1kumm2tprO3so22SKRjp2UDrQB5d4/trPQorOO2dtQW5yZZTg7M+lcDoF3faVqmNKujcckoGjLYP+16Ctr4iz3epym08PXSXlvbS5S5CbTGx6oV9q7vwVqWkeFdKZb+xK6rLEHnkK/60e1AFTwZ481K2s75/EAtntNpZZgdq/ka4eWwgaO71zUFW+iv5fLgjHQZ4GzFer654S0DxP4eXU9IQ/Z5Yy3lwqSGGOm0dwe1aHgYW/hv4d6aNXxtiZlXMJU8u20bSMg49aAOY+KsNz4d+GWjWmmFo4oZYzKGQtxjJB/E1D8M9VtLi/a0mtLYw3yY3oMqeOmO1N1/4iahY6tqix232m2m2i3trkArgDBxj1ri9LTVbzxbb32l2yWNzjebWJuB7gUAa/wARPCGhS+I0jFtqdibFvMTyTzMeuVx/D9atS6rbeG/D154n1u8gnljhMcNtISF6cA+r5xWh4w+IXhzwtBb3fjFmvNTaMiO3TG4H0wO3vXl/w3+HmufF3Vm13xOJNP8ABxuDPDZKSvndcbPbsW79qALfwI8Eaj8RvFY8b+L4mXSbR82Nq6fJM3UbQf4F4+prrv2qvidBoXh6bwpo9wp1a9XZdBDgwQkfzYfpXffE3xdo/wAJ/h4UsvJtZ47c2+l2YGcuFwvH90HBJr4D1/Wb7xBrF1qmrXDXF7cuZJJG7k/yHtQBnUUUUAFFFFAGhRRRQAVq+HdaudC1GO7tXIAPzr2IrKpc0Ae2azpmleONMW/tVA1EoFMa8dO9c54Z8R3ng3Vjaa5ZfaLYcLv6KK4zw9rt7oVz59nIfm4Kk16Tps+k+MdLuYtU2rqW390Qec0Aeu/D+68G+I5jNp+grNdTDbJE5zt9xWf8VPhdFpUJ1Lw/++hTJmhY5KV4dpdzrvw61yCYMzW+7OAcKR9a9w0X4iQeNreWS3LW12o4GePpjvQBhfCq7s71pLOdgsUmUKD+Fj3p3ij4f6tpWpTw/Z2mtx++ilx2r0nwjotn5sdzLYtFeuSBLCoKsfU46Vs6zFrl78MNat2M8mpq7qSVw3l/7P4UAfNMkkwih/fSKNxBiB6monuJBP8ALGZCh4jbt71pPoV9aiGZkmwOjSIfm9qs3+mGSEXgia2niH70Adc9M0ANbWLeTSZItWsXnnBysy/we1UJrixYWk8ccvlKrAo3rWj4ZsYNa1EWcl9FZq2B5snQk17FpHwU0DSlj1TXtUlvLa3HmBFO2I988daAND4HwppfgtLi9u0slvgwtopnCjj+IZ+orjvgPqfiO8vfFWkafLbyaZaXkrm9U5Z3JPCitD9pjxLpGk+A7G0sYQbqdNtlInHlpjDY/ACvM/gdqb6Bp2m3sF2sdzc3JWOLP/Hx1GG/GgCDxlPqltqs66pcSWVxJOSJWU/MBV/weratB5wzcShti3WOtfTGj6hovi1Lm2u7S0lv7bat1ayqGMZOcde1ZXjDw/LBYpF4etrfTUjPDwxDH5CgDB8C+C477RJn1ENAyy7hxw2O5rU1vUY9A8OTCxS+h/eBRLDnHWofBWpazaWl1F4k1SyFspwkuMPn39qyvHnjbTPD86NqOqR3F0kRxFHjaV9cetAHW6tJJfQabFeXMlnaRRCeW4Z8SS8dBXiHxc+KdlqyjSrKLZbxEpGpPzyH3rzzxZ421PxpqwXRbq8VPu+acgKPTFS6f4QgsDFfajeKJ/vSTyHLH6CgCv4X8L6lqd+13qDMilh5cPdhXd6l4ii8K6ZLa3yQ2tyFO1ZR++x/s1xerfEm10gTW3hi1aZmQxvdz9QT3FeX6lqV5qk/nahcvcSf3nOaANTxJr0mp3crQzXLxSD5zMSWzWB29u1IT+FFACUUUUAVbr/WD6VDU11/rB9KhoAKvaJqt7omqW+o6XcPb3tu26KVOqmqNFAH3X8Bfi5YfEPQho+vyQjxBHGUmhkAC3SdNwzwc91ryf4y/CnU/ht4jHjTwJGx0mJjLLEvJtSeox1KHJ+lfOVrcTWlzHcWsskM8bBkkjYqykdwRX2X8Fvj9pniyO20DxgsNlqrx+UJ5CBBdHpjn7rH0PB7UAcX4H+MHm/ZLK9htV0XUDsuTI/ME5/oTXs1zaRi3i0i5j86Jl822uo23KorzP41/s/w/Zb3XfAbpaj/AF9xprNiFgOSyH+H1x09MVzXw0+OdqHtNL8WRzWVvbxeRDLZDPzerA8/lQB6O+i6jCl7/Z8iC3kY73c8yH0ottS0iS+todT0ee3vrZPkaI7Vz/eNW9Kv9Ou9Qs5bWfz4Jf3iOJRh2P8As1PqeljxD4ljMtpMZAdrhjsUD2oAxLyCOHxxYJHqCzS6ihVYIhtP51vGLT1uY7O7N+mpRlhK54jAycVxfiLVdD/4Sa2046ip1PT3/dSD92bf8T96m6r43m1bUm8O+FJbjVfE0rgy3igGGFRjJz0NAFvxA8ulW7xy3dolnNJtjli/1p/CtWWzt4vCltE2oT/Zy+TcxqfM57VsX1nYI9vP9nt9Q1q0RRctNgRq/bA6ZNUjeaxbC4GoQ2kc0/KWTAElT3UCgDKj0vVtMkW7hX7RbSDbbi4lDM31q1puq6DYSXzXGsRR38Fu5vLWNgzpx0UelLq2vx+G9P8A7TuIVu7O1jPlwOp3PIegUfWvlXxo13aavPf3Uka3+qo080CEhrbc2dp98UAfXf7Ld/cXPgW6hngmjtjeSy20kjfNJGzZzjqKk8YeGvE9x4sOyzE+hqQbZoGG9G7lhXN/s5a9cap4Gsby1024mvtJJsppBKFjkjPQkdyB6V7RovijR/FNncHQrtb1IpPJuBC5V4j3z3FAHjXjFLzQLqNn0p8RbdzEYErHvx1qG68P61q18b+0lj1QGISy2s+VEaD+Fe5r6KMasqqyhgOm7msTUI9Qt9WF1bLZpYBMSswwx9zQBxPwj1Fvtk0AgtIobpTIkVqxxDjqCD061N8YNe1G00GdNP8AKtXDYTzgC0x9FHUVe8LWNja+LNX1VJY/J8tR54wsb55OO3GKzfF/xV8MafIYZLUanqNud8Vqu0yE9iuaAMPw/wCFdTm0231XxXf29lpQQSyxsm2QH13HoK4rxn8WtP8ADzaj4a+HVhcatrVyu1dQTEuN3VQBySB/Ol1v/hbHxiDWcWnr4d8LXR5+0DawUf3v4m+gxXpfgHwD4U+DnhdtR1Ga2F9FGTdanKMFu+EB6D0AoA8z+EnwFvtXvYfEvxQLzuw3RabKSW9vM9B/s/nXpXxW+MXh/wCG+kw21gkN/qDAxwWduwCRgDq5HRQcDA5rxP4y/tF3Gu2cuk+CzLZ2chKy3Zykrp6D+7mvnJmLEliSTySaAOv+J3xB1j4ia4uo60Y0ESeXDBEMJGvt7+9cdRRQAUUUUAFFFFAGhRRRQAUUUUAKDU1ncyWtzHNA7RyochlPIqClHBzQB6ZpviGz8SWtvputskVjH90H7zt7mjWfB2r6PK+raBIIrbbu/dsSCPavM+AQR1HIrr/DnjzVdGBiknNzbbcLE/IFAHUeD/ixrOkanZJNdS2VmZB56EEh/wA+lfUPhP4taFrJKPcxgHAVh0/Gvlo6/wCHfE6J/adr/p5UiOKIbRu7ZrMh8O3Gl5NpeYvZGysUZysY96APvF20q8ijif7JNGfmRSFIz7CszxD4V8P6layJf20MQlG3evyGvjCz8SeM9JcWkfn3Cqd25D/KtV/i940aRIvImkWJSNsgyR9KAPW5vg4dH18JpupR3iT5dYLrC7APcV3OteIdO0PwwLDW3treG2ULMBKG6dhXyXe+PfFms3Cy3DStcJna5JTYPQVzd3capcidb+C4kkuG3M0zs35ZoA2Pi/41fxv4pkuol8uwtk8m1iH3QP7341sztpttpmgzaYGimjiDM+cqJBz+HNeeW+mX9ySttaTS4O0bR19QK7DTPD2uN4Ylijt2MpkxFA/3nPoKAOx8BfFdfC/jS/v9Xj3zX0IjuJozkHHQ1va7+0G9zpMtvCZJJFf9ztXHmL23GvOLbwlpkiINUvPsWpr/AMfFtMcFa054PCmmWgEzIZl+6QeDQAaz468V+JbMpZWy21tIu129D6iqUPhefU9tzq09xdXAwDJIcIB6fSq+peOrOEJFpduSiDv0J9653VfF+q6ivlvP5Mf9yLgUAdZPq9j4fgeKBIvO7YridV8Q3+pOTNIQvO3noKyXdpGLSMWb1JpD90UABbgYGPxpM0lFACmkoooAKKKKAKt1/rB9Khqa6/1g+lQ0AFFFFABRRRQB6x8P/jp4r8K28On3NwuraOGw9teAOSndQ555HrkV7z4V8E/Cj4raJ/a+h2A0/USCrxxTskltJ7pnafY4wa+Lqu6Tql7pF5Hd6bdTWtxGwZXicqcj6UAfQWqeDfHXwoNzOlh/b2moTNDf2+S1ufVl7fyrb8EfE7+2bSX7VqF5eXjkeaXUR7Pceo7VV8E/tUXSt9n8aaRFPE2F+0WXyMB3LISQfwxXqRtvhZ8TNONrpN5p8FxIu7Nky286Z7Yx6+xoA+a/jvc6Prmprf6LdSzzxOLeZDDtAb/e71Ssf7Z+HMFq9uDA95s+13ET7iqHkLx04Neu337OHiPSpp18LeJbeS0aUTLHeQgsWHTJwRn8KbcWvxisILqJ/Cei38ZXaz/ZUYyY4Bxn2oA6+zvtBsdX0e08QXVm0l3AtxDsdgcYyGf/AOvUGo6na67/AGv4gsdXh1Y6ZmGK4jXYsGeAMDk9a8q1+2+KEi22oXHhS4tSfkmkt7VGfA6ABgcCqPhrwn8Tri8vHj8P30EEg8xo1jSASEEEZGMEn6UAamk6drHia6vU1rXLuQ2ZE016oCw20XXhMcnFcn4ys/hm+s291pniHWL5I3/04XEXzXHP/LNuMf5xXrjWnj/xT4fvtFbwCumXrwYN7LN5SyDspx1NcLpn7MPje5KG9uNLtFk+/mUyMoz6Af1oA9v+HVje6R4Xtrz4ceFP7O065PmSWmo3TeZNnpICxOBiuzm0xE0yVZjpuhuzCW5ubNhG27uCRjn3Ncz4C+GHinw/p39map4+vrvTEULFFBCI3jHoHYsce1VdY/Z+8NX8hlk1rxDDJI++ZxfZ84/7W4EfligDpbvxDY+H9Tt5JPFdo9k8RzBdSh3lbtsI6V53rfxz1DVfES6R4R0Se4dNySxzRbllPs3YV6VH4Y8AeH7mG6uINJjuoI/LWW6lVmAHfDHr74rndc+OPw48P2k0tnfQXk0blRBYw/MzeucAY96APPrXwB8SfiK5OvXC+FdGibCWYXc0nqQARj6mu98L/CjwV8M7qbxDrGovc3CqNt1qsqkQ4HO3gf1NeS+Lv2qdVuPMi8LaRbWiHIWe6zI49wAQM/UGvAfE3inXPE9491r+qXd9KzFsTSEqp/2V6L9ABQB9YfEP9pzQ9LWW08IWzapdbSBcyZSFG+nVv0r5d8b+O/Efja+Nz4i1Ka5/uwg7Yk/3UHArl6KACiiigAooooAKKKKACiiigDQooooAKKKKACiiigAooooAcvB3KcMOhHWrttqN9AT9nvLhQRhiDzVEcUZOTzQB0dr4s1KGMRtIH29HPU1ei8azBhI1tEXxgseo+lcdnjFGTQB3j+NofskX7hZpgc/vFwBVafx5eyyo/wBktfl7Fa4zJpKAOx/4Tu/FwJo4YIiBgKi4H1rLuvE+rXToZL2SIo+9THwVNYeeMdqMnNAF3UtQu9SkaW/laaVsfOx5NVZDuIyDgdOcimAkcjrRmgBScim0UUAFFFFABRRRQAUUUUAFFFFAFW6/1g+lQ1Ndf6wfSoaACiiigAooooAKKKKACnxSPFIskTsjqcqynBB9QaZRQB6P4f8AjV4+0ORGt/EFxcRqu3yroCVSB9Rn9a9C039qvxTEYxqGjaRcIow5jEkbN/48QPyr52ooA+sV/aztjDFu8LSiXcPM/wBLBG3vj5etT3/7WOnBLgWHhu5ZwB5LS3AAY99wA4/OvkeigD6fP7WN8SgHhq2UY+Y/aC3PsMCud139p/xfebP7LtrGwABDfJ5m7356V4FRQB6Rq/xt+IeqxmO48S3McZOdsEaRY/FVB/WsW9+JHjG+00WF34i1GW2DbgGl+bP+91/WuRooAmubq4upDJdTyzSHq0jlifxNQ0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial brain MRI of child with Sturge-Weber syndrome demonstrating atrophy of the left hemisphere and contrast enhancement of the surface of the left hemisphere, particularly prominent over the occipital lobe. The left hemisphere is indicated by a white arrow in both images.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Bodensteiner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19843=[""].join("\n");
var outline_f19_24_19843=null;
var title_f19_24_19844="Colectomy for mid transverse colon cancer";
var content_f19_24_19844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colectomy for mid transverse colon cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 545px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depict the extent of a colectomy for a malignant lesion located in the mid transverse colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19844=[""].join("\n");
var outline_f19_24_19844=null;
var title_f19_24_19845="Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information";
var content_f19_24_19845=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?26/8/26757?source=see_link\">",
"    see \"Ovine polyvalent crotalidae North and South American snake antivenom: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/16/39171?source=see_link\">",
"    see \"Ovine polyvalent crotalidae North and South American snake antivenom: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6516314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CroFab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antivenin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/8/26757?source=see_link\">",
"      see \"Ovine polyvalent crotalidae North and South American snake antivenom: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Antivenom dosage is based on venom load and severity of symptoms and not on patient size; therefore, a reduced, weight-based antivenom dose in pediatric patients is",
"     <b>",
"      not",
"     </b>",
"     recommended (Behm, 2003; Lavonas, 2011a; Offerman, 2002). Clinicians are encouraged to contact their local poison control center or clinical toxicologist for consultation when treating any envenomed patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Crotalid envenomation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial dose: 4-6 vials as soon as possible and ideally within 6 hours of snakebite; monitor for 1 hour following infusion to determine if control of envenomation is achieved (arrest of local manifestations and normalization of coagulation studies and other systemic signs). If control is not achieved, repeat with  additional dose of 4-6 vials until initial control is achieved. Some experts recommend doubling the initial dose in patients presenting with life-threatening symptoms such as respiratory distress, cardiovascular collapse, significant hemorrhage, or severe neurologic toxicity (Goto, 2009; Lavonas, 2011a).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance dose (begin once control of envenomation achieved): 2 vials every 6 hours for up to 18 hours. Optimal dosing beyond 18 hours has not been established; however, treatment may be continued if deemed necessary based on patient condition.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6519242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CroFab&reg;: Derived from",
"     <i>",
"      Crotalus adamanteus, C. atrox, C. scutulatus",
"     </i>",
"     , and",
"     <i>",
"      Agkistrodon piscivorus",
"     </i>",
"     snake venoms [contains thimerosal; derived from or manufactured with papain]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6516316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstitute each vial with 18 mL NS and mix by continuous manual inversion until no solid material is visible. Do not shake. A faster dissolution has been shown using 25 mL SWI for reconstitution and hand rolling/inverting which may allow for more rapid administration (Quan, 2010). After reconstitution, further dilute",
"     <b>",
"      total",
"     </b>",
"     dose (4-6 vials) in 250 mL NS; lower infusion volumes may be considered for patients &lt;10 kg or fluid sensitive patients, such as those with congestive heart failure, chronic lung disease, or renal insufficiency (Goto, 2009; Johnson, 2008; Offerman, 2002; Pizon, 2007). Administer I.V. at an initial rate of 25-50 mL/hour for the first 10 minutes; if tolerated and no allergic reaction observed, then increase rate so that total dose infuses over 60 minutes, usually to 250 mL/hour. Continue to monitor closely. Epinephrine and diphenhydramine should be available during the infusion. Decreasing the rate of infusion may help control some adverse effects, such as fever, nausea, low back pain, and wheezing.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; use within 4 hours of reconstitution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of patients with North American crotalid envenomations [eg, rattlesnakes (",
"     <i>",
"      Crotalus",
"     </i>",
"     ,",
"     <i>",
"      Sistrurus",
"     </i>",
"     ), copperheads, and cottonmouth/water moccasins (",
"     <i>",
"      Agkistrodo",
"     </i>",
"     n)] [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F6519437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Chills, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Anorexia, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Asthma, cough, dyspnea, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylaxis, anaphylactoid reaction, hypersensitivity reactions, serum sickness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Angioedema, chest discomfort, dizziness, erythema, headache, hyperhidrosis, lip swelling, musculoskeletal chest pain, tachycardia, tachypnea, tongue swelling, tracheal edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to",
"     <i>",
"      Crotalidae",
"     </i>",
"     Polyvalent Immune Fab (Ovine) or any component, including papaya or papain, unless the benefits outweigh the risks and appropriate management for anaphylaxis is readily available",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in patients with allergies to papaya, other papaya extracts, papain, chymopapain, or the pineapple-enzyme bromelain since papain is used in the manufacturing process; may also have cross allergenicity with dust mite and latex allergens.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Coagulopathy, characterized by decreased fibrinogen, decreased platelets, and elevated prothrombin time, may recur following treatment with CroFab&reg; possibly due to leaching of retained venom at the envenomation site; reported incidence ~50% in clinical trials; repeat dosing may be necessary. Recurrent coagulopathy may persist for 1-2 weeks or longer and may require repeat dosing (Miller, 2010; Ruha, 2011); typically reported in patients who experienced coagulopathy during the initial treatment, but may occur in any patient; consider additional monitoring for at least 1 week following initial treatment and evaluate for other pre-existing conditions associated with bleeding disorders.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Anaphylaxis and anaphylactoid reactions are possible due to sheep proteins in the antivenin. Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available prior to administration. Incidence of acute hypersensitivity reactions may be lower than previously thought (Buchanan, 2009; Cannon, 2008; Lavonas, 2011). This product lacks the immunogenic Fc fragments and proteins found in the older equine-derived product. Sensitization to proteins may occur; use caution when administering repeat courses for subsequent envenomations.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Contains thimerosal (0.03 mg of mercury per vial; maximum dose of 18 vials would deliver &le;0.6 mg mercury); accumulation of thimerosal has been associated with neurological and renal toxicity; developing fetuses and young children are most susceptible; the presence of thimerosal should not deter use as the risks of untreated crotalid envenomations far outweigh the risk of thimerosal exposure.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6519209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6516321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6516322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Products contain thimerosal which may be associated with mercury-related toxicities, including neurological and renal toxicities in the fetus and very young children.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; CBC, platelet count, prothrombin time, aPTT, fibrinogen levels, fibrin split products, clot retraction, bleeding and coagulation times, BUN, electrolytes, bilirubin; size of bite area (repeat every 15-30 minutes); intake and output; signs and symptoms of anaphylaxis/allergy. CBC, platelet counts, and clotting studies should be  evaluated at 6-hour intervals until patient is stable.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A venom-specific fragment of IgG, which binds and neutralizes venom toxin, helping to remove the toxin from the target tissue and eliminate it from the body",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1046645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Onset of action: Stability of patient or reduction in symptoms may be seen within 1 hour of administration",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Unbound Fab: 110 mL/kg (Seifert, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 12-23 hours (based on limited data)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Speculated to occur via reticuloendothelial system (Dart, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Unbound Fab: 5.9 mL/h/kg (Seifert, 2001)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/16/39171?source=see_link\">",
"      see \"Ovine polyvalent crotalidae North and South American snake antivenom: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     After hospital discharge, contact physician immediately if unusual bleeding/bruising or signs and symptoms of allergic reaction/serum sickness (rash, pruritus, urticaria) occur.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F2973573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Envenomation Category:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Minimal:",
"     </b>",
"     Swelling, pain, and bruising are limited to immediate bite site; no systemic signs and symptoms; normal coagulation parameters; no clinical evidence of bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Moderate:",
"     </b>",
"     Swelling, pain, and bruising are limited to less than a full extremity (or &lt;50 cm if bite was on head or trunk); systemic signs and symptoms are not life-threatening (nausea, vomiting, oral paresthesia, unusual taste, mild hypotension, mild tachycardia, tachypnea); coagulation parameters may be abnormal; no bleeding other than minor hematuria, gum bleeding, or nosebleeds, if not severe",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Severe:",
"     </b>",
"     Swelling, pain, and bruising involve more than the entire extremity or threaten the airway; systemic signs and symptoms are markedly abnormal (severe alteration of mental status, severe hypotension, severe tachycardia, tachypnea, respiratory insufficiency); coagulation parameters are abnormal; serious bleeding or severe threat of bleeding",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Behm MO and Kearns GL, \"Crotaline Fab Antivenom for Treatment of Children With Rattlesnake Envenomation,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(6 Pt 1):1458&ndash;9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/14654633/pubmed\" id=\"14654633\" target=\"_blank\">",
"        14654633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buchanan JA, Varney SM, Mlynarchek SL, et al, \"Immediate Adverse Events (AEs) After Administration of Crotalidae Polyvalent Immune Fab (Fav AV),\"",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 2009, 47(7):703.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cannon R, Ruha AM, and Kashani J, \"Acute Hypersensitivity Reactions Associated With Administration of Crotalidae Polyvalent Immune Fab Antivenom,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2008, 51(4):407-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/18191286/pubmed\" id=\"18191286\" target=\"_blank\">",
"        18191286",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dart RC, Seifert SA, Carroll L, et al, \"Affinity-Purified, Mixed Monospecific Crotalid Antivenom Ovine Fab for the Treatment of Crotalid Venom Poisoning,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      ,  1997, 30(1):33-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/9209222/pubmed\" id=\"9209222\" target=\"_blank\">",
"        9209222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goto CS and Feng SY, \"Crotalidae Polyvalent Immune Fab for the Treatment of Pediatric Crotaline Envenomation,\"",
"      <i>",
"       Pediatr Emer Care",
"      </i>",
"      2009, 25(4):273-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/19369845/pubmed\" id=\"19369845\" target=\"_blank\">",
"        19369845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson PN, McGoodwin L, and Banner W Jr, \"Utilisation of Crotalidae Polyvalent Immune Fab (Ovine) for Viperidae Envenomations in Children,\"",
"      <i>",
"       Emerg Med J",
"      </i>",
"      , 2008, 25(12):793-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/19033492/pubmed\" id=\"19033492\" target=\"_blank\">",
"        19033492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lavonas EJ, Kokko J, Schaeffer TH, et al, &ldquo;Short-Term Outcomes After Fab Antivenom Therapy for Severe Crotaline Snakebite,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2011, 579(2):128-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/20952098/pubmed\" id=\"20952098\" target=\"_blank\">",
"        20952098",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lavonas EJ, Ruha AM, Banner W, et al, \"Unified Treatment Algorithm for the Management of Crotaline Snakebite in the United States: Results of an Evidence-Informed Consensus Workshop,\"",
"      <i>",
"       BMC Emerg Med",
"      </i>",
"      , 2011a, 11:2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/21291549/pubmed\" id=\"21291549\" target=\"_blank\">",
"        21291549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller AD, Young MC, DeMott MC, et al, \"Recurrent Coagulopathy and Thrombocytopenia in Children Treated With Crotalidae Polyvalent Immune Fab: A Case Series,\"",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2010, 26(8):576-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/20693856/pubmed\" id=\"20693856\" target=\"_blank\">",
"        20693856",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Offerman SR, Bush SP, Moynihan JA, et al, \"Crotaline Fab Antivenom for the Treatment of Children With Rattlesnake Envenomation,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2002, 110(5):968-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/1241503/pubmed\" id=\"1241503\" target=\"_blank\">",
"        1241503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pizon AF, Riley BD, LoVecchio F, et al, \"Safety and Efficacy of Crotalidae Polyvalent Immune Fab in Pediatric Crotaline Envenomations,\"",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 2007, 14(4):373-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/17296804/pubmed\" id=\"17296804\" target=\"_blank\">",
"        17296804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan AN, Quan D, and Curry SC, &ldquo;Improving Crotalidae Polyvalent Immune Fab Reconstitution Times,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 2010, 28(5):593-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/20579555/pubmed\" id=\"20579555\" target=\"_blank\">",
"        20579555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruha AM, Curry SC, Albrecht C, et al, \"Late Hematologic Toxicity Following Treatment of Rattlesnake Envenomation With Crotalidae Polyvalent Immune Fab Antivenom,\"",
"      <i>",
"       Toxicon",
"      </i>",
"      , 2011, 57(1):53-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/20920516/pubmed\" id=\"20920516\" target=\"_blank\">",
"        20920516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seifert SA and Boyer LV, \"Recurrence Phenomena After Immunoglobulin Therapy for Snake Envenomations: Part 1. Pharmacokinetics and Pharmacodynamics of Immunoglobulin Antivenoms and Related Antibodies,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2001, 37(2):189-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19845/abstract-text/11174238/pubmed\" id=\"11174238\" target=\"_blank\">",
"        11174238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17062 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-77.94.48.4-CE85A84A2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19845=[""].join("\n");
var outline_f19_24_19845=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516314\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046640\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046633\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519242\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516316\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046643\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046635\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046642\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519437\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046647\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046632\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046631\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519209\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516321\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516322\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046639\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046630\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046645\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046646\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046637\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973573\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17062\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17062|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/8/26757?source=related_link\">",
"      Ovine polyvalent crotalidae North and South American snake antivenom: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/16/39171?source=related_link\">",
"      Ovine polyvalent crotalidae North and South American snake antivenom: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_24_19846="Isosorbide mononitrate: Drug information";
var content_f19_24_19846=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isosorbide mononitrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/27/15796?source=see_link\">",
"    see \"Isosorbide mononitrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F185079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Imdur&reg;;",
"     </li>",
"     <li>",
"      Monoket&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F185080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-ISMN&reg;;",
"     </li>",
"     <li>",
"      Imdur&reg;;",
"     </li>",
"     <li>",
"      PMS-ISMN;",
"     </li>",
"     <li>",
"      PRO-ISMN",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F185126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F185083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Regular release tablet:",
"     </i>",
"     Initial: 5-20 mg twice daily with the 2 doses given 7 hours apart (eg, 8 AM and 3 PM) to decrease tolerance development; patients initiating therapy with 5 mg twice daily (eg, small stature) should be titrated up to 10 mg twice daily in first 2-3 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release tablet:",
"     </i>",
"     Initial: 30-60 mg given once daily in the morning; titrate upward as needed, giving at least 3 days between increases; maximum daily single dose: 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Tolerance to nitrate effects develops with chronic exposure. Dose escalation does not overcome this effect. Tolerance can only be overcome by short periods of nitrate absence from the body. Short periods of nitrate withdrawal may help minimize tolerance. Recommended twice daily dosage regimens incorporate this interval. Administer sustained release tablet once daily in the morning.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F185084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Start with lowest recommended adult dose.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F185085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: Dose supplementation is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peritoneal dialysis: Dose supplementation is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11593043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F185059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monoket&reg;: 10 mg [DSC], 20 mg [DSC] [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 30 mg, 60 mg, 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imdur&reg;: 30 mg, 60 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imdur&reg;: 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F185044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F185063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer around-the-clock. Immediate release tablet should be scheduled twice daily with doses 7 hours apart (8 AM and 3 PM); extended release tablet may be administered once daily in the morning upon rising with a half-glassful of fluid and should not be chewed or crushed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F185062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of angina pectoris",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F185134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Imdur&reg; may be confused with Imuran&reg;, Inderal&reg; LA, K-Dur&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Monoket&reg; may be confused with Monopril&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F185124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (13% to 35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina (&le;2%), flushing (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (&le;4%), fatigue (&le;4%), pain (&le;4%), emotional lability (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (&le;2%), rash (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (&le;3%), abdominal pain (&le;2%), diarrhea (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (&le;4%), cough increased (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Apoplexy, arrhythmia, bradycardia, dyspnea, edema, hyper-/hypotension, methemoglobinemia (rare, overdose), MI, orthostatic hypotension, pallor, palpitation, paresthesia, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F185066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to isosorbide mononitrate or any component of the formulation; hypersensitivity to organic nitrates; concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil, or vardenafil)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F185048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/bradycardia: Severe hypotension can occur; paradoxical bradycardia and increased angina pectoris can accompany hypotension. Orthostatic hypotension can also occur; ethanol can accentuate this. Use with caution in volume depletion and moderate hypotension, and with extreme caution with inferior wall MI and suspected right ventricular infarctions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intracranial pressure increased: Nitrates may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM): Avoid use in patients with HCM with outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (Gersh, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PDE-5 inhibitors: Avoid concurrent use with PDE-5 inhibitors (eg, sildenafil, tadalafil, vardenafil). When nitrate administration becomes medically necessary, may administer nitrates only if 24 hours have elapsed after use of sildenafil or vardenafil (48 hours after tadalafil use) (O&rsquo;Connor, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tolerance: Appropriate dosing intervals are needed to minimize tolerance development. Tolerance can only be overcome by short periods of nitrate absence from the body. Dose escalation does not overcome this effect.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F185121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F185053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosiglitazone: Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of myocardial ischemia was reported for users of this combination in a meta-analysis.  Management: Consider alternatives to this combination when possible.  Rosiglitazone prescribing information states that the combination of rosiglitazone and a nitrate is not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F185076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Caution with ethanol (may increase risk of hypotension).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F185055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer dependent) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11593066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Adverse events in the offspring were observed with use later in pregnancy at doses that were also maternally toxic.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F185089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F185068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Imdur Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $319.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $335.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $470.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Isosorbide Mononitrate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $111.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $142.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $293.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Isosorbide Mononitrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $50.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $73.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F185057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for orthostasis, increased hypotension",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F185069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Angistad (PH);",
"     </li>",
"     <li>",
"      Angitrate (ZA);",
"     </li>",
"     <li>",
"      Apo-ISMN (HK);",
"     </li>",
"     <li>",
"      Cardismo (ID);",
"     </li>",
"     <li>",
"      Cardisorb (HU);",
"     </li>",
"     <li>",
"      Cincordil (BR);",
"     </li>",
"     <li>",
"      Conpin (DE);",
"     </li>",
"     <li>",
"      Corangin (CH, NZ);",
"     </li>",
"     <li>",
"      Corangin SR (TW);",
"     </li>",
"     <li>",
"      Coxine (TW);",
"     </li>",
"     <li>",
"      Coxine SR (TW);",
"     </li>",
"     <li>",
"      Danlixin (CL);",
"     </li>",
"     <li>",
"      Duride (AU, NZ, TW);",
"     </li>",
"     <li>",
"      Effox (PL);",
"     </li>",
"     <li>",
"      Elan (IT);",
"     </li>",
"     <li>",
"      Elantan (AT, CR, CZ, DE, DO, EC, GT, HK, HN, IE, KP, LU, MX, MY, NI, PA, PE, PH, PK, SG, SV, VE);",
"     </li>",
"     <li>",
"      Elantan LA (MY);",
"     </li>",
"     <li>",
"      Elantan Long (CL, CZ, DE, HK, MY, PH, SG);",
"     </li>",
"     <li>",
"      Elonton SR (KP);",
"     </li>",
"     <li>",
"      Etimonis (CL);",
"     </li>",
"     <li>",
"      Imdex (HK, TH);",
"     </li>",
"     <li>",
"      Imdex CR (SG);",
"     </li>",
"     <li>",
"      Imdur (BF, BJ, CI, CL, CY, DK, EE, ET, GB, GH, GM, GN, HK, IE, KE, LR, LU, MA, ML, MR, MU, MW, NE, NG, PH, PT, SC, SD, SE, SG, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Imdur 60 (MX, TW);",
"     </li>",
"     <li>",
"      Imdur Durules (AU, KP);",
"     </li>",
"     <li>",
"      Imtrate (NZ);",
"     </li>",
"     <li>",
"      Imtrate SR (AU);",
"     </li>",
"     <li>",
"      Ismexin (FI);",
"     </li>",
"     <li>",
"      ISMN (AT, DE);",
"     </li>",
"     <li>",
"      ISMN AL (HU);",
"     </li>",
"     <li>",
"      ISMN Genericon (HR);",
"     </li>",
"     <li>",
"      ISMN Pharmavit (HU);",
"     </li>",
"     <li>",
"      ISMO (CN, DK, GB, IE, IT, NL, SE);",
"     </li>",
"     <li>",
"      Ismo (LU);",
"     </li>",
"     <li>",
"      Ismo 20 (BB, BM, BS, BZ, GY, IN, JM, MY, NZ, PR, SR, TH, TT, TW, ZA);",
"     </li>",
"     <li>",
"      Ismo-20 (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Ismox (FI);",
"     </li>",
"     <li>",
"      Isobid (KP);",
"     </li>",
"     <li>",
"      Isolan (AR);",
"     </li>",
"     <li>",
"      Isomon (GR);",
"     </li>",
"     <li>",
"      Isomonat (AT, CZ);",
"     </li>",
"     <li>",
"      Isomonit (DE, LU, PL);",
"     </li>",
"     <li>",
"      Isonate (PH);",
"     </li>",
"     <li>",
"      Isopen-20 (TH);",
"     </li>",
"     <li>",
"      Isorat (TR);",
"     </li>",
"     <li>",
"      Isosorbide (CY, HR);",
"     </li>",
"     <li>",
"      Isospan SR (HU);",
"     </li>",
"     <li>",
"      Isotril ER (KP);",
"     </li>",
"     <li>",
"      Monicor (FR);",
"     </li>",
"     <li>",
"      Monis (CO);",
"     </li>",
"     <li>",
"      Monit 20 (IN);",
"     </li>",
"     <li>",
"      Mono Corax (DE);",
"     </li>",
"     <li>",
"      Mono Corax Retard (DE);",
"     </li>",
"     <li>",
"      Mono Mack (CY, HU, LU, MX);",
"     </li>",
"     <li>",
"      Mono-Mack (CZ);",
"     </li>",
"     <li>",
"      Mono-Sanorania (DE);",
"     </li>",
"     <li>",
"      Monobide (EC);",
"     </li>",
"     <li>",
"      Monoclair (DE);",
"     </li>",
"     <li>",
"      Monocord 40 (IL);",
"     </li>",
"     <li>",
"      Monocord 50 SR (IL);",
"     </li>",
"     <li>",
"      Monodur Durules (AU);",
"     </li>",
"     <li>",
"      Monoket (IT, NO, PY, SE, UY);",
"     </li>",
"     <li>",
"      Monoket OD (NO, SE);",
"     </li>",
"     <li>",
"      Monoket Retard (AT, IT);",
"     </li>",
"     <li>",
"      Monolong (DE);",
"     </li>",
"     <li>",
"      Monolong 40 (IL);",
"     </li>",
"     <li>",
"      Monolong 60 (IL);",
"     </li>",
"     <li>",
"      Mononit (PE, PL);",
"     </li>",
"     <li>",
"      Mononit 20 (IL);",
"     </li>",
"     <li>",
"      Monopront (FI);",
"     </li>",
"     <li>",
"      Monosan (RU);",
"     </li>",
"     <li>",
"      Monosorbitrate (IN);",
"     </li>",
"     <li>",
"      Monosordil (GR);",
"     </li>",
"     <li>",
"      Monotrate (IN);",
"     </li>",
"     <li>",
"      Montra (PH);",
"     </li>",
"     <li>",
"      Nitramin (GR);",
"     </li>",
"     <li>",
"      Olicard (BG, HR, HU);",
"     </li>",
"     <li>",
"      Pentacard (BE, ID);",
"     </li>",
"     <li>",
"      Rangin (HU);",
"     </li>",
"     <li>",
"      Solotrate (TH);",
"     </li>",
"     <li>",
"      Sorbimon (HU);",
"     </li>",
"     <li>",
"      Sorbinate SR (TH);",
"     </li>",
"     <li>",
"      Uniket (ES);",
"     </li>",
"     <li>",
"      Vasotrate (IN, PH);",
"     </li>",
"     <li>",
"      Vasotrate-60 OD (PH);",
"     </li>",
"     <li>",
"      Vasotrate-OD (SG);",
"     </li>",
"     <li>",
"      Xismox XL (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F185047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nitroglycerin and other nitrates form free radical nitric oxide. In smooth muscle, nitric oxide activates guanylate cyclase which increases guanosine 3&rsquo;5&rsquo; monophosphate (cGMP) leading to dephosphorylation of myosin light chains and smooth muscle relaxation. Produces a vasodilator effect on the peripheral veins and arteries with more prominent effects on the veins. Primarily reduces cardiac oxygen demand by decreasing preload (left ventricular end-diastolic pressure); may modestly reduce afterload; dilates coronary arteries and improves collateral flow to ischemic regions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F185065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release: &ge;6 hours (Thadani, 1987); Extended release: &ge;12-24 hours (Anderson, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Nearly complete and low intersubject variability in its pharmacokinetic parameters and plasma concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~0.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Mononitrate: ~5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Predominantly urine (2% as unchanged drug); feces (1% of dose)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19846/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheitlin MD, Hutter AM Jr, Brindis RG, et al, &ldquo;ACC/AHA Expert Consensus Document. Use of Sildenafil (Viagra) in Patients With Cardiovascular Disease. American College of Cardiology/American Heart Association,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):273-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19846/abstract-text/9935041/pubmed\" id=\"9935041\" target=\"_blank\">",
"        9935041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flaherty JT, &ldquo;Hemodynamic Attenuation and the Nitrate Dose-Free Interval: Alternative Dosing Strategies for Transdermal Nitroglycerin,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1985, 56(17):321-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19846/abstract-text/3895880/pubmed\" id=\"3895880\" target=\"_blank\">",
"        3895880",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19846/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19846/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Baker DW, Chin MH, et al, &ldquo;ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2001, 38(7):2101-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19846/abstract-text/11738322/pubmed\" id=\"11738322\" target=\"_blank\">",
"        11738322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Connor RE, Brady W, Brooks SC, et al, \"Part 10: Acute Coronary Syndromes: 2010 American Heart Association Care Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):787-817.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19846/abstract-text/20956226/pubmed\" id=\"20956226\" target=\"_blank\">",
"        20956226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parker JO, &ldquo;Eccentric Dosing With Isosorbide-5-Mononitrate in Angina Pectoris,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1993, 72(12):871-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19846/abstract-text/8213541/pubmed\" id=\"8213541\" target=\"_blank\">",
"        8213541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parker JO, Fanell B, Lahey KA, et al, &ldquo;Effect of Intervals Between Doses on the Development to Tolerance to Isosorbide Dinitrate,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1987, 316(23):1440-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19846/abstract-text/3574424/pubmed\" id=\"3574424\" target=\"_blank\">",
"        3574424",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thadani U, Prasad R, Hamilton SF, et al, &ldquo;Isosorbide-5-Mononitrate in Angina Pectoris: Plasma Concentrations and Duration of Effects After Acute Therapy,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1987, 42(1):58-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19846/abstract-text/3595067/pubmed\" id=\"3595067\" target=\"_blank\">",
"        3595067",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Villaneuva C, Minana J, Ortiz J, et al, &ldquo;Endoscopic Litigation Compared With Combined Treatment With Nadolol and Isosorbide Mononitrate to Prevent Recurrent Variceal Bleeding,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(9):647-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/24/19846/abstract-text/11547718/pubmed\" id=\"11547718\" target=\"_blank\">",
"        11547718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8581 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19846=[""].join("\n");
var outline_f19_24_19846=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185079\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185080\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185126\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185083\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185084\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185085\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11593043\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185059\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185044\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185063\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185062\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185134\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185124\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185066\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185048\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185121\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185053\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185076\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185055\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11593066\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185089\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185068\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185057\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185069\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185047\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185065\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8581\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8581|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/27/15796?source=related_link\">",
"      Isosorbide mononitrate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_24_19847="Biphasic and protracted anaphylaxis";
var content_f19_24_19847=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biphasic and protracted anaphylaxis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/24/19847/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/24/19847/contributors\">",
"     Phillip L Lieberman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/24/19847/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/24/19847/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/24/19847/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/24/19847/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/24/19847/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of anaphylaxis begin quickly, escalate, and then resolve completely, particularly when appropriate treatment is administered. However, some anaphylactic reactions resolve and recur hours later, or do not resolve completely for hours or even days.",
"   </p>",
"   <p>",
"    Atypical patterns of anaphylaxis, the incidence of atypical patterns of reactions, and proposed risk factors for these reactions will be reviewed here. The diagnosis and treatment of anaphylaxis, fatal anaphylaxis, and other topics related to anaphylaxis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38888?source=see_link\">",
"     \"Differential diagnosis of anaphylaxis in children and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS AND INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three recognized temporal patterns of anaphylaxis: uniphasic, biphasic, and protracted [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Uniphasic anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uniphasic anaphylactic reactions are the most common type, accounting for an estimated 80 to 90 percent of all episodes. A uniphasic response usually peaks within 30 minutes to one hour after symptoms appear and resolves either spontaneously or with treatment within the next 30 minutes to one hour.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Protracted anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A protracted anaphylactic reaction lasts hours to days without clearly resolving completely. The exact frequency of protracted episodes of anaphylaxis is unknown, although they appear to be uncommon. The literature consists only of case reports and small series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/2-6\">",
"     2-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Biphasic anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biphasic reactions are characterized by a uniphasic response, followed by an asymptomatic period of an hour or more, and then a subsequent return of symptoms without further exposure to antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/7\">",
"     7",
"    </a>",
"    ]. Biphasic anaphylaxis reactions can occur in patients of any age and have been described in both children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/8-11\">",
"     8-11",
"    </a>",
"    ] and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/4,8,9,12-25\">",
"     4,8,9,12-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of the incidence of biphasic reactions vary from 1 to 23 percent of all anaphylactic reactions. The best estimates of incidence come from series of patients with anaphylaxis (from various causes) who presented for acute care and were then systematically contacted following treatment to determine if symptoms recurred. In one such study, the incidence of biphasic anaphylaxis was 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have evaluated the incidence of biphasic anaphylaxis in selected clinical settings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biphasic reactions occurred in 10 and 23 percent of cases in two studies of patients receiving immunotherapy, both of which included adults and children [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rates of biphasic anaphylaxis were much lower in a study of children undergoing oral food challenges (2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link&amp;anchor=H16#H16\">",
"       \"Oral food challenges for diagnosis and management of food allergies\", section on 'Safety'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following case reports vividly illustrate protracted and biphasic anaphylactic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/3,4,21\">",
"     3,4,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Protracted reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 33 year old male developed hives in the groin, followed the next day by abdominal cramps and bloating, vomiting, angioedema of the lip, wheezing, tightness of the throat, and generalized hives [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/3\">",
"     3",
"    </a>",
"    ]. He attributed these symptoms to clams eaten 14 hours before the onset of symptoms. On day three, the gastrointestinal symptoms continued and he developed transient lightheadedness. He presented to the hospital on day four, with continued urticaria, gastrointestinal discomfort, and mild tachycardia. Evaluation was unrevealing and he was treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , and intravenous fluids, with gradual improvement over the next two days. Serum tryptase samples drawn on the fourth and fifth days of illness were elevated, with return to normal when repeated several months later. An IgE immunoassay to clam was negative at the time of hospitalization, but low positive several months later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biphasic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 76 year old atopic male sustained approximately 15 vespid stings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/23\">",
"     23",
"    </a>",
"    ]. Within 10 minutes, he developed urticaria, erythema, and hypotension",
"    <span class=\"nowrap\">",
"     (90/60",
"    </span>",
"    mmHg, measured by a family member). A clinician was called to his home. Upon evaluation, the patient had cutaneous signs and symptoms, but no objective respiratory, CNS, or cardiovascular abnormalities, and his blood pressure had returned to normal",
"    <span class=\"nowrap\">",
"     (120/70",
"    </span>",
"    mmHg). He was treated with parenteral \"antihistamine and corticosteroid\" and observed for 45 minutes in his home. The urticaria subsided and the clinician left the home. Approximately 40 minutes after the departure of the clinician, the patient again developed urticaria, followed by angioedema of the neck. The symptoms worsened and the clinician was called back. The patient died, despite attempts at resuscitation. The autopsy showed \"generalized edema of the lungs, brain, glottis, and bowels, due to the severe characteristic systemic compromise of anaphylaxis.\"",
"   </p>",
"   <p>",
"    The remainder of this topic will focus on biphasic anaphylaxis, since more data are available regarding biphasic compared with protracted reactions, and biphasic reactions occurring after a patient has been discharged pose the greatest clinical dilemma for the treating clinician. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Clinical implications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Severity of recurrent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The case described above illustrates that the severity of recurrent symptoms is unpredictable, and the second phase of symptoms does not necessarily resemble the first [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/23\">",
"     23",
"    </a>",
"    ]. The majority of studies found that recurrent symptoms are usually less severe than the initial symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/13,15,26-28\">",
"     13,15,26-28",
"    </a>",
"    ]. Urticaria seems to be particularly common during the second wave of symptoms and this is often the only symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/16\">",
"     16",
"    </a>",
"    ]. However, the second phase of an anaphylaxis episode can be more severe or even fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/13,16,23\">",
"     13,16,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Timing of recurrent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The period of time between resolution of initial symptoms and onset of recurrent symptoms varies substantially. Studies have reported asymptomatic intervals ranging from 1 to 30 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/8,15-17,22,29\">",
"     8,15-17,22,29",
"    </a>",
"    ]. One study reported a biphasic reaction that occurred 72 hours after the resolution of initial symptoms, although this appears to be an exception to the usual temporal pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large study involving 103 patients who were contacted within 72 hours of an emergency department visit for anaphylaxis, the average time to onset of recurrent symptoms was 10 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/16\">",
"     16",
"    </a>",
"    ]. However, 40 percent of patients in this series had recurrent symptoms more than 10 hours after resolution of initial symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     THEORIES OF PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of biphasic anaphylaxis is not known, although several theories have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One theory propounds that the biphasic response, like allergic responses seen in the skin and the respiratory tract following allergen challenge, is due to the influx of inflammatory cells that occurs in response to cytokines and chemotactic factors released during the initial response [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/28\">",
"       28",
"      </a>",
"      ]. Mast cell degranulation is responsible for the initial symptoms in the skin following injection of allergen, or in the lung following inhalation of allergen. This is followed over the next two to eight hours by a highly reproducible influx of other inflammatory cells, including eosinophils, basophils, and lymphocytes. These cells are responsible for delayed swelling at the site of skin testing, and the late phase asthmatic response.",
"      <br/>",
"      <br/>",
"      The above model does not account for the variability seen in biphasic anaphylactic responses. Recurrent symptoms can occur as early as one hour and as late as three days after resolution of the first reaction, and this period is highly variable from patient to patient.",
"      <br/>",
"      <br/>",
"      Histologic findings in biphasic anaphylaxis do not support the above theory either. Studies of patients experiencing fatal biphasic reactions most often lack the characteristic inflammatory cell infiltrates in organs involved in the event [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/30\">",
"       30",
"      </a>",
"      ]. The cell that accumulates in the tissues after fatal anaphylaxis is usually the eosinophil, and in some reports, no cellular infiltrate is found at all.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other theories of the pathogenesis of biphasic allergic reactions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The biphasic response is related to a second wave of mast cell degranulation: In some murine models of anaphylaxis, it was noted that orally-administered antigens could result in biphasic degranulation of mast cells [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/31\">",
"       31",
"      </a>",
"      ]. Peak periods of mediator release consistently occurred at 30 minutes and 72 hours after a single oral challenge. An inflammatory infiltrate was apparent by 72 hours. However, this model would not explain cases of biphasic anaphylaxis in humans that occur quickly (ie, one to eight hours after resolution of the first response).",
"     </li>",
"     <li>",
"      In a murine model of penicillin-induced anaphylaxis, it was found that a late occurring synthesis of platelet activating factor (PAF) was responsible for a second delayed reaction [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/32\">",
"       32",
"      </a>",
"      ]. This was in part due to release of tumor necrosis factor alpha (TNF-alpha) from mast cells during the initial reaction, because inhibition of TNF-alpha inhibition resulted in ablation of both the late phase response and the late increase in PAF. The role of PAF in murine anaphylaxis is well established. Also, serum PAF levels are significantly elevated in humans with severe or fatal anaphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18778?source=see_link\">",
"       \"Pathophysiology of anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another theory suggests that biphasic responses have no unique pathogenesis, but simply represent a protracted event that undergoes a temporary remission, and then recurs when therapy \"wears off.\" In this theory, the biphasic reaction is simply a form of a protracted reaction with only two phases. However, it seems unlikely that this explanation would account for episodes occurring as late as 24 hours or later after the event.",
"     </li>",
"     <li>",
"      A final theory about the pathogenesis of biphasic anaphylaxis implicates uneven antigen absorption. Some series reported that biphasic reactions were more common following oral allergen exposure, although intravenously-administered antigens have also caused biphasic reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/8,13\">",
"       8,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POSSIBLE RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the data available, it is not possible to predict which patients will develop a biphasic response. Several features of the initial anaphylactic event have been cited as possible risk factors for the development of a second phase, although none has been established as definite, and studies have reached contradictory conclusions in some cases. The following discussion will focus on the findings from prospective studies when possible, since these are less prone to bias [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/13,26,27\">",
"     13,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Severe initial symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies reported that markers of severe initial reactions were more common among patients who subsequently had recurrent symptoms, suggesting that severity of the initial reaction might be a risk factor. Specifically, the need for more than one dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    or intravenous fluids for hypotension were noted. However, these results, obtained in retrospective studies, were confirmed in some, but not all prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/13,26,27\">",
"     13,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Suboptimal or delayed treatment of initial reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings of several studies suggest that patients who developed biphasic reactions received less aggressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delayed treatment for their initial symptoms, compared with patients with uniphasic reactions.",
"   </p>",
"   <p>",
"    A retrospective review of 282 patients presenting to an emergency department with a diagnosis of anaphylaxis reported that biphasic reactions occurred in 5.3 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients with biphasic responses took three times longer to arrive at the emergency department after the onset of their first symptoms compared with uniphasic reactors, suggesting the delayed treatment of initial symptoms might increase the risk of recurrent symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    appeared to predispose to biphasic events in a retrospective study of 105 children with nonfatal anaphylaxis, of whom 6 percent had biphasic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/8\">",
"     8",
"    </a>",
"    ]. Among the biphasic reactors, the median time from the onset of symptoms to the initial administration of epinephrine was 190 minutes, compared to 48 minutes for those with uniphasic reactions. Patients with or without biphasic reactions did not differ significantly in severity of reaction or the percentage of patients treated with epinephrine or glucocorticoids.",
"   </p>",
"   <p>",
"    In the large study involving 103 patients, of whom 20 had biphasic reactions, there was a statistically significant difference between uniphasic and biphasic reactors with regard to the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    administered during initial treatment, with uniphasic and biphasic receiving 0.39 and 0.30 mg, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are not believed to alter immediate events in anaphylaxis, since mast cells are relatively resistant to their pharmacologic effects. Glucocorticoids are administered in the treatment of anaphylaxis largely based upon the theory that they may prevent or reduce the later inflammatory changes that follow. However, the evidence in support of this practice is weak. In the study of 103 patients mentioned previously, more uniphasic reactors received glucocorticoids and at higher doses (55 percent, average dose 63 mg) compared with biphasic reactors (35 percent, 31 mg), although this fell just short of statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/16\">",
"     16",
"    </a>",
"    ]. Other studies have found no evidence that glucocorticoids reduce the rates of biphasic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Delayed resolution of initial symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the study of 103 patients described previously [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/16\">",
"     16",
"    </a>",
"    ], uniphasic reactors responded more quickly to initial treatment compared with biphasic reactors (ie, resolution in 112 versus 133 minutes). In addition, when patients with biphasic symptoms beginning",
"    <strong>",
"     later than",
"    </strong>",
"    <strong>",
"     nine hours",
"    </strong>",
"    after initial resolution (\"later biphasic reactors\") were compared to those with recurrent symptoms in one to eight hours, the later biphasic reactors were even slower to respond to initial treatment (ie, resolution in 193 versus 133 minutes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ingested allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective series of 25 patients found that recurrent or prolonged reactions were more likely if the offending agent had been administered by mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/13\">",
"     13",
"    </a>",
"    ]. However, a subsequent larger study did not confirm this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/27\">",
"     27",
"    </a>",
"    ]. Biphasic reactions have been reported with an array of allergens, including ingested, injected, and intravenously administered substances, as well as in idiopathic anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of biphasic reactions following allergen immunotherapy found that the only identifiable difference between patients with biphasic and uniphasic reactions was a higher incidence of asthma and low peak expiratory flow in those with biphasic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/26\">",
"     26",
"    </a>",
"    ]. Other studies have not found asthma to be associated with biphasic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of beta-adrenergic blocker medications, older age, and concomitant cardiovascular disease have also been suggested as predisposing factors to biphasic responses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/19\">",
"     19",
"    </a>",
"    ]. Again, other studies did not see a correlation between biphasic reactions and these factors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CLINICAL IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with protracted anaphylaxis clearly must be observed for extended periods or admitted to a hospital. In contrast, the uncertain risk of biphasic anaphylaxis presents a clinical dilemma.",
"   </p>",
"   <p>",
"    At present, there is no consensus about the optimal observation period following successful treatment for anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/18,34-36\">",
"     18,34-36",
"    </a>",
"    ]. Until more conclusive data are available, we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with severe anaphylaxis should be admitted to an observation unit or to a hospital for at least 24 hours. We would include in this group patients requiring multiple doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      , intravenous fluids for hypotension, laryngeal edema, or significant respiratory compromise.",
"     </li>",
"     <li>",
"      A prolonged period of observation should be considered for patients with reactions that were characterized by one or more of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A delay of greater than 30 minutes between the time of exposure to the antigen and the appearance of symptoms",
"     </li>",
"     <li>",
"      A delay of more than 60 minutes between onset of symptoms and initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"     </li>",
"     <li>",
"      A slow response to initial therapy",
"     </li>",
"     <li>",
"      A previous history of a biphasic response",
"     </li>",
"     <li>",
"      Reactions occurring in older patients, those with cardiovascular disease, or those taking beta-blockers",
"      <br/>",
"      <br/>",
"      However, the optimal period of observation for such patients is not clear. A period of 12 hours is suggested, based upon the study described previously, in which recurrent symptoms appeared an average of 10 hours after resolution of the initial reaction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with anaphylaxis that resolved promptly and completely with treatment, we suggest a minimum observation period of two hours. Some anaphylaxis guidelines recommend a minimum of four or six hours [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If a patient is sent home after only a few hours, it is preferable to supply them with an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjector, rather than just a prescription for one [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/37\">",
"       37",
"      </a>",
"      ]. Alternatively, the patient should be urged to fill the prescription immediately. All patients should be instructed in how and when to use the autoinjector, prior to discharge. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H37#H37\">",
"       \"Anaphylaxis: Rapid recognition and treatment\", section on 'Care upon resolution'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=see_link\">",
"       \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All discharged patients should be informed that symptoms can recur up to three days after the initial episode, and in some cases, can be more severe than the initial symptoms. They should also receive education about returning to a medical facility immediately if symptoms reappear and preferably should have an anaphylaxis emergency action plan (",
"      <a class=\"graphic graphic_form graphicRef60439 \" href=\"UTD.htm?2/42/2722\">",
"       form 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19847/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"       \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"       \"Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"       \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are three recognized patterns of anaphylaxis: uniphasic, biphasic, and protracted. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions and incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biphasic reactions occur in up to 23 percent of cases of anaphylaxis. In the largest study, the average time to onset of recurrent symptoms was 10 hours after resolution of initial symptoms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions and incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The severity of recurrent symptoms is unpredictable. In most patients, recurrent symptoms are less severe than the initial symptoms, and isolated urticaria is common. However, recurrent symptoms are not the same as initial symptoms, and in a minority of patients, can be more severe or even fatal. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for biphasic anaphylaxis have not been established, and thus, it is not possible to predict which patients will develop recurrent symptoms based on available data. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Possible risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be informed about the possibility of recurrent symptoms for up to three days after the initial episode of anaphylaxis. If possible, an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjector should be dispensed to the patient prior to discharge or the patient should obtain an autoinjector within hours of discharge.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Golden D. Patterns of anaphylaxis: Acute and late phase features of allergic reactions. In: Anaphylaxis, Wiley, Chichester [Novartis Foundation Symposium 257], 2004. p.101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/2\">",
"      Zisa G, Riccobono F, Calamari AM, et al. A case of protracted hypotension as unique symptom of a biphasic anaphylaxis to amoxicillin. Eur Ann Allergy Clin Immunol 2009; 41:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/3\">",
"      Vinuya RZ, Simon MR, Schwartz LB. Elevated serum tryptase levels in a patient with protracted anaphylaxis. Ann Allergy 1994; 73:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/4\">",
"      Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/5\">",
"      Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007; 120:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/6\">",
"      Lockey RF, Bukantz SC. Allergic emergencies. Med Clin North Am 1974; 58:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/7\">",
"      Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol 2005; 95:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/8\">",
"      Lee JM, Greenes DS. Biphasic anaphylactic reactions in pediatrics. Pediatrics 2000; 106:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/9\">",
"      Hogan MB, Kelly MA, Wilson NW. Idiopathic anaphylaxis in children. Ann Allergy Asthma Immunol 1998; 81:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/10\">",
"      J&auml;rvinen KM, Amalanayagam S, Shreffler WG, et al. Epinephrine treatment is infrequent and biphasic reactions are rare in food-induced reactions during oral food challenges in children. J Allergy Clin Immunol 2009; 124:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/11\">",
"      Mehr S, Liew WK, Tey D, Tang ML. Clinical predictors for biphasic reactions in children presenting with anaphylaxis. Clin Exp Allergy 2009; 39:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/12\">",
"      Rudders SA, Banerji A, Corel B, et al. Multicenter study of repeat epinephrine treatments for food-related anaphylaxis. Pediatrics 2010; 125:e711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/13\">",
"      Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol 1986; 78:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/14\">",
"      Douglas DM, Sukenick E, Andrade WP, Brown JS. Biphasic systemic anaphylaxis: an inpatient and outpatient study. J Allergy Clin Immunol 1994; 93:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/15\">",
"      Brady WJ Jr, Luber S, Carter CT, et al. Multiphasic anaphylaxis: an uncommon event in the emergency department. Acad Emerg Med 1997; 4:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/16\">",
"      Ellis AK, Day JH. Incidence and characteristics of biphasic anaphylaxis: a prospective evaluation of 103 patients. Ann Allergy Asthma Immunol 2007; 98:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/17\">",
"      Brazil E, MacNamara AF. \"Not so immediate\" hypersensitivity--the danger of biphasic anaphylactic reactions. J Accid Emerg Med 1998; 15:252.",
"     </a>",
"    </li>",
"    <li>",
"     Forrest-Hay A, Taylor C, Tolchard S. Biphasic anaphylaxis in a UK emergency department. Presented at Open Paper Presentations of the 2003 Scientific Symposium of the Resuscitation Council of the United Kingdom (Abstract).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/19\">",
"      Brady WJ Jr, Luber S, Joyce TP. Multiphasic anaphylaxis: report of a case with prehospital and emergency department considerations. J Emerg Med 1997; 15:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/20\">",
"      Brady WJ Jr, Bright HL. Occurrence of multiphasic anaphylaxis during a transcontinental air flight. Am J Emerg Med 1999; 17:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/21\">",
"      Ellis AK, Day JH. Biphasic anaphylaxis with an unusually late onset second phase: a case report. Canadian J Allergy Clin Immunol 1997; 2:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/22\">",
"      Smit DV, Cameron PA, Rainer TH. Anaphylaxis presentations to an emergency department in Hong Kong: incidence and predictors of biphasic reactions. J Emerg Med 2005; 28:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/23\">",
"      Cortellini G, Corvetta A, Campi P, et al. A case of fatal biphasic anaphylaxis secondary to multiple stings: adrenalin and/or a longer observation time could have saved the patient? Eur Ann Allergy Clin Immunol 2005; 37:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/24\">",
"      Novembre E, Calogero C, Mori F, et al. Biphasic anaphylactic reaction to Ketorolac tromethamine. Int J Immunopathol Pharmacol 2006; 19:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/25\">",
"      Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol 2006; 97:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/26\">",
"      Confino-Cohen R, Goldberg A. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study. Ann Allergy Asthma Immunol 2010; 104:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/27\">",
"      Scranton SE, Gonzalez EG, Waibel KH. Incidence and characteristics of biphasic reactions after allergen immunotherapy. J Allergy Clin Immunol 2009; 123:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/28\">",
"      Popa VT, Lerner SA. Biphasic systemic anaphylactic reaction: three illustrative cases. Ann Allergy 1984; 53:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/29\">",
"      Lertnawapan R, Maek-a-nantawat W. Anaphylaxis and biphasic phase in Thailand: 4-year observation. Allergol Int 2011; 60:283.",
"     </a>",
"    </li>",
"    <li>",
"     Lieberman P. Anaphylaxis and anaphylactoid reactions. In: Middleton's allergy: Principles and practice, 6th ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St. Louis, MO 2003. p.1497.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/31\">",
"      Yang PC, Berin MC, Yu L, Perdue MH. Mucosal pathophysiology and inflammatory changes in the late phase of the intestinal allergic reaction in the rat. Am J Pathol 2001; 158:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/32\">",
"      Choi IW, Kim YS, Kim DK, et al. Platelet-activating factor-mediated NF-kappaB dependency of a late anaphylactic reaction. J Exp Med 2003; 198:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/33\">",
"      Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008; 358:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/34\">",
"      Kemp SF. The post-anaphylaxis dilemma: how long is long enough to observe a patient after resolution of symptoms? Curr Allergy Asthma Rep 2008; 8:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/35\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005; 115:S483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/36\">",
"      Soar J, Deakin CD, Nolan JP, et al. European Resuscitation Council guidelines for resuscitation 2005. Section 7. Cardiac arrest in special circumstances. Resuscitation 2005; 67 Suppl 1:S135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19847/abstract/37\">",
"      Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007; 120:1373.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 396 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19847=[""].join("\n");
var outline_f19_24_19847=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS AND INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Uniphasic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Protracted anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Biphasic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Protracted reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biphasic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Severity of recurrent symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Timing of recurrent symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      THEORIES OF PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POSSIBLE RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Severe initial symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Suboptimal or delayed treatment of initial reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Epinephrine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Delayed resolution of initial symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ingested allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CLINICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/396\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/396|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?2/42/2722\" title=\"form 1\">",
"      Anaphylaxis action plan",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38888?source=related_link\">",
"      Differential diagnosis of anaphylaxis in children and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18778?source=related_link\">",
"      Pathophysiology of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=related_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_24_19848="HIV treatment as prevention";
var content_f19_24_19848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HIV treatment as prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/24/19848/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/24/19848/contributors\">",
"     Myron S Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/24/19848/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/24/19848/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/24/19848/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/24/19848/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/24/19848/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12048600\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who are chronically infected with HIV, potent antiretroviral therapy (ART) has dramatically reduced morbidity and mortality through viral suppression and robust immune recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, millions of new HIV infections occur globally every year and there is no vaccine or effective microbicide yet available for the prevention of HIV transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39018?source=see_link\">",
"     \"The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/12/29898?source=see_link\">",
"     \"The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-rich countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &ldquo;Treatment as prevention&rdquo; describes the personal and public health benefits of using ART to suppress detectable viremia, which decreases the risk of HIV transmission to others [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/3\">",
"     3",
"    </a>",
"    ]. The term &ldquo;HIV serodiscordant couples&rdquo; refers to an HIV-seropositive person who is sexually active with an HIV-uninfected partner. This topic will specifically address the use of ART in the HIV-infected partner to decrease the sexual transmission of HIV to the uninfected partner.",
"   </p>",
"   <p>",
"    The use of ART for postexposure prophylaxis in occupational exposures and for preexposure prophylaxis among HIV-seronegative individuals is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=see_link\">",
"     \"Management of healthcare personnel exposed to HIV\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26410?source=see_link\">",
"     \"Nonoccupational exposure to HIV in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link\">",
"     \"Pre-exposure prophylaxis against HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12048614\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR HIV SEXUAL TRANSMISSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12048621\">",
"    <span class=\"h2\">",
"     High levels of viremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmitting partners appear to have higher levels of HIV RNA than nontransmitting partners [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1345656\">",
"    <span class=\"h3\">",
"     Acute HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission events appear to be more frequent from patients with acute HIV infection and late-stage disease (ie, AIDS) compared with chronic infection; these observations are probably linked to the high levels of viremia that are seen during early and late infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During acute HIV infection, there is ramp-up of viremia followed by onset of a cellular immune response, which leads to a new lower viral &ldquo;set point&rdquo; (eg, equilibrium) seen in chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Acute infection is also associated with increased viral shedding in genital secretions for several weeks after infection compared with the stable lower levels seen in chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One modelling study estimated that 38 percent of all HIV transmissions in Malawi were attributable to sexual contact with acutely infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/10\">",
"     10",
"    </a>",
"    ]. A phylogenetic analysis of patients with acute and early HIV infection, including mostly men who have sex with men, was similarly suggestive of transmission networks during early infection, with evidence of infection with viruses that could be grouped into closely related clusters [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/11\">",
"     11",
"    </a>",
"    ]. Additionally, some animal data also support an increase in viral infectivity during newly acquired infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1345663\">",
"    <span class=\"h3\">",
"     Chronic HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with chronic infection, a dose-response relationship also exists between the magnitude of the viral load in the blood and genital compartments and the risk of HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For example, in a study of 415 HIV-serodiscordant couples in Uganda, the baseline serum viral load was higher in the transmitting partners than the non-transmitting partners (ie, 90,000 versus 38,000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, there were no HIV transmission events from HIV-infected partners whose baseline viral load was &lt;1500",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    suggesting that a threshold for transmission may exist [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have shown that HIV can still be intermittently detected in seminal fluid of some HIV-infected men, despite suppression of HIV viremia with antiretroviral therapy (ART) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. HIV can be occasionally detected in the vaginal secretions of women despite the use of ART that suppresses replication in blood [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/17\">",
"     17",
"    </a>",
"    ]. However, it is unclear whether this poses a significant transmission risk in serodiscordant couples. A meta-analysis in 5021 heterosexual discordant couples with 461 HIV transmission events found no evidence of transmission from an HIV-seropositive partner with treatment-induced viral suppression, although the number of person years of follow-up was low [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/18\">",
"     18",
"    </a>",
"    ]. Results of the HIV Prevention Trials Network 052 trial similarly suggest a low risk of HIV transmission in the setting of effective antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12048635\">",
"     'Clinical trials: HIV Prevention Trials Network (HPTN) 052 trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23498389\">",
"    <span class=\"h2\">",
"     Lack of circumcision",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV transmission rates among uncircumcised males are higher than for circumcised males. Randomized controlled trials in Africa have demonstrated that circumcision reduces the likelihood of female-to-male HIV transmission by 50 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The biologic basis for this observation may be related to a high density of HIV target cells in male foreskin, including Langerhans cells and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/23\">",
"     23",
"    </a>",
"    ]. However, male circumcision does not decrease the risk of HIV transmission to the female partner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link&amp;anchor=H3280947#H3280947\">",
"     \"Prevention of sexually transmitted infections\", section on 'Male circumcision'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23498396\">",
"    <span class=\"h2\">",
"     Unprotected intercourse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unprotected intercourse increases the risk of HIV transmission and acquisition; however, consistent use of condoms is an effective method of preventing HIV infection in women and men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In a meta-analysis of 12 studies of HIV-serodiscordant couples, HIV seroconversion rates were much higher among those who never used condoms versus those who always did (ie, 6.7 seroconversions versus 0.9 seroconversions per 100 person years) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link&amp;anchor=H11#H11\">",
"     \"Prevention of sexually transmitted infections\", section on 'Condom use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23498559\">",
"    <span class=\"h2\">",
"     Sexually transmitted disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually transmitted diseases (STD) have been long known to increase the risk of both acquiring and transmitting HIV infection. Several studies have shown an increased incidence of HIV infection in patients with genital ulcerative diseases, such as herpes simplex virus and syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/7,26-28\">",
"     7,26-28",
"    </a>",
"    ]. The effect of these infections on HIV risk is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link&amp;anchor=H20#H20\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'HSV-2 and risk of HIV transmission'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\", section on 'HIV transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other STDs of the genital tract also appear to increase HIV infection risk. In a prospective study of 242 South African women with high-risk sexual behavior, 28 became infected with HIV over 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/29\">",
"     29",
"    </a>",
"    ]. Presence of a concurrent sexually transmitted infection was associated with an increased risk of infection with HIV (HR 3.29, 95% CI 1.5-7.2). The incremental risk for HIV infection with Neisseria gonorrhoeae infection was greater than that with other infections (Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis). The majority of women with STDs were asymptomatic. Urethral inflammation from STDs may also increase the risk of HIV transmission. In 83 HIV-infected men on antiretroviral therapy with undetectable plasma HIV levels, a concurrent sexually transmitted disease or urethritis was an independent predictor of detectable HIV in the semen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Population-based studies have generally been unable to show a decrease in HIV incidence through treatment of STD infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/30\">",
"     30",
"    </a>",
"    ]. However, this may reflect problems with methodology, patient adherence, and overlapping interventions with the control group in these studies as opposed to a true lack of preventive benefit with STD treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23499016\">",
"    <span class=\"h1\">",
"     HIV PREVENTION STRATEGIES AND PUBLIC HEALTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of December 2010, 34 million people were estimated to be living with",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    and more than 35 million have died since the beginning of the epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potent antiretroviral medications reduce viral replication in both blood plasma and genital secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/4\">",
"     4",
"    </a>",
"    ], problems with complete suppression notwithstanding (see above). Since the risk of HIV sexual transmission is strongly correlated with the concentration of HIV RNA in the blood and genital tracts, viral suppression with ART should decrease the risk of HIV transmission.",
"   </p>",
"   <p>",
"    Some modeling studies have suggested that biomedical interventions could have a significant impact on decreasing HIV transmission in HIV endemic countries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In one model, all patients in Africa 15 years of age or older were tested for HIV infection and all newly diagnosed patients were immediately started on ART [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/32\">",
"     32",
"    </a>",
"    ]. With this &ldquo;test-and-treat&rdquo; strategy, the model estimated that the incidence of HIV would decline to 1 case per 1000 persons by the year 2016. Emerging data on decreased HIV transmission with effective HIV treatment suggest that any cost-analysis of ART must consider the benefits of HIV therapy on overall morbidity and mortality and HIV transmission risk [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/3,35\">",
"     3,35",
"    </a>",
"    ]. One analysis that took both these effects into account suggested that ART initiation at presentation (versus waiting until CD4 cell count decreased to below 250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    would be very cost-effective in resource-limited settings over the scope of a patient&rsquo;s lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/36\">",
"     36",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6428166\">",
"    <span class=\"h1\">",
"     EFFICACY OF HIV TREATMENT FOR THE PREVENTION OF TRANSMISSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12048635\">",
"    <span class=\"h2\">",
"     Clinical trials: HIV Prevention Trials Network (HPTN) 052 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HPTN 052 trial recruited 1763 HIV-1 serodiscordant heterosexual couples at 13 sites in nine countries in Africa, Asia, South America, and North America from 2005 to 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/19\">",
"     19",
"    </a>",
"    ]. The trial was designed to determine if treatment of the HIV-infected sex partner decreased the risk of HIV transmission to the uninfected partner. HIV treatment-na&iuml;ve partners were eligible for ART if their CD4 count was between 350 and 550",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    Couples were required to be in a stable relationship for three months.",
"   </p>",
"   <p>",
"    The serodiscordant couples were randomly assigned to the &ldquo;early ART&rdquo; arm (initiation of HIV treatment at enrollment) or &ldquo;delayed ART&rdquo; arm (initiation of HIV treatment when the CD4 count dropped to less than 250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or after an AIDS-related illness). ART consisted mainly of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    . The median CD4 count was approximately 440",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    with a median viral load of 4.4 log. Viral gene sequences were analyzed among seroconverters to see if HIV transmission was linked between couples.",
"   </p>",
"   <p>",
"    After 1.7 years of follow-up, the Data and Safety Monitoring Board recommended that the trial should be stopped because of significant benefits observed in the early therapy arm. Specifically:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of a total of 28 linked HIV transmission events, 27 occurred in the delayed therapy group (HR 0.04; 0.01-0.26). HIV-infected women were the source of infection in 18 of 27 infections.",
"     </li>",
"     <li>",
"      Viral sequencing determined that seven transmissions were genetically &ldquo;unlinked&rdquo;, consistent with ongoing high-risk behaviors.",
"     </li>",
"     <li>",
"      Although 54 percent of the study participants were recruited from Africa, 82 percent of the transmissions occurred in this region.",
"     </li>",
"     <li>",
"      Seventeen of 28 HIV transmission events were related to HIV-infected subjects with CD4 counts &gt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      A high plasma viral load at baseline increased the risk of HIV transmission; the median plasma viral load in 27 participants at the visit most proximal to the detection of HIV-1 transmission was 4.9 log.",
"     </li>",
"     <li>",
"      A reduced risk of HIV transmission was associated with a self-report of &ldquo;100 percent use&rdquo; of condoms compared with &ldquo;less than 100 percent use&rdquo; (HR 0.35; 0.14-0.88).",
"     </li>",
"     <li>",
"      Patients in the early therapy arm also had a lower risk of an HIV-related clinical event than those in the delayed therapy arm over the 1.7-year period of follow-up (HR 0.59; 95% CI, 0.40-0.88). No difference in mortality rates was seen between the arms.",
"     </li>",
"     <li>",
"      The difference in the rate of clinical events was most closely associated with the incidence of extrapulmonary TB (3 versus 17 cases in the early and delayed groups, respectively). More than half of these cases of TB occurred in India. Of note, only 4 percent of study participants in either group had received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      prophylaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, HIV transmission may occur with lower frequency in asymptomatic chronic disease compared with acute infection or advanced AIDS; however, since the vast majority of HIV-infected patients globally fall within the category of asymptomatic HIV infection, any impact on these transmission events is likely to be substantial, as demonstrated by this trial. (See",
"    <a class=\"local\" href=\"#H12048614\">",
"     'Risk factors for HIV sexual transmission'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Follow-up of participants in the HPTN 052 trial continues, in order to determine the durability of ART for prevention and further evaluate if the delay of ART led to deleterious clinical consequences. A subsequent analysis demonstrated a continued reduction in HIV-related clinical events, including tuberculosis, herpes and candidal infections, and skin abnormalities, among patients who had initially been assigned to receive immediate versus delayed ART [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/37\">",
"     37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1711238\">",
"    <span class=\"h2\">",
"     Trials in progress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials are now in progress to address whether ART, combined with other prevention strategies, can reduce population level HIV incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To date, there are no clinical trial data on the use of ART to prevent HIV transmission among men who have sex with men (MSM). Although viral suppression with ART may also decrease HIV transmission among HIV-serodiscordant couples, the risk and benefit may differ; one observational study is in progress [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6428667\">",
"    <span class=\"h2\">",
"     Observational studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies in Africa have shown that when ART is offered to an HIV-infected patient, transmission of HIV infection to the uninfected sexual partner is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Similarly, in a large retrospective study of almost 39,000 heterosexual serodiscordant couples in China, the incidence of HIV infection among uninfected partners was lower if the infected partner was on ART versus untreated (1.3 versus 2.6 infections per 100 person years, respectively, adjusted HR 0.74, 95% CI 0.65&ndash;0.84) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/44\">",
"     44",
"    </a>",
"    ]. Such ecological studies, which examine relationships between exposures and outcomes at the group level, have a number of methodological challenges, including selection bias, confounding, and assumptions about the time lag of effects, which limit the ability to link the exposure to the outcome for the individual [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/45\">",
"     45",
"    </a>",
"    ]. Nevertheless, these results indicate the importance of continued evaluation of ART as a prevention strategy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12048642\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the HPTN 052 trial discussed above, adverse clinical events (grade 3 or 4) were similar in both arms (14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/19\">",
"     19",
"    </a>",
"    ]. These events included various infections, psychiatric and neurologic disorders, gastrointestinal illnesses and nutritional deficiencies.",
"   </p>",
"   <p>",
"    Grade 3 or 4 laboratory events were more common in the early therapy group and included neutropenia, elevated alkaline phosphatase, and hyperbilirubinemia; most of the latter laboratory findings occurred among patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , which is known to raise levels of indirect bilirubin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link&amp;anchor=H22#H22\">",
"     \"HIV protease inhibitors\", section on 'Atazanavir (reyataz)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12048649\">",
"    <span class=\"h1\">",
"     CLINICAL MANAGEMENT OF HIV SERODISCORDANT COUPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the HIV Prevention Trials Network (HPTN) 052 trial discussed above, there was a relative reduction of 96 percent in the number of linked HIV transmissions after early initiation of antiretroviral therapy (ART) among those with a CD4 cell count between 350 and 550",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    Counseling regarding safer sex may have contributed to overall low rates of HIV transmission observed in this trial (2.2 transmission",
"    <span class=\"nowrap\">",
"     events/100",
"    </span>",
"    person years in the delayed arm). Heterosexual HIV serodiscordant couples were educated about the risk of unprotected anal intercourse and the added benefit of using condoms in reducing HIV transmission.",
"   </p>",
"   <p>",
"    Physicians can explain the results of the HPTN 052 trial to heterosexual HIV-discordant couples with the following key points [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/18,19,46,47\">",
"     18,19,46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ART greatly decreases the risk of HIV transmission to the HIV-seronegative sexual partner.",
"     </li>",
"     <li>",
"      The benefits of ART are directly related to complete viral suppression, which requires a high level of drug adherence.",
"     </li>",
"     <li>",
"      Consistent condom use reduces the risk of HIV transmission and acquisition",
"     </li>",
"     <li>",
"      Among several discordant couples, the HIV-negative partners acquired HIV outside the relationship, consistent with ongoing risk behaviors.",
"     </li>",
"     <li>",
"      HIV RNA shedding can be detected from the genital tract despite ART-associated viral suppression in the blood compartment [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/13-16,48\">",
"       13-16,48",
"      </a>",
"      ]; however, it is not clear whether such treated patients can transmit virus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pre-exposure prophylaxis for the HIV-uninfected partner in a serodiscordant couple can also reduce the risk of HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/49\">",
"     49",
"    </a>",
"    ]. While these two strategies have not been compared directly, ART for the HIV-infected partner has the additional benefit of possibly reducing the AIDS and non-AIDS morbidity and mortality for that individual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link&amp;anchor=H1251769#H1251769\">",
"     \"Pre-exposure prophylaxis against HIV infection\", section on 'Clinical data in heterosexual individuals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12048656\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy in resource-limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all HIV-infected patients in a serodiscordant heterosexual partnership in resource-limited settings, we recommend initiation of antiretroviral therapy, when feasible, in order to prevent transmission to the uninfected partner. This recommendation is consistent with guidance from both the World Health Organization (WHO) and the United States President's Emergency Plan for AIDS Relief (PEPFAR) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The WHO recommends ART initiation for personal health in all patients with a CD4 cell count &lt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    In addition, the WHO released new guidelines in 2012 that recommend ART for the HIV-infected patient in a relationship with an uninfected individual, regardless of CD4 cell count, to reduce transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/50\">",
"     50",
"    </a>",
"    ]. When resources for ART are limited, however, priority should be given to those HIV-infected patients who need it for their own health.",
"   </p>",
"   <p>",
"    In the HPTN 052 trial, the impact of ART on the reduction of HIV transmission was most notable in Africa. Factors that may have contributed to these results include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/19,52,53\">",
"     19,52,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher levels of viremia seen in sub-Saharan African patients compared with patients living in resource-rich settings",
"     </li>",
"     <li>",
"      The type of dominant circulating virus (ie, Clade C)",
"     </li>",
"     <li>",
"      Increased numbers of sexual encounters and lower rates of condom use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This trial also demonstrated that HIV-associated morbidity was lower among those who initiated &ldquo;early ART\" compared with &ldquo;delayed ART&rdquo;, although mortality rates were similar. Much of the morbidity seen in this trial was related to TB, which supports the recommendation by the WHO that HIV-infected patients in TB endemic countries should also receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/54\">",
"     54",
"    </a>",
"    ]. Epidemiologic studies also suggest that ART decreases the risk of tuberculosis among HIV-infected patients living in TB endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12048663\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy in resource-rich settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012, HIV treatment guidelines from the Department of Health and Human Services (DHHS) and the International AIDS Society-USA were updated to recommended ART for all HIV-infected patients, regardless of CD4 cell count, to decrease AIDS and non-AIDS associated morbidities and mortalities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19848/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The rationale for expanding treatment and the strength of those recommendations are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H26#H26\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'Treatment recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H5768904#H5768904\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'Impact of ART on risk of other comorbidities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these considerations, all patients should be counseled regarding the potential merits of earlier therapy to their own health and to their partners&rsquo; health, balanced with the possible toxicities of chronic ART. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10794?source=see_link\">",
"     \"Adverse effects of antiretroviral therapy in developing countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H796185\">",
"    <span class=\"h2\">",
"     Condom use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another option to decrease transmission among HIV serodiscordant couples includes consistent use of condoms and should be offered regardless of ART use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link&amp;anchor=H11#H11\">",
"     \"Prevention of sexually transmitted infections\", section on 'Condom use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12048670\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;HIV discordant couples&rdquo; is a term that is used to refer to an HIV-seropositive person who is sexually active with an HIV-uninfected partner. &ldquo;Treatment as HIV prevention&rdquo; describes the personal and public health benefits of using antiretroviral therapy (ART) to suppress detectable viremia, which decreases the risk of sexual transmission of HIV infection. (See",
"      <a class=\"local\" href=\"#H12048600\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for HIV sexual transmission include high levels of viremia, lack of circumcision, unprotected intercourse, and sexually transmitted disease. (See",
"      <a class=\"local\" href=\"#H12048614\">",
"       'Risk factors for HIV sexual transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinical trial demonstrated that antiretroviral therapy, initiated in a CD4 cell count range of 350 to 550",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      in an HIV-infected patient, was associated with a 96 percent reduction in HIV transmission to an uninfected heterosexual sex partner compared with starting ART at a lower CD4 cell count (ie, &lt;250",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      or with the onset of an HIV-related illness. (See",
"      <a class=\"local\" href=\"#H12048635\">",
"       'Clinical trials: HIV Prevention Trials Network (HPTN) 052 trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition, heterosexual couples who always used condoms were at lower risk of HIV transmission events compared with those who used condoms less frequently. (See",
"      <a class=\"local\" href=\"#H12048635\">",
"       'Clinical trials: HIV Prevention Trials Network (HPTN) 052 trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early use of ART was associated with a lower risk of morbidity, while adverse events related to treatment were comparable. (See",
"      <a class=\"local\" href=\"#H6428667\">",
"       'Observational studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV discordant couples need to be aware that the benefits of ART are directly linked to complete viral suppression, which requires a high level of treatment adherence. (See",
"      <a class=\"local\" href=\"#H12048649\">",
"       'Clinical management of HIV serodiscordant couples'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In resource-limited settings, the prioritization of ART should reflect the maximal clinical and public health benefits possible, pending more widely available medications and clinical resources. Thus, in such settings, initiation of ART for personal health is recommended when the CD4 cell count is &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      For HIV-infected patients who are in a stable heterosexual relationship with an uninfected partner, we recommend initiation of ART regardless of CD4 cell count, where feasible (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Earlier antiretroviral therapy is also associated with clinical benefit in the HIV-infected host. (See",
"      <a class=\"local\" href=\"#H12048656\">",
"       'Antiretroviral therapy in resource-limited settings'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"       \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In resource-rich settings, initiation of immediate ART is more readily accomplished. Thus, in such settings, all HIV-infected patients, regardless of CD4 cell count, should be offered ART to reduce their AIDS and non-AIDS associated morbidity and mortality. ART can also be expected to decrease the risk of transmitting HIV to an uninfected partner. For patients in a heterosexual relationship with an uninfected partner, who would otherwise choose not to take ART for their own health, we recommend ART to reduce the risk of transmission of HIV (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12048663\">",
"       'Antiretroviral therapy in resource-rich settings'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"       \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HIV-serodiscordant couples should also be advised that consistent condom use reduces the risk of HIV transmission and acquisition. (See",
"      <a class=\"local\" href=\"#H12048649\">",
"       'Clinical management of HIV serodiscordant couples'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/1\">",
"      Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/2\">",
"      Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/3\">",
"      Padian NS, McCoy SI, Karim SS, et al. HIV prevention transformed: the new prevention research agenda. Lancet 2011; 378:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/4\">",
"      Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:77ra29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/5\">",
"      Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/6\">",
"      Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/7\">",
"      Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/8\">",
"      Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/9\">",
"      Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/10\">",
"      Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011; 378:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/11\">",
"      Pao D, Fisher M, Hu&eacute; S, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS 2005; 19:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/12\">",
"      Ma ZM, Stone M, Piatak M Jr, et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009; 83:3288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/13\">",
"      Sheth PM, Kovacs C, Kemal KS, et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS 2009; 23:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/14\">",
"      Lambert-Niclot S, Tubiana R, Beaudoux C, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey. AIDS 2012; 26:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/15\">",
"      Pasquier C, Saun&eacute; K, Raymond S, et al. Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy. J Clin Microbiol 2009; 47:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/16\">",
"      Politch JA, Mayer KH, Welles SL, et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS 2012; 26:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/17\">",
"      Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/18\">",
"      Attia S, Egger M, M&uuml;ller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/19\">",
"      Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/20\">",
"      Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/21\">",
"      Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/22\">",
"      Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/23\">",
"      Donoval BA, Landay AL, Moses S, et al. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol 2006; 125:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/24\">",
"      Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/25\">",
"      Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004; 82:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/26\">",
"      Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/27\">",
"      Reynolds SJ, Risbud AR, Shepherd ME, et al. High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India. Sex Transm Infect 2006; 82:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/28\">",
"      Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/29\">",
"      Mlisana K, Naicker N, Werner L, et al. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis 2012; 206:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/30\">",
"      Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010; 24:621.",
"     </a>",
"    </li>",
"    <li>",
"     UNAIDS Report on the Global AIDS Epidemic, 2012. Joint United Nations Programme on HIV/AIDS And World Health Organization, December 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/32\">",
"      Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/33\">",
"      Abbas UL. Uptake of biomedical interventions for prevention of sexually transmitted HIV. Curr Opin HIV AIDS 2011; 6:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/34\">",
"      Palombi L, Bernava GM, Nucita A, et al. Predicting trends in HIV-1 sexual transmission in sub-Saharan Africa through the Drug Resource Enhancement Against AIDS and Malnutrition model: antiretrovirals for 5 reduction of population infectivity, incidence and prevalence at the district level. Clin Infect Dis 2012; 55:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/35\">",
"      Hontelez JA, de Vlas SJ, Tanser F, et al. The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS One 2011; 6:e21919.",
"     </a>",
"    </li>",
"    <li>",
"     Walensky RP, Ross EL, Kumarasamy N, et al. The cost-effectiveness of treatment as prevention: analysis of the HPTN 052 trial. Presented at the 19th annual International AIDS Conference, Washington DC, August 2012,  #FRLBC01.",
"    </li>",
"    <li>",
"     Grinsztejn B, Hosseinipour M, Swindells S, et al. Effect of early versus delayed initiation of antiretroviral therapy on clinical outcomes in the HPTN 052 randomized clinical trial. Presented at the 19th annual International AIDS Society Conference, Washington DC, August 2012, #THLBB05.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/38\">",
"      Smith K, Powers KA, Kashuba AD, Cohen MS. HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS 2011; 6:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/39\">",
"      Boily MC, M&acirc;sse B, Alsallaq R, et al. HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med 2012; 9:e1001250.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.hptn.org/research_studies.asp (Accessed on September 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/41\">",
"      Muessig KE, Smith MK, Powers KA, et al. Does ART prevent HIV transmission among MSM? AIDS 2012; 26:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/42\">",
"      Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/43\">",
"      Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/44\">",
"      Jia Z, Ruan Y, Li Q, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/45\">",
"      Smith MK, Powers KA, Muessig KE, et al. HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med 2012; 9:e1001260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/46\">",
"      Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/48\">",
"      Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/49\">",
"      Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization, Guidance on couples HIV testing and counselling, April 2012. file://www.who.int/hiv/pub/guidelines/9789241501972/en/ (Accessed on June 05, 2012).",
"    </li>",
"    <li>",
"     PEPFAR Prevention Guidance, August 2011. file://www.pepfar.gov/guidance/171094.htm#EVIDENCE AND IMPLEMENTATION GUIDANCE ON SPECIFIC INTERVENTIONS (Accessed on June 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/52\">",
"      Dyer JR, Kazembe P, Vernazza PL, et al. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 1998; 177:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/53\">",
"      Novitsky V, Ndung'u T, Wang R, et al. Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS 2011; 25:1515.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Guidelines for Intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings, Geneva, 2011. (Accessed on August 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/55\">",
"      Severe P, Pape J, Fitzgerald D. A randomized clinical trial of early versus standard antiretroviral therapy for HIV-infected patients with a CD4 T-cell count of 200-350 cells/mL (CIPRAHT001). Paper presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 12-15, 2009; San Francisco, CA. Abstract:H1230c.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/56\">",
"      Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. file://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/ (Accessed on April 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19848/abstract/58\">",
"      Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16612 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19848=[""].join("\n");
var outline_f19_24_19848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12048670\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12048600\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12048614\">",
"      RISK FACTORS FOR HIV SEXUAL TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12048621\">",
"      High levels of viremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1345656\">",
"      - Acute HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1345663\">",
"      - Chronic HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23498389\">",
"      Lack of circumcision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23498396\">",
"      Unprotected intercourse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23498559\">",
"      Sexually transmitted disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23499016\">",
"      HIV PREVENTION STRATEGIES AND PUBLIC HEALTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6428166\">",
"      EFFICACY OF HIV TREATMENT FOR THE PREVENTION OF TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12048635\">",
"      Clinical trials: HIV Prevention Trials Network (HPTN) 052 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1711238\">",
"      Trials in progress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6428667\">",
"      Observational studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12048642\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12048649\">",
"      CLINICAL MANAGEMENT OF HIV SERODISCORDANT COUPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12048656\">",
"      Antiretroviral therapy in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12048663\">",
"      Antiretroviral therapy in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H796185\">",
"      Condom use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12048670\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10794?source=related_link\">",
"      Adverse effects of antiretroviral therapy in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=related_link\">",
"      Management of healthcare personnel exposed to HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26410?source=related_link\">",
"      Nonoccupational exposure to HIV in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=related_link\">",
"      Pre-exposure prophylaxis against HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39018?source=related_link\">",
"      The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/12/29898?source=related_link\">",
"      The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-rich countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_24_19849="Chickenpox oral 2";
var content_f19_24_19849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83137%7EDERM%2F83136%7EDERM%2F51866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83137%7EDERM%2F83136%7EDERM%2F51866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Oral manifestations of varicella (chickenpox)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gingival vesicle in a patient with chickenpox.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral manifestation of varicella (chickenpox)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraoral herpes zoster",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions are present on the palate in a unilateral distribution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19849=[""].join("\n");
var outline_f19_24_19849=null;
var title_f19_24_19850="Subacute and chronic low back pain: Pharmacologic and noninterventional treatment";
var content_f19_24_19850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/24/19850/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/24/19850/contributors\">",
"     Roger Chou, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/24/19850/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/24/19850/contributors\">",
"     Steven J Atlas, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/24/19850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/24/19850/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/24/19850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 84 percent of adults have low back pain at some time in their lives [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The long-term outcome of low back pain is generally favorable. In one prospective study, 90 percent of patients with low back pain seen initially in primary care did not seek care after three months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/3\">",
"     3",
"    </a>",
"    ]. However, given how common low back pain is, persistent symptoms affect millions of individuals. Subacute low back pain is commonly defined as back pain lasting between 4 and 12 weeks and chronic low back pain as pain that persists for 12 or more weeks.",
"   </p>",
"   <p>",
"    The initial evaluation of patients with low back pain, regardless of its duration, includes history taking and a targeted physical examination focusing on neurologic screening to exclude serious underlying pathology (eg, malignancy, infection, or cauda equina syndrome). On the basis of this evaluation, patients are triaged into broad diagnostic categories that include nonspecific low back pain, radiculopathy, or other specific pathology (eg, spinal stenosis, ankylosing spondylitis, and vertebral compression fracture) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients (&gt;85 percent) who are seen in primary care have \"nonspecific low back pain,\" which is low back pain that cannot reliably be attributed to a specific disease or spinal pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/7\">",
"     7",
"    </a>",
"    ]. Rapid improvement in pain and disability and return to work are the norm in the first month [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients who do not improve within four weeks of the onset of low back symptoms should be re-evaluated and may require further diagnostic testing to identify a specific cause for their symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite persistent pain, patients with subacute symptoms still have a favorable prognosis. For patients whose symptoms persist beyond three months, however, the goal of treatment moves from \"cure\" to controlling pain, maintaining function, and preventing disability. Factors associated with development of chronic disability include pre-existing psychological conditions, other types of chronic pain, job dissatisfaction or stress, and dispute over compensation issues [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/9\">",
"     9",
"    </a>",
"    ]. Approximately 5 percent of people with back pain disability account for 75 percent of the costs associated with low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/10\">",
"     10",
"    </a>",
"    ]. Effective methods for reducing the risk of progression to chronic pain have not been definitively identified [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is likely that many patients with chronic low back pain are not receiving evidence-based care. One survey of households in North Carolina, for example, identified 732 adults with chronic low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/13\">",
"     13",
"    </a>",
"    ]. Responses indicated overutilization of unproven interventions (traction, corsets), high use of second-line medications (opioids and muscle relaxants) and underutilization of exercise therapy and, for patients with depression, antidepressants.",
"   </p>",
"   <p>",
"    A glossary of terms used in the discussion of low back pain is presented in a table (",
"    <a class=\"graphic graphic_table graphicRef79662 \" href=\"UTD.htm?22/54/23406\">",
"     table 1",
"    </a>",
"    ). Criteria used in this review to classify magnitude of benefits for the most commonly reported outcomes (pain relief or improvement in function) are presented in a table (",
"    <a class=\"graphic graphic_table graphicRef58592 \" href=\"UTD.htm?33/62/34795\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Relatively few randomized trials have evaluated patients specifically with subacute low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/14\">",
"     14",
"    </a>",
"    ], sciatica, or spinal stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], results from trials evaluating mixed populations (subacute with either acute or chronic patients) are commonly applied to both groups. This topic presents recommendations for initial management of patients with subacute and chronic low back pain, including self-care advice, medication, activity and physical treatments, and noninvasive physical modalities. Interventional and surgical therapies for subacute and chronic low back pain and treatment recommendations for acute low back pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=see_link\">",
"     \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=see_link\">",
"     \"Subacute and chronic low back pain: Surgical treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=see_link\">",
"     \"Treatment of acute low back pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A summary of the multiple interventions for subacute and chronic low back pain discussed in these topics is presented in a set of tables (",
"    <a class=\"graphic graphic_table graphicRef72902 \" href=\"UTD.htm?7/38/7789\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61982 \" href=\"UTD.htm?38/46/39661\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77165 \" href=\"UTD.htm?15/17/15646\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63348 \" href=\"UTD.htm?43/23/44412\">",
"     table 6",
"    </a>",
"    ). Guidelines from the American College of Physicians and the American Pain Society, including an algorithm for diagnosis and treatment of low back pain, have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SELF-CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Self-care advice",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with low back pain, regardless of duration or severity, should be instructed in self-care techniques. Initial advice should stress the importance of maintaining activity as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients who require a period of bedrest to relieve severe symptoms should be encouraged to return to normal activities as soon as possible.",
"   </p>",
"   <p>",
"    A systematic review of randomized trials has found that bedrest did not improve either function or pain, compared to usual activity, for patients with sciatica [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/17\">",
"     17",
"    </a>",
"    ]. Advice to remain active was as effective as 'standard' physical therapy (any combination of exercises, mobilization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    manipulation, superficial heat or cold, and advice) for improvement in function in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/18\">",
"     18",
"    </a>",
"    ]. However, patients randomly assigned to physical therapy were more likely to report a perceived benefit than those receiving activity advice.",
"   </p>",
"   <p>",
"    Self-care education books based on evidence-based guidelines (such as The Back Book [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/19\">",
"     19",
"    </a>",
"    ]) are an inexpensive and efficient method for supplementing clinician-provided back information and advice [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/20\">",
"     20",
"    </a>",
"    ]. Several randomized trials have shown self-care education books to be similar in effectiveness, or only slightly inferior, to interventions with higher direct costs such as supervised exercise, massage, acupuncture, and spinal manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/17,21-23\">",
"     17,21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bed mattress choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;A medium-firm mattress may be the preferred mattress choice, based on findings from a European randomized trial (n = 313) in which patients randomly assigned to a firm mattress, compared to a medium-firm mattress, were less likely to experience improvement in pain-related disability at 90 days (68 versus 82 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/24\">",
"     24",
"    </a>",
"    ]. The medium-firm mattress was superior to a firm mattress for improvement of pain while lying in bed (odds ratio [OR] 2.36, 95% CI 1.13-4.93) and pain-related disability (OR 2.10, 1.24-3.56).",
"   </p>",
"   <p>",
"    Although these results suggest providers should not recommend a firm mattress for chronic low back pain, the firmness rating scale was a European standard, and the term \"medium-firm\" may mean different things to different manufacturers in different countries.",
"   </p>",
"   <p>",
"    Another randomized study comparing back conforming mattresses (waterbed and foam) with a firm mattress suggested less pain and improved sleep for the conforming mattresses, with higher dropout rates for patients assigned to the firm mattress [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lumbar supports",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no compelling evidence that lumbar supports are effective in patients with subacute and chronic low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/26\">",
"     26",
"    </a>",
"    ]. A systematic review of eight trials for treatment of low back pain found overall poor study quality, inadequate randomization, and generally low compliance with the intervention. The conclusion was that evidence conflicted whether lumbar supports used as supplements to other treatments were effective in the treatment of low back pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications are commonly used for patients with low back pain. Most evidence of efficacy comes from short-term trials, so the relative benefits and safety of use for prolonged periods in patients with subacute and chronic pain is uncertain. Thus, limiting the duration of use for most medications is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several classes of analgesic medications are effective for moderate, short-term pain relief in patients with subacute or chronic low back pain. Each class of medication is associated with unique trade-offs involving benefits, risks, and costs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acetaminophen and nonsteroidals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short courses of nonopioid analgesic medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or nonsteroidal antiinflammatory drugs (NSAIDs), are often considered first-line pharmacologic options for acute exacerbations of subacute or chronic low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/6\">",
"     6",
"    </a>",
"    ]. A systematic review of randomized trials found that nonsteroidal medications were effective for short-term symptom relief in patients with subacute and chronic low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonsteroidal antiinflammatory drugs are associated with well-known gastrointestinal and renal side effects. Additionally, exposure to COX-2 selective inhibitors is associated with an increased risk of myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/28\">",
"     28",
"    </a>",
"    ]. Cardiovascular and gastrointestinal risk factors should be assessed before prescribing NSAIDs and the lowest effective dose should be prescribed for the shortest period necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is not known to be associated with myocardial infarction or gastrointestinal bleeding. One systematic review found no clear difference between acetaminophen and NSAIDs for pain relief in patients with low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/27\">",
"     27",
"    </a>",
"    ]. However, systematic reviews of patients with osteoarthritis (not limited to the back) consistently found acetaminophen slightly inferior to NSAIDs for pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two systematic reviews and meta-analyses of opioid use specifically for chronic back pain identified few high-quality or long-term trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One meta-analysis found that opioid medications, compared with placebo or nonopioid analgesics, did not significantly reduce pain in patients with chronic low back pain [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/33\">",
"       33",
"      </a>",
"      ]. One included trial (n = 213) found opioids superior to placebo for improvement in pain intensity (standardized mean difference [SMD] 0.40, 95% CI 0.77-0.07). However, patients in this study were treated with opioids prior to allocation to continued opioids or placebo during a run-in-period, so poorer outcomes in the placebo group could have been due in part to opioid cessation and withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/35\">",
"       35",
"      </a>",
"      ]. Three other trials found no significant differences between opioids and control (placebo or nonopioid analgesics).",
"     </li>",
"     <li>",
"      The other meta-analysis found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      was minimally more effective than placebo for improving function (SMD 0.17, 95% CI 0.04 - 0.30) and for pain relief (SMD 0.71, 0.39-1.02) in three trials, but in a fourth trial there was no difference between opioids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      for either pain relief or function [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/34\">",
"       34",
"      </a>",
"      ]. Systematic reviews of opioids for chronic non-cancer pain conditions in general (not restricted to low back pain), however, find consistent evidence that opioids are moderately effective for pain relief, though the trials often do not address whether pain relief is associated with functional improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two trials published after the meta-analyses were conducted found that treatment for 12 weeks with opioid medications was more effective than placebo for chronic low back pain by 17 to 23 points on a 100-point scale [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of the use of opioids for chronic and subacute low back pain rarely quantify the risk of important adverse events, such as abuse or addiction. One systematic review found aberrant drug-taking behaviors in up to 24 percent of patients receiving opioids for low back pain, but most studies had important methodological shortcomings, including poorly described or validated methods for identifying aberrant drug-related behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Opioids may be appropriate for short-term use in patients with severe acute exacerbations of low back pain but should be used with caution for long-term treatment of patients with chronic back pain. Opioid use should be monitored closely, and restricted to patients not highly vulnerable to drug dependence, abuse, or addiction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants, particularly the tricyclic antidepressants, have been used to treat various chronic pain syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several meta-analyses evaluating the effect of antidepressants versus placebo for short-term therapy (eight weeks or less) in patients with nonspecific back pain have led to conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Longer-term trials of antidepressants for chronic low back pain are not available.",
"   </p>",
"   <p>",
"    Use of antidepressants was slightly more effective than placebo for low back pain relief in two meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], with an estimated SMD of 0.41 (95% CI 0.22-0.61) for pain relief but no difference for activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/40\">",
"     40",
"    </a>",
"    ]. Use of tricyclic antidepressants, but not SSRIs or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    , was associated with the slightly improved pain relief.",
"   </p>",
"   <p>",
"    Another meta-analysis, which differed from the earlier studies in the selection criteria used, trials included, and methods for analyzing results, found no difference between antidepressant and placebo treatment for relief of pain or depression and no difference between types of antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three randomized trials sponsored by the drug manufacturer found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    more effective than placebo for low back pain. However, differences were small (&lt;1 point on 0 to 10 pain or function scales) and patients were more likely to discontinue duloxetine compared to placebo due to adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Duloxetine was approved by the US Food and Drug Administration in 2012 for treatment of low back pain.",
"   </p>",
"   <p>",
"    Antidepressants are associated with a higher risk of adverse events (most commonly drowsiness, dry mouth, and dizziness) compared to placebo. Because of small or questionable benefits and known side effects, antidepressants are not a first-line treatment for chronic low back pain. Depression is common in patients with chronic low back pain, and clinicians should assess for and treat depression appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40296?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of chronic pain in adults\", section on 'Psychiatric comorbidity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Skeletal muscle relaxants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review found insufficient evidence to determine whether skeletal muscle relaxants are effective for subacute or chronic low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/47\">",
"     47",
"    </a>",
"    ]. In the only trial evaluating efficacy of a skeletal muscle relaxant available in the US, there was no difference in short-term reduction of muscle spasm between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/48\">",
"     48",
"    </a>",
"    ]. Pain relief and improvement in function were not reported in this trial. Two other trials evaluated flupirtine and tolperisone, which are not available in the US. Both medications were more effective than placebo.",
"   </p>",
"   <p>",
"    The systematic review also found skeletal muscle relaxants associated with more central nervous system adverse events (primarily sedation) than placebo (relative risk [RR] 2.04, 95% CI 1.23 to 3.37) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32693?source=see_link\">",
"     carisoprodol",
"    </a>",
"    is metabolized to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/43/19125?source=see_link\">",
"     meprobamate",
"    </a>",
"    , a controlled substance because of its abuse and addiction potential. In general, short-term use of skeletal muscle relaxants may be considered as adjunctive therapy to analgesics in patients with acute exacerbations of chronic low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/47\">",
"     47",
"    </a>",
"    ], but there is insufficient data to recommend their use for chronic stable low back pain. The lack of clear benefit, well known side effects affecting the central nervous system, and the potential for dependence suggest that this class of medication should not be recommended for prolonged use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are often used as skeletal muscle relaxants, though not approved by the US FDA for this indication. Data on effectiveness of benzodiazepines for subacute or chronic low back pain is limited. A systematic review identified three trials of benzodiazepines, but two evaluated a benzodiazepine not available in the US (tetrazepam) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/47\">",
"     47",
"    </a>",
"    ]. Both trials found tetrazepam more effective than placebo for short-term pain intensity (pooled RR 0.82, 95% CI 0.72-0.94 after five to seven days and RR 0.71, 0.54-0.93) and overall improvement (pooled RR 0.63, 0.42-0.97). The only trial evaluating a benzodiazepine available in the US found no difference between diazepam and placebo for muscle spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/48\">",
"     48",
"    </a>",
"    ]. Because of limited evidence on efficacy and potential for addiction and abuse, benzodiazepines should not be used for long-term treatment of chronic low back pain, although a short course may be indicated for acute exacerbations of chronic low back pain in patients less vulnerable to abuse and addiction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antiepileptic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of effectiveness of several antiepileptic medications for symptomatic treatment in patients with subacute or chronic low back pain is currently based on a few small studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For chronic radiculopathy, two trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/49,50\">",
"       49,50",
"      </a>",
"      ], one trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/51\">",
"       51",
"      </a>",
"      ], and one trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/52\">",
"       52",
"      </a>",
"      ] showed only small or unclear effects on pain, which may be offset by their side effects. &nbsp;",
"     </li>",
"     <li>",
"      For non-radicular low back pain, one trial found",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      moderately superior to placebo for pain relief and slightly superior for functional improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/53\">",
"       53",
"      </a>",
"      ], but a second trial found no difference between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      and placebo in pain or function [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      for spinal stenosis was evaluated in one small (n = 55) open label trial [",
"      <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/55\">",
"       55",
"      </a>",
"      ]. The addition of gabapentin, titrated to 2400",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      to a regimen of supervised exercise therapy, lumbar supports, and NSAIDs in patients with pseudoclaudication and spinal stenosis on CT or MRI, moderately improved mean pain scores, compared to no gabapentin, at four months (2.9 versus 4.7 on a 0 to 10 scale).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional well-designed trials are needed before antiepileptic medications can be recommended for low back pain (with or without radiculopathy) or spinal stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118398087\">",
"    <span class=\"h2\">",
"     Glucosamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucosamine has been extensively studied and is widely used to treat osteoarthritis, particularly of the knee and hip. However, there are little data to support its use for low back pain. In a six-month randomized trial of 250 patients with chronic low back pain and degenerative lumbar osteoarthritis, there were no differences in pain or quality-of-life scores between the glucosamine sulfate (1500 mg daily) and placebo arms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/56\">",
"     56",
"    </a>",
"    ]. The use of glucosamine for the treatment of knee osteoarthritis is discussed elsewhere. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anti-TNF-alpha therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic anti-tumor necrosis factor (TNF)-alpha therapy, which is primarily used in the treatment of inflammatory rheumatologic and bowel disease, does not appear to have a role for patients with chronic low back pain. This was suggested in the FIRST II trial (n = 40), which found no differences in pain or functional outcomes between a single intravenous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or saline infusion at three-month and one-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Epidural and intradiscal injections of anti-TNF-alpha therapy have also been evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=see_link&amp;anchor=H6#H6\">",
"     \"Subacute and chronic low back pain: Nonsurgical interventional treatment\", section on 'Intradiscal injection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ACTIVITY AND PHYSICAL TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to self care instruction, all patients with subacute and chronic low back pain should be advised to incorporate physical activity into their treatment plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Exercise therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different types of exercise are commonly used in patients with subacute or chronic low back pain. Exercise programs include core strengthening (eg, abdominal and trunk extensor),",
"    <span class=\"nowrap\">",
"     flexion/extension",
"    </span>",
"    movements, directional preference, general physical fitness, aerobic exercise, mind-body exercises (eg, yoga and pilates), and functional restoration programs. Exercise therapy is safe, readily available, helps alleviate pain symptoms, and improve functional. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6841?source=see_link\">",
"     \"Exercise-based therapy for low back pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients with subacute or chronic low back pain should be advised to remain as active as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Back schools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Back school is an intervention consisting of education and a skill program, including exercise therapy. Generally, lessons are provided to groups of patients and supervised by a physical therapist or other therapist trained in back rehabilitation. A systematic review found inconsistent evidence on effectiveness of back schools versus placebo or wait list controls, though most trials found no benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/59\">",
"     59",
"    </a>",
"    ]. Results were better for trials in an occupational setting and for more intensive programs based on the original Swedish back school (providing information on the anatomy of the back, biomechanics, optimal posture, ergonomics, and back exercises in four group sessions over a two week period [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/60\">",
"     60",
"    </a>",
"    ]), though any observed benefits were small.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Spinal manipulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal manipulation is a form of manual therapy that involves the movement of a joint beyond its usual end range of motion but not past its anatomic range of motion (termed the \"paraphysiologic zone\"). Loads are applied to the spine using short or long lever methods. Short lever high-velocity movement of the joint is frequently accompanied by an audible cracking or popping sound. Spinal manipulation is most commonly associated with chiropractic (short lever techniques) but is also performed by other spine providers, including osteopathic physicians and physical therapists. Spinal mobilization, employing low velocity passive movement within or at the limit of joint range, is often used in conjunction with spinal manipulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41222?source=see_link\">",
"     \"Spinal manipulation in the treatment of musculoskeletal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For chronic low back pain, a systematic review of randomized controlled trials found lumbar spinal manipulation to have no advantage over general practitioner care, analgesics, physical therapy, exercises, or back school [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/61\">",
"     61",
"    </a>",
"    ]. Other systematic reviews concluded that spinal manipulation has a small beneficial effect [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/62-65\">",
"     62-65",
"    </a>",
"    ], including one systematic review focusing on spinal manipulation for subacute low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious adverse events following lumbar spinal manipulation (such as worsening lumbar disc herniation or cauda equina syndrome) are rare. The risk of a serious adverse event, including data from observational studies, has been estimated at less than one per one million patient visits [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. One systematic review found no serious complications reported in over 70 controlled clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/68\">",
"     68",
"    </a>",
"    ]. Such low rates of adverse events are likely to be contingent on adherence to recommendations to avoid lumbar spinal manipulation in patients with progressive or severe neurologic deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acupuncture is an intervention consisting of the insertion of needles at specific predetermined acupuncture points. Evidence on the efficacy of acupuncture versus sham acupuncture is inconsistent. Two systematic reviews found acupuncture moderately more effective than no treatment for short-term (&lt;three months) pain relief and improvement in function, and more effective than sham acupuncture for pain relief, but not for improvement in function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. However, two well-blinded trials not included in the systematic reviews found no difference between acupuncture and sham acupuncture for either pain or function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. It is unclear if the effectiveness of sham acupuncture derives from some attribute of superficial needling or is solely a placebo effect. Acupuncture is likely to be most beneficial in patients who have high expectations of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link&amp;anchor=H21#H21\">",
"     \"Acupuncture\", section on 'Low back pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Massage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of studies to evaluate the effectiveness of massage therapy in chronic low back pain is hampered by differences in the comparator interventions, types of massage, and duration and frequency of massage sessions. A systematic review found that massage was moderately superior to joint mobilization, relaxation therapy, physical therapy, acupuncture, sham laser, and self-care education [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/74\">",
"     74",
"    </a>",
"    ]. The review concluded that massage might be beneficial for subacute and chronic nonspecific low back pain, especially in combination with exercise and education.",
"   </p>",
"   <p>",
"    Although subsequent randomized trials have confirmed the short-term benefits of massage therapy, long-term benefits in low back pain have not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. One large randomized trial in 579 patients with chronic or recurrent low back pain found that six sessions of massage therapy, with or without a minimal exercise intervention, reduced disability and pain at three months compared to usual care, but benefits were not sustained at 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/75\">",
"     75",
"    </a>",
"    ]. Six sessions of massage were similarly effective compared to six sessions of the Alexander technique. Another trial in 401 patients with chronic nonspecific low back pain found that 10 sessions of massage therapy reduced disability and pain at 10 weeks compared to usual care [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/76\">",
"     76",
"    </a>",
"    ]. The benefits waned over time with no clinically meaningful difference at 12 month follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL AND MULTIDISCIPLINARY INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of psychological approaches to patients with chronic low back pain have been evaluated. A systematic review found cognitive-behavioral therapy superior to wait list control for short-term pain relief, though there were no differences in function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/77\">",
"     77",
"    </a>",
"    ]. Results were less conclusive for other types of psychological intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/78\">",
"     78",
"    </a>",
"    ]. In a subsequent, 12-month randomized trial in patients with subacute or chronic low back pain, those randomly assigned to group cognitive behavioral therapy reported less pain and disability compared to no further treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Interdisciplinary rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interdisciplinary, or multidisciplinary, therapy combines physical, vocational, and behavioral components provided by multiple health care professionals. Intensity and content of interdisciplinary therapy vary widely. Systematic reviews found intensive interdisciplinary therapy more effective than non-interdisciplinary rehabilitation for both chronic and subacute low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14072?source=see_link\">",
"     \"Occupational low back pain: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Functional restoration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional restoration, also known as work hardening or work conditioning, involves simulated or actual work tests in a supervised environment to improve strength, endurance, flexibility, and fitness for injured workers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14072?source=see_link\">",
"     \"Occupational low back pain: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PHYSICAL MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of physical modalities, in addition to the physical treatments already discussed (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Activity and physical treatments'",
"    </a>",
"    above) have been used in patients with chronic low back pain. For most of these modalities, there is little evidence of benefit from randomized controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/82\">",
"     82",
"    </a>",
"    ], although patient expectations of benefit and placebo effects may play a role in their therapeutic value [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Interferential therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferential therapy is the superficial application of a medium frequency alternating current, modulated to produce low frequencies up to 150 Hz. There is no convincing evidence from three trials that interferential therapy is effective for chronic low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/83-85\">",
"     83-85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Low-level laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-level laser therapy (LLLT), used by some physical therapists, is provided as a single wavelength of light, between 632 and 904 nm, directed at the area of discomfort. For chronic low back pain or back pain of unspecified duration, four trials found laser therapy superior to sham therapy for pain relief and improvement in function up to one year following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. However, another trial found no difference between laser and sham in patients also receiving exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/90\">",
"     90",
"    </a>",
"    ]. Another trial found no differences between laser, exercise, and the combination of laser plus exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review found some evidence of short-term benefit in relief of low back pain, compared to sham therapy, but protocols for treatment dosage, duration, and wavelength were inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/92\">",
"     92",
"    </a>",
"    ]. The review concluded that data were insufficient to draw conclusions regarding effectiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite being widely used for the treatment of many musculoskeletal pain syndromes, few studies have evaluated ultrasound. It is usually performed in combination with other physical therapy modalities, and its beneficial effect is thought to be due to heating of deep tissues. For chronic low back pain, two small (n = 10 and n = 36) trials reported inconsistent results for ultrasound versus sham ultrasound, with the larger trial reporting no differences [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. A systematic review concluded that ultrasound is ineffective in the treatment of chronic low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Short-wave diathermy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shortwave diathermy is the elevation of the temperature of deep tissues by application of shortwave electromagnetic radiation with a frequency range from 10 to 100 MHz. Two trials found no differences between short-wave diathermy and sham diathermy manipulation for chronic low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/96,97\">",
"     96,97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Traction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traction involves drawing or pulling in order to stretch the lumbar spine. A variety of methods are used and typically involve a harness around the lower rib cage and around the iliac crest, the pulling action performed via free weights and a pulley, motorized equipment, inversion techniques, or an overhead harness.",
"   </p>",
"   <p>",
"    For mixed duration low back pain with or without sciatica, a systematic review found no convincing evidence from nine trials that continuous or intermittent traction is more effective than placebo, sham, or no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/98\">",
"     98",
"    </a>",
"    ]. Although autotraction was more effective than placebo, sham, or no treatment in patients with sciatica, it was only evaluated in two trials with methodological shortcomings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Transcutaneous electrical nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcutaneous electrical nerve stimulation (TENS) refers to the use of a small battery-operated device to provide continuous electrical impulses via surface electrodes, with the goal of providing symptomatic relief by modifying pain perception. A systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/99\">",
"     99",
"    </a>",
"    ] included one small (n = 30) trial that found transcutaneous electrical nerve stimulation superior to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/100\">",
"     100",
"    </a>",
"    ], but a larger (n = 145), well-blinded trial found no differences between TENS and sham TENS on any measured outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Percutaneous electrical nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous electrical nerve stimulation (PENS) involves insertion of acupuncture-like needles and applying low-level electrical stimulation. The insertion points target dermatomal levels for local pathology, rather than acupuncture points.",
"   </p>",
"   <p>",
"    Although several trials found PENS moderately to substantially superior to sham PENS for pain relief, effects on function were inconsistent, all trials had methodological shortcomings, and some trials only measured outcomes at the end of a two-week course of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/102-105\">",
"     102-105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PENS is not currently widely available in the US.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     OPTIMIZING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no trials evaluating optimal sequencing of therapies, and there is no evidence that care directed by one spine provider specialty is superior to other specialties or primary care providers. Decision tools and other methods for individualizing therapy are in early stages of development, and may not be practical for use in primary care settings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient expectations of benefit from a treatment should be taken into consideration when choosing interventions, as they appear to influence outcomes. Other factors to consider when choosing among therapies include cost, convenience, and availability of skilled providers for specific therapies. Clinicians should avoid interventions not proven effective, as a number of non-pharmacologic therapies are supported by at least fair evidence of moderate benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547189\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are insufficient data to recommend the use of specific interventions for primary prevention of low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/24/19850/abstract/107\">",
"     107",
"    </a>",
"    ]. Primary prevention is a challenge due to the limited inability to predict a person's likelihood of developing low back pain. However, exercise therapy may have a role in secondary prevention, particularly for those predisposed to having recurrent low back pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6841?source=see_link&amp;anchor=H25#H25\">",
"     \"Exercise-based therapy for low back pain\", section on 'Prevention of LBP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=see_link\">",
"       \"Patient information: Low back pain in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=see_link\">",
"       \"Patient information: Low back pain in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients (&gt;85 percent) who are seen in primary care have \"nonspecific low back pain;\" rapid improvement in pain, disability, and return to work are the norm in the first month. Subacute low back pain is commonly defined as back pain lasting between 4 and 12 weeks and chronic low back pain as pain that persists for 12 or more weeks. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients remain active, and limit bedrest (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest patients be given evidence-based self-care information literature to supplement verbal advice (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest not advising patients to switch to a very firm mattress or other surface (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We also suggest not advising use of lumbar supports (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Self-care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest short courses of nonopioid analgesic medications (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or nonsteroidal antiinflammatory drugs) for acute exacerbations of subacute or chronic low back pain (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest prescribing opioids for chronic low back pain only for short-term use in patients with low vulnerability for drug abuse who are experiencing severe acute exacerbations of back pain (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Rarely, opioids may also be appropriate for severely disabled patients with chronic low back pain who do not respond to other measures, and who are assessed to have low vulnerability for drug abuse. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression is common in patients with chronic low back pain, and clinicians should assess for and treat depression with usual antidepressant medications. We suggest a trial of tricyclic antidepressants for treatment of chronic low back pain in patients, with or without depression, who have not responded to other measures (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using skeletal muscle relaxants or benzodiazepines for chronic low back pain (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest not treating patients for chronic low back pain with antiepileptic medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pharmacologic therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest home and supervised exercise therapy that includes an individualized regimen incorporating stretching and strengthening for motivated patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Aerobic activities should be recommended for all patients, including patients with low back pain. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Exercise therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many additional noninterventional treatment strategies have been advocated for patients with chronic low back pain. For patients interested in particular modalities, we suggest trials of Yoga (Viniyoga), spinal manipulation, massage therapy, or cognitive behavioral therapy, which are moderately more effective than sham or placebo treatment or appear to have effects comparable to exercise therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest functional restoration or interdisciplinary rehabilitation for patients who are more severely impaired by their back pain (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest that patients with chronic pain who are interested or open to acupuncture be referred for a trial of acupuncture when alternatives are limited (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Acupuncture, as with other therapies, is likely to be most beneficial in patients who have high expectations of benefit. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Activity and physical treatments'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Psychological and multidisciplinary interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using the following modalities for low back pain: interferential therapy, low-level laser therapy, short-wave diathermy, traction, TENS, ultrasound, or PENS (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Physical modalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors to consider in advising a treatment regimen include cost, convenience, availability of skilled providers, and patient preference. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Optimizing therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/1\">",
"      Deyo RA, Tsui-Wu YJ. Descriptive epidemiology of low-back pain and its related medical care in the United States. Spine (Phila Pa 1976) 1987; 12:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/2\">",
"      Cassidy JD, Carroll LJ, C&ocirc;t&eacute; P. The Saskatchewan health and back pain survey. The prevalence of low back pain and related disability in Saskatchewan adults. Spine (Phila Pa 1976) 1998; 23:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/3\">",
"      Croft PR, Macfarlane GJ, Papageorgiou AC, et al. Outcome of low back pain in general practice: a prospective study. BMJ 1998; 316:1356.",
"     </a>",
"    </li>",
"    <li>",
"     Bigos SJ, Boyer OR, Braen GR, et al. Acute low back problems in adults. Clinical Practice Guideline Number 4. US Department of Health and Human Services; Rockville, MD 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/5\">",
"      Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA 1992; 268:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/6\">",
"      Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007; 147:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/7\">",
"      van Tulder MW, Assendelft WJ, Koes BW, Bouter LM. Spinal radiographic findings and nonspecific low back pain. A systematic review of observational studies. Spine (Phila Pa 1976) 1997; 22:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/8\">",
"      Pengel LH, Herbert RD, Maher CG, Refshauge KM. Acute low back pain: systematic review of its prognosis. BMJ 2003; 327:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/9\">",
"      Gatchel RJ, Polatin PB, Mayer TG. The dominant role of psychosocial risk factors in the development of chronic low back pain disability. Spine (Phila Pa 1976) 1995; 20:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/10\">",
"      Frymoyer JW, Cats-Baril WL. An overview of the incidences and costs of low back pain. Orthop Clin North Am 1991; 22:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/11\">",
"      Hay EM, Mullis R, Lewis M, et al. Comparison of physical treatments versus a brief pain-management programme for back pain in primary care: a randomised clinical trial in physiotherapy practice. Lancet 2005; 365:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/12\">",
"      Jellema P, van der Windt DA, van der Horst HE, et al. Should treatment of (sub)acute low back pain be aimed at psychosocial prognostic factors? Cluster randomised clinical trial in general practice. BMJ 2005; 331:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/13\">",
"      Carey TS, Freburger JK, Holmes GM, et al. A long way to go: practice patterns and evidence in chronic low back pain care. Spine (Phila Pa 1976) 2009; 34:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/14\">",
"      Pengel HM, Maher CG, Refshauge KM. Systematic review of conservative interventions for subacute low back pain. Clin Rehabil 2002; 16:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/15\">",
"      Vroomen PC, de Krom MC, Slofstra PD, Knottnerus JA. Conservative treatment of sciatica: a systematic review. J Spinal Disord 2000; 13:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/16\">",
"      Luijsterburg PA, Verhagen AP, Ostelo RW, et al. Effectiveness of conservative treatments for the lumbosacral radicular syndrome: a systematic review. Eur Spine J 2007; 16:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/17\">",
"      Hagen KB, Jamtvedt G, Hilde G, Winnem MF. The updated cochrane review of bed rest for low back pain and sciatica. Spine (Phila Pa 1976) 2005; 30:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/18\">",
"      Frost H, Lamb SE, Doll HA, et al. Randomised controlled trial of physiotherapy compared with advice for low back pain. BMJ 2004; 329:708.",
"     </a>",
"    </li>",
"    <li>",
"     The Back Book, 2nd Rev ed., The Stationery Office, London 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/20\">",
"      Burton AK, Waddell G, Tillotson KM, Summerton N. Information and advice to patients with back pain can have a positive effect. A randomized controlled trial of a novel educational booklet in primary care. Spine (Phila Pa 1976) 1999; 24:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/21\">",
"      Cherkin DC, Deyo RA, Batti&eacute; M, et al. A comparison of physical therapy, chiropractic manipulation, and provision of an educational booklet for the treatment of patients with low back pain. N Engl J Med 1998; 339:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/22\">",
"      Cherkin DC, Eisenberg D, Sherman KJ, et al. Randomized trial comparing traditional Chinese medical acupuncture, therapeutic massage, and self-care education for chronic low back pain. Arch Intern Med 2001; 161:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/23\">",
"      Sherman KJ, Cherkin DC, Erro J, et al. Comparing yoga, exercise, and a self-care book for chronic low back pain: a randomized, controlled trial. Ann Intern Med 2005; 143:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/24\">",
"      Kovacs FM, Abraira V, Pe&ntilde;a A, et al. Effect of firmness of mattress on chronic non-specific low-back pain: randomised, double-blind, controlled, multicentre trial. Lancet 2003; 362:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/25\">",
"      Bergholdt K, Fabricius RN, Bendix T. Better backs by better beds? Spine (Phila Pa 1976) 2008; 33:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/26\">",
"      van Duijvenbode IC, Jellema P, van Poppel MN, van Tulder MW. Lumbar supports for prevention and treatment of low back pain. Cochrane Database Syst Rev 2008; :CD001823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/27\">",
"      Roelofs PD, Deyo RA, Koes BW, et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev 2008; :CD000396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/28\">",
"      Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/29\">",
"      A COMPARISON of prednisolone with aspirin on other analgesics in the treatment of rheumatold rthritis. Ann Rheum Dis 1959; 18:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/30\">",
"      Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006; :CD004257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/31\">",
"      Wegman A, van der Windt D, van Tulder M, et al. Nonsteroidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee? A systematic review of evidence and guidelines. J Rheumatol 2004; 31:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/32\">",
"      Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004; 63:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/33\">",
"      Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007; 146:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/34\">",
"      Deshpande A, Furlan A, Mailis-Gagnon A, et al. Opioids for chronic low-back pain. Cochrane Database Syst Rev 2007; :CD004959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/35\">",
"      Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 2005; 6:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/36\">",
"      Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006; 174:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/37\">",
"      Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/38\">",
"      Hale ME, Ahdieh H, Ma T, et al. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007; 8:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/39\">",
"      Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/40\">",
"      Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med 2002; 162:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/41\">",
"      Staiger TO, Gaster B, Sullivan MD, Deyo RA. Systematic review of antidepressants in the treatment of chronic low back pain. Spine (Phila Pa 1976) 2003; 28:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/42\">",
"      Urquhart DM, Hoving JL, Assendelft WW, et al. Antidepressants for non-specific low back pain. Cochrane Database Syst Rev 2008; :CD001703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/43\">",
"      Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine (Phila Pa 1976) 2010; 35:E578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/44\">",
"      Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009; 16:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/45\">",
"      Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010; 11:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/46\">",
"      Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/47\">",
"      van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the cochrane collaboration. Spine (Phila Pa 1976) 2003; 28:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/48\">",
"      Basmajian JV. Cyclobenzaprine hydrochloride effect on skeletal muscle spasm in the lumbar region and neck: two double-blind controlled clinical and laboratory studies. Arch Phys Med Rehabil 1978; 59:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/49\">",
"      McCleane GJ. Does gabapentin have an analgesic effect on background, movement and referred pain? A randomised, double-blind, placebo controlled study. The Pain Clinic 2001; 13:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/50\">",
"      Yildirim K, Sisecioglu M, Karatay S, et al. The effectiveness of gabapentin in patients with chronic radiculopathy. The Pain Clinic 2003; 15:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/51\">",
"      Baron R, Freynhagen R, T&ouml;lle TR, et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010; 150:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/52\">",
"      Khoromi S, Patsalides A, Parada S, et al. Topiramate in chronic lumbar radicular pain. J Pain 2005; 6:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/53\">",
"      Muehlbacher M, Nickel MK, Kettler C, et al. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin J Pain 2006; 22:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/54\">",
"      Atkinson J, Slater M, Patel S, et al. Gabapentin for chronic back pain: A randomized clinical trial. J Pain (Suppl) 2010; 11:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/55\">",
"      Yaksi A, Ozg&ouml;nenel L, Ozg&ouml;nenel B. The efficiency of gabapentin therapy in patients with lumbar spinal stenosis. Spine (Phila Pa 1976) 2007; 32:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/56\">",
"      Wilkens P, Scheel IB, Grundnes O, et al. Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. JAMA 2010; 304:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/57\">",
"      Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. Spine (Phila Pa 1976) 2005; 30:2724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/58\">",
"      Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. Spine (Phila Pa 1976) 2006; 31:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/59\">",
"      Heymans MW, van Tulder MW, Esmail R, et al. Back schools for nonspecific low back pain: a systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine (Phila Pa 1976) 2005; 30:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/60\">",
"      Forssell MZ. The back school. Spine (Phila Pa 1976) 1981; 6:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/61\">",
"      Rubinstein SM, van Middelkoop M, Assendelft WJ, et al. Spinal manipulative therapy for chronic low-back pain: an update of a Cochrane review. Spine (Phila Pa 1976) 2011; 36:E825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/62\">",
"      Bronfort G, Haas M, Evans RL, Bouter LM. Efficacy of spinal manipulation and mobilization for low back pain and neck pain: a systematic review and best evidence synthesis. Spine J 2004; 4:335.",
"     </a>",
"    </li>",
"    <li>",
"     Brown A, Angus A, Chen S, et al. Costs and outcomes of chiropractic treatment for low back pain. Ottawa Canadian Coordinating Office for Health Technology Report No.: 56. July 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/64\">",
"      Ferreira ML, Ferreira PH, Latimer J, et al. Does spinal manipulative therapy help people with chronic low back pain? Aust J Physiother 2002; 48:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/65\">",
"      Ferreira ML, Ferreira PH, Latimer J, et al. Efficacy of spinal manipulative therapy for low back pain of less than three months' duration. J Manipulative Physiol Ther 2003; 26:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/66\">",
"      Oliphant D. Safety of spinal manipulation in the treatment of lumbar disk herniations: a systematic review and risk assessment. J Manipulative Physiol Ther 2004; 27:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/67\">",
"      Stevinson C, Ernst E. Risks associated with spinal manipulation. Am J Med 2002; 112:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/68\">",
"      Meeker WC, Haldeman S. Chiropractic: a profession at the crossroads of mainstream and alternative medicine. Ann Intern Med 2002; 136:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/69\">",
"      Furlan AD, van Tulder MW, Cherkin DC, et al. Acupuncture and dry-needling for low back pain. Cochrane Database Syst Rev 2005; :CD001351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/70\">",
"      Manheimer E, White A, Berman B, et al. Meta-analysis: acupuncture for low back pain. Ann Intern Med 2005; 142:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/71\">",
"      Brinkhaus B, Witt CM, Jena S, et al. Acupuncture in patients with chronic low back pain: a randomized controlled trial. Arch Intern Med 2006; 166:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/72\">",
"      Haake M, M&uuml;ller HH, Schade-Brittinger C, et al. German Acupuncture Trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. Arch Intern Med 2007; 167:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/73\">",
"      Kalauokalani D, Cherkin DC, Sherman KJ, et al. Lessons from a trial of acupuncture and massage for low back pain: patient expectations and treatment effects. Spine (Phila Pa 1976) 2001; 26:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/74\">",
"      Furlan AD, Imamura M, Dryden T, Irvin E. Massage for low back pain: an updated systematic review within the framework of the Cochrane Back Review Group. Spine (Phila Pa 1976) 2009; 34:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/75\">",
"      Little P, Lewith G, Webley F, et al. Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain. BMJ 2008; 337:a884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/76\">",
"      Cherkin DC, Sherman KJ, Kahn J, et al. A comparison of the effects of 2 types of massage and usual care on chronic low back pain: a randomized, controlled trial. Ann Intern Med 2011; 155:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/77\">",
"      Ostelo RW, van Tulder MW, Vlaeyen JW, et al. Behavioural treatment for chronic low-back pain. Cochrane Database Syst Rev 2005; :CD002014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/78\">",
"      Hoffman BM, Papas RK, Chatkoff DK, Kerns RD. Meta-analysis of psychological interventions for chronic low back pain. Health Psychol 2007; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/79\">",
"      Lamb SE, Hansen Z, Lall R, et al. Group cognitive behavioural treatment for low-back pain in primary care: a randomised controlled trial and cost-effectiveness analysis. Lancet 2010; 375:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/80\">",
"      Guzm&aacute;n J, Esmail R, Karjalainen K, et al. Multidisciplinary rehabilitation for chronic low back pain: systematic review. BMJ 2001; 322:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/81\">",
"      Karjalainen K, Malmivaara A, van Tulder M, et al. Multidisciplinary biopsychosocial rehabilitation for subacute low back pain in working-age adults: a systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine (Phila Pa 1976) 2001; 26:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/82\">",
"      Maher CG. Effective physical treatment for chronic low back pain. Orthop Clin North Am 2004; 35:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/83\">",
"      Hurley DA, McDonough SM, Dempster M, et al. A randomized clinical trial of manipulative therapy and interferential therapy for acute low back pain. Spine (Phila Pa 1976) 2004; 29:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/84\">",
"      Hurley DA, Minder PM, McDonough SM, et al. Interferential therapy electrode placement technique in acute low back pain: a preliminary investigation. Arch Phys Med Rehabil 2001; 82:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/85\">",
"      Werners R, Pynsent PB, Bulstrode CJ. Randomized trial comparing interferential therapy with motorized lumbar traction and massage in the management of low back pain in a primary care setting. Spine (Phila Pa 1976) 1999; 24:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/86\">",
"      Basford JR, Sheffield CG, Harmsen WS. Laser therapy: a randomized, controlled trial of the effects of low-intensity Nd:YAG laser irradiation on musculoskeletal back pain. Arch Phys Med Rehabil 1999; 80:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/87\">",
"      Blythin P. Triage in the UK. Nursing (Lond) 1988; 3:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/88\">",
"      Soriano F, Rios R. Gallium arsenide laser treatment of chronic low back pain: a prospective, randomized and double blind study. Laser Ther 1998; 10:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/89\">",
"      Toya S, Motegi M, Inomata K, et al. Report on a computer-randomized double blind clinical trial to determine the effectiveness of the GaAlAs (830nm) diode laser for attenuation in selected pain groups. Laser Ther 1994; 6:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/90\">",
"      Klein RG, Eek BC. Low-energy laser treatment and exercise for chronic low back pain: double-blind controlled trial. Arch Phys Med Rehabil 1990; 71:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/91\">",
"      Gur A, Karakoc M, Cevik R, et al. Efficacy of low power laser therapy and exercise on pain and functions in chronic low back pain. Lasers Surg Med 2003; 32:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/92\">",
"      Yousefi-Nooraie R, Schonstein E, Heidari K, et al. Low level laser therapy for nonspecific low-back pain. Cochrane Database Syst Rev 2007; :CD005107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/93\">",
"      Ansari NN, Ebadi S, Talebian S, et al. A randomized, single blind placebo controlled clinical trial on the effect of continuous ultrasound on low back pain. Electromyogr Clin Neurophysiol 2006; 46:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/94\">",
"      ROMAN MP. A clinical evaluation of ultrasound by use of a placebo technic. Phys Ther Rev 1960; 40:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/95\">",
"      Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. Phys Ther 2001; 81:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/96\">",
"      Gibson T, Grahame R, Harkness J, et al. Controlled comparison of short-wave diathermy treatment with osteopathic treatment in non-specific low back pain. Lancet 1985; 1:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/97\">",
"      Sweetman BJ, Heinrich I, Anderson JA. A randomized controlled trial of exercises, short wave diathermy, and traction for low back pain, with evidence of diagnosis-related response to treatment. J Orthop Rheumatol 1993; 6:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/98\">",
"      Clarke J, van Tulder M, Blomberg S, et al. Traction for low back pain with or without sciatica: an updated systematic review within the framework of the Cochrane collaboration. Spine (Phila Pa 1976) 2006; 31:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/99\">",
"      Khadilkar A, Milne S, Brosseau L, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain. Cochrane Database Syst Rev 2005; :CD003008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/100\">",
"      Cheing GL, Hui-Chan CW. Transcutaneous electrical nerve stimulation: nonparallel antinociceptive effects on chronic clinical pain and acute experimental pain. Arch Phys Med Rehabil 1999; 80:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/101\">",
"      Deyo RA, Walsh NE, Martin DC, et al. A controlled trial of transcutaneous electrical nerve stimulation (TENS) and exercise for chronic low back pain. N Engl J Med 1990; 322:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/102\">",
"      Yokoyama M, Sun X, Oku S, et al. Comparison of percutaneous electrical nerve stimulation with transcutaneous electrical nerve stimulation for long-term pain relief in patients with chronic low back pain. Anesth Analg 2004; 98:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/103\">",
"      Ghoname EA, Craig WF, White PF, et al. Percutaneous electrical nerve stimulation for low back pain: a randomized crossover study. JAMA 1999; 281:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/104\">",
"      Ghoname EA, White PF, Ahmed HE, et al. Percutaneous electrical nerve stimulation: an alternative to TENS in the management of sciatica. Pain 1999; 83:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/105\">",
"      Weiner DK, Rudy TE, Glick RM, et al. Efficacy of percutaneous electrical nerve stimulation for the treatment of chronic low back pain in older adults. J Am Geriatr Soc 2003; 51:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/106\">",
"      Childs JD, Fritz JM, Flynn TW, et al. A clinical prediction rule to identify patients with low back pain most likely to benefit from spinal manipulation: a validation study. Ann Intern Med 2004; 141:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/24/19850/abstract/107\">",
"      Choi BK, Verbeek JH, Tam WW, Jiang JY. Exercises for prevention of recurrences of low-back pain. Cochrane Database Syst Rev 2010; :CD006555.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7770 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19850=[""].join("\n");
var outline_f19_24_19850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SELF-CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Self-care advice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bed mattress choice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lumbar supports",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHARMACOLOGIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acetaminophen and nonsteroidals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Skeletal muscle relaxants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antiepileptic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H118398087\">",
"      Glucosamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anti-TNF-alpha therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ACTIVITY AND PHYSICAL TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Exercise therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Back schools",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Spinal manipulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Massage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PSYCHOLOGICAL AND MULTIDISCIPLINARY INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Interdisciplinary rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Functional restoration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PHYSICAL MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Interferential therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Low-level laser therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Short-wave diathermy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Traction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Transcutaneous electrical nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Percutaneous electrical nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      OPTIMIZING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H547189\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7770\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7770|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/54/23406\" title=\"table 1\">",
"      Glossary LBP terms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/62/34795\" title=\"table 2\">",
"      Magnitude of effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/38/7789\" title=\"table 3\">",
"      Meds for subacute LBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/46/39661\" title=\"table 4\">",
"      Nonpharm Rx subacute LBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/17/15646\" title=\"table 5\">",
"      Interventional Rx LBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/23/44412\" title=\"table 6\">",
"      Surg vs nonsurg Rx LBP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40296?source=related_link\">",
"      Evaluation of chronic pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6841?source=related_link\">",
"      Exercise-based therapy for low back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14072?source=related_link\">",
"      Occupational low back pain: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=related_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=related_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41222?source=related_link\">",
"      Spinal manipulation in the treatment of musculoskeletal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=related_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=related_link\">",
"      Subacute and chronic low back pain: Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=related_link\">",
"      Treatment of acute low back pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_24_19851="Medications with plant origins";
var content_f19_24_19851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of conventional medications with plant origins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Herb common name (Latin name)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atropine",
"       </td>",
"       <td>",
"        Belladona (Atropa belladonna)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Codeine",
"       </td>",
"       <td>",
"        Poppy (Papaver somniferum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colchicine",
"       </td>",
"       <td>",
"        Autumn crocus (Colchicum autumnale)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digoxin",
"       </td>",
"       <td>",
"        Foxglove (Digitalis purpurea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ephedrine",
"       </td>",
"       <td>",
"        Ephedra (Ephedra sinica)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reserpine",
"       </td>",
"       <td>",
"        Rauwolfia (Rauvolfia serpentine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylic acid",
"       </td>",
"       <td>",
"        Willow bark (Salix purpurea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scopolamine",
"       </td>",
"       <td>",
"        Jimson weed (Datura stramonium)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Taxol",
"       </td>",
"       <td>",
"        Pacific yew (Taxus brevifolia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine",
"       </td>",
"       <td>",
"        Madagascar periwinkle (Catharanthus roseus)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19851=[""].join("\n");
var outline_f19_24_19851=null;
var title_f19_24_19852="Propose ICD10 crit CA fatigue";
var content_f19_24_19852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed (1998 draft) ICD-10 criteria for cancer-related fatigue",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       Six (or more) of the following symptoms have been present every day or nearly every day during the same two-week period in the past month, and at least one of the symptoms is (A1) significant fatigue.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A1.",
"      </td>",
"      <td colspan=\"1\">",
"       Significant fatigue, diminished energy, or increased need to rest, disproportionate to any recent change in activity level",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A2.",
"      </td>",
"      <td>",
"       Complaints of generalized weakness or limb heaviness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A3.",
"      </td>",
"      <td>",
"       Diminished concentration or attention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A4.",
"      </td>",
"      <td>",
"       Decreased motivation or interest to engage in usual activities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A5.",
"      </td>",
"      <td>",
"       Insomnia or hypersomnia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A6.",
"      </td>",
"      <td>",
"       Experience of sleep as unrefreshing or nonrestorative",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A7.",
"      </td>",
"      <td>",
"       Perceived need to struggle to overcome inactivity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A8.",
"      </td>",
"      <td colspan=\"1\">",
"       Marked emotional reactivity (eg, sadness, frustration, or irritability) to feeling fatigued",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A9.",
"      </td>",
"      <td>",
"       Difficulty completing daily tasks attributed to feeling fatigued",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A10.",
"      </td>",
"      <td>",
"       Perceived problems with short-term memory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A11.",
"      </td>",
"      <td>",
"       Postexertional malaise lasting several hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B.",
"      </td>",
"      <td>",
"       The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C.",
"      </td>",
"      <td colspan=\"1\">",
"       There is evidence from the history, physical examination, or laboratory findings that the symptoms are a consequence of cancer or cancer therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D.",
"      </td>",
"      <td colspan=\"1\">",
"       The symptoms are not primarily a consequence of comorbid psychiatric disorders such as major depression, somatization disorder, somatoform disorder, or delirium",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: World Health Organization. The ICD-10 classification of mental and behavioral disorders: Diagnostic criteria for research. Copyright &copy; World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19852=[""].join("\n");
var outline_f19_24_19852=null;
var title_f19_24_19853="Damaging shear forces in ARDS";
var content_f19_24_19853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shear forces",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 438px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When lung units collapse, they may stretch adjacent, non- atelectatic lung units and create damaging shear forces",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19853=[""].join("\n");
var outline_f19_24_19853=null;
var title_f19_24_19854="Twin birth gestational age";
var content_f19_24_19854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Gestational age distribution of twin births: United States, 1990, 2000, and 2005",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 329px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Martin, JA, Hamilton, BE, Sutton, PD, et al. Births: Final Data for 2005. Natl Vital Stat Rep 2007; 56:1. Available at: file://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_06.pdf (Accessed March 13, 2009).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19854=[""].join("\n");
var outline_f19_24_19854=null;
var title_f19_24_19855="Time of puberty onset";
var content_f19_24_19855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Timing of puberty in white and black girls in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 604px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this study, the first signs of puberty occurred at a younger age than had been previously reported; the mean age of onset was earlier for black versus white girls.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Herman-Giddens, ME, Slora, EJ, Wasserman, RC, et al, Pediatrics 1997; 99:505.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_24_19855=[""].join("\n");
var outline_f19_24_19855=null;
